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Phenylpropanolamine (PPA), a synthetic sympathomimetic amine 
structurall y related to ephedrine has been widely used over t he past 
40 years as a nasal decongestant and appetite suppressant. It has 
been the focus of much controversy concerning the efficacy of the drug 
in its use as an anorectic agent, and due to the side effects caused 
by the higher doses of PPA required for appetite suppression. 
Although extensively used, there is little information concerning the 
determination of PPA in biological fluids and on the pharmacokinetics 
of this drug. An adaptation of a published high-performance liquid 
chromatographic (HPLC) assay for PPA in serum and urine using U.V. 
detection at 210 nm is presented. PPA was separated in the reversed-
phase mode. The method has a limit of sensitivity of 5.0 ng/mL and 
10.0 ng/mL in serum and urine respectively. Serum concentration data 
following a single 25 mg dose of phenylpropanolamine in human 
volunteers demonstrate the application of the analytical method for 
bioavailability and pharmacokinetic studies. 
After the administration of 25 mg, 50 mg or 100 mg PPA.HCl solutions 
to 5 human volunteers, a dose proportionality study demonstrated that 
PPA appears to exhibit linear kinetics. Linear one body compartment 
kinetics were assumed and the wagner-Nelson method used to transform 
in vivo serum data to absorption plots. The serum data were fitted to 
a model using nonl inear regression techniques to characterize the 
pharmacokinetic processes of PPA. The absorption of phenylpropanol-
amine appears to be discontinuous and the drug seems to favour a two 
body compartment model. The pharmacokinetic parameters obtained from a 
steady state study using multiple dosing of PPA.HCl solutions compared 
xiii 
with those found from previous studies after the administration of 
sustained-release formulations. 
A plasma protein binding study using equilibrium dialysis demonstrated 
that PPA is not highly protein bound in the blood. 
1 
CHAP'l'E,R 1 
INI'RODUCTION 
Phenylpropanolamine hydrochloride is a synthetic sympathomimetic drug, 
structurally and pharmacologically related to ephedrine and 
amphetamine. The drug is a more potent vasoconstrictor than ephedrine 
or amphetamine but is less active in its central stimulant effect and 
has less beta-activity (1). Phenylpropanolamine is used widely as the 
active component of over-the-counter (QTC) preparations for the 
symptomatic relief of rhinitis, sinusitis and cough. It is also 
commonly found in QTC appetite suppressants and as a component of 
legal stimulants (1). 
The most commonly reported adverse reaction of phenylpropanolamine is 
a rise in blood pressure but other reactions such as psychotic 
disturbances have also occurred (2). 
1.1 PHYSICOCHEMICAL PROPERTIES OF PHENYLPROPANOLAMINE (4) 
1.1.1 Description 
1.1.1.1 Name, Formula, Molecular Mass 
Phenylpropanolamine hydrochloride, sometimes referred to as dl-
norephedrine, can also be named in a number of ways: 
(a) a-(l-aminoethyl)benzenemethanol hydrochloride 
(b) a-(l-aminoethyl)benzyl alcohol hydrochloride 
(c) (±)-2-amino-phenylpropan-l-ol hydrochloride 
(d) 2-amino-l-phenyl-l-propanol hydrochloride 
(e) a-hydroxy-8-aminopropylbenzene hydrochloride 
(f) I-phenyl-2-amino-l-propanol hydrochloride 
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FIGURE 1.1 Phenylpropanolamine hydrochloride 
OH H 
;/\\-!-~-N H2' H Cl \==.1- I I 
H CH3 
1.1.1.2 Appearance, Odour, Colour and Taste 
The compound is a white to creamy-white crystalline powder with an 
aromatic odour. It has a bitter taste (4). 
1.1.2 Synthesis 
Phenylpropanolamine hydrochloride is prepared by reacting benzaldehyde 
with nitroethane in 95% ethanol in the presence of sodium hydroxide to 
form a-(I-nitroethyl)benzyl alcohol and then reducing this nitro-
alcohol to the corresponding amino compound. A stream of hydrogen 
chloride passed into a suitable solution of the base yields the 
hydrochloride (3). 
1.1 . 3 Physical Properties 
1.1 . 3.1 Solubility 
Soluble in 2.5 parts of water and in 9 parts of alcohol (95 per cent); 
insoluble in chloroform and in solvent ether. After sonicating for 
one minute at ambient temperature the following solubilities were 
established (4). 
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TABLE 1 .1 Solubility of PPA.HCl 
Solvent mg/ml Solubility 
Water >SO-<l 000 Soluble 
Methanol >SO-<l 000 Soluble 
Isopropanol > 10-<33.3 Sparingly soluble 
Diethylether >O . S Practically insoluble 
Ethyl acetate >0.5 Practically insoluble 
Chloroform >O.S Practically insoluble 
Benzene >O.S Practically insoluble 
Carbon tetrachloride >O.S Practically insoluble 
Acetonitrile >O.S Practicaily insoluble 
Acetone >O.S Practically insoluble 
Cyclohexane >O.S Practically insoluble 
1.1.3.2 Melting Range 
Phenylpropanolamine hydrochloride crystals melt at 190-194°C. The free 
base melts at 101-101.SOC (5). 
1.1.3.3 Specific Rotation 
The specific rotation [aJ 25D, of phenylpropanolamine hydrochloride in 
water is +32° (6). 
1.1.3.4 Crystal Structure 
Phenylpropanolamine hydrochloride has a monoclinic crystal system with 
possible space 
(centrosymmetric). 
° 
groups of P21 (non-centrosymmetric) 
The cell dimensions are a ~ 7. 448A, 
or P2/m 
b ~ 9.461)1., 
c ~ 14.S9SA, 
molecules (7). 
in Fig. 1.2. 
~ 103.4° with each asymmetric unit containing two 
The crystal structure of phenylpropanolamine is shown 
FIGURE 1.2 
4 
The crystal structure projected along y . Solid circles 
denote chloride ions 
1.1.3.5 Dissociation Constant 
The pK of phenylpropanolamine hydrochloride determined potentio-
a 
metrically at 20·C is 9.44 + 0.04 (8). 
1.1.3.6 Infrared Spectrum 
The infrared spectrum of phenylpropanolamine hydrochloride is shown in 
Fig. 1.3. It was obtained from a Nujol mull between KBr plates . 
FIGURE 1.3 
.. 
" 
I" i I-
" 
• , 
... 
I 
Infrared spectrum of phenylpropanolamine hydrochloride 
in Nujol mull. 
, , , 
"'" -
"'" 
• I I I , • 
2000 1100 IteO ,.eo 1100 )cat 
w,,~IOt, 
, 
'" 
, 
-
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Characteristic band assignments are listed below (4) . 
-1 Frequency (em ) 
3368 
3303 
2800-2400 
1990 
1623 
1598 
1581 
1508, 1491 
1450 
1329 
1241, 1208 
1128,1088, 1054 
1031 
816, 802 
747, 703 
Assigrunen t 
O-H stretching 
NH; stretching 
NH+ 
3 
NH+ 
3 
NH; out of plane deformation 
C=C aromatic stretching 
NH; out of plane deformation 
C=C aromatic stretching 
O-H out of plane deformation 
NH; in plane deformation 
O-H in plane deformation 
C-H in plane deformation, monosubstituted 
benzene 
C-O stretching 
NH; rocking 
C-H out of plane deformation, monosubstituted 
benzene 
1.1.3.7 Differential Scanning Calorimetry 
A single endotherm was observed with an onset temperature of 194.5°C 
which corresponds to the melting point. The heat of transition (~H 
-1 
melting) calculated in relation to an indium standard is 168 + 6 Jg 
The thermogram is depicted in Fig. 1.4 (4). 
FIGURE 1.4 
6 
Differential scanning calorimetry curve of phenylpro-
panolamine hydrochloride. 
• 50 '00 .. '50 .00 
1.1.3.8 Proton Magnetic Resonance Spectrum 
The 60MHz 
CDCL3 with 
proton magnetic spectrum of 
tetramethylsilane (TMS) as 
phenylpropanolamine base 
the internal standard 
in 
is 
depicted in Fig. 1.5 (4). The integration and multiplicities are 
consistent with the proton assignments. Chemical shifts (6) in ppm 
relative to TMS are: 
Proton Nwnber Chemical 
assignment of protons J(Hz) Shift (6 ) Mul tiplici ty 
- CH3 3 9.0 0.94 Doublet 
-NH2 • -OH 3 2.07 Singlet 
N-C-H 1 9.0 3.12 Quintuplet 
O-C-H 1 9.0 4.51 Doublet 
Aromatic 5 7.41 Singlet 
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FIGURE 1.5 Proton magnetic resonance spectrum of phenylpropanolamine 
in CDC1 3 
• • 
, 
.. .... 
An inspection of the D20 exchange spectrum shows disappearance of the 
resonance at 2.07 ppm. This corresponds to three protons, one 
hydroxyl proton and two amino protons. 
1.1.3.9 Ultraviolet Spectrum 
The ultraviolet spectrum of phenylpropanolamine hydrochloride in 
methanol at a concentration of 1 mg/ml was obtained with a Beckman 
Acta M VI ultraviolet spectrometer. 
is depicted in Fig. 1.6. and shows 
Absorption 
Solution Maxima (nm) 
Methanol 264.0 
258.0 
252.0 
The spectrum obtained in methanol 
shoulders at 267, 248 and 243 nm. 
E 
133.63 
179.04 
145 . 44 
s 
FIGURE 1.6 Ultraviolet spectrum of phenylpropanolamine hydrochloride 
in methanol. 
E 
co 
co 
co 
N 
1.1.3 . 10 Mass Spectrum 
co 
------------------- ~ 
WAVELENGTH (nm) 
The low resolution mass spectrum of phenylpropanolamine hydrochloride 
is shown in Fig. 1.7 . Direct probe at SO·C into the ion source was 
used to obtain the mass spectrum (4). The molecular ion is not 
observed . The assignments of some of the major ions formed are : 
m/e % Ion 
132 17 Ph-CH=C(CH2 )NH; 
105 29 Ph-C=O+ 
91 26 Ph-CH; 
77 100 Ph+ 
i 
I ,. 
I 
I 
I 
I 
I 
! 
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FIGURE 1. 7 Mass spectrum of phenylpropanolamine hydrochloride. 
.. 
I 
11,1, 
i 
l.il, I, 
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" 
w 
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.. 
"" '" 
'w ~ ,m ~, 
1.2 MODE OF ACTION OF PHENYLPROPANOLAMINE 
Phenylpropanolamine hydrochloride (PPA, HCl) is a sympathomimetic 
phenylethylisopropylamine with largely indirect actions . It displaces 
endogenous sympathetic transmitters particularly norepinephrine from 
storage sites. PPA has some direct effects (9, 10). It posesses both 
alpha-l and beta-l agonist properties in vitro (9, 11), and minor 
central nervous activating effects. The alpha effects are 
predominantly vasoconstrictive in character although bladder trigone 
and uterine smooth muscle may be effected . The beta effects are 
occasionally seen as increased heart rate although tachycardia is 
seldom noted in animals or humans with intact cholinergic reflex 
mechanisms (12). It is not clear from published data whether PPA has 
beta-2 agonist activity. 
An indirectly- acting sympathomimetic amine crosses the cell membrane 
of adrenergic neurones, usually by an active process. Within the axon 
varicosity, it crosses the membranes of storage vesicles and displaces 
noradrenaline in the cytoplasm which may then act on the effector cell 
(13) or be O-methylated by an enzyme, catechol-0- methyltransferase 
(COMT) . The responses elicit ed are therefore similar to those of 
noradrenaline (13). Indirectly-acting sympathomimetics also exhibit 
tachyphylaxis ; that is, repeated injections of these drugs become less 
effective as the releasable stores of noradrenaline are depleted (13). 
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Phenylpropanolamine primarily causes the arterioles to contract by 
alpha- adrenergic stimulation , and only slightly influences capillary 
width (14) . It is believed that PPA constricts the pre-capillary 
sphincters by its direct action on alpha-adrenergic receptors, and 
thus reduces blood flow to the turbinates thereby minimizing venous 
pooling with its resultant nasal congestion (15). 
The central 
understood 
nervous system (CNS) actions of PPA are not 
(16) . PPA is absorbed into the blood 
completely 
after oral 
administration, crosses the blood-brain barrier and acts as a CNS 
stimulant via its sympathomimetic activity (17). This activity is 
related primarily to the blockage of presynaptic neuronal uptake of 
catecholamines, introduction of an increased release of noradrenaline 
from the presynaptic neuron, monamine oxidase inhibition, and agonist 
stimulation of post-synaptic alpha receptors (18). 
Phenylpropanolamine has some central stimulating effects, manifest as 
improved reaction skills and flicker recognition (19, 20). The basic 
stimulatory action of sympathomimetic drugs is probably to increase 
arousal via nor adrenergic pathways in the ascending reticular 
activating system (13). 
The neurophysiological substrate of appetite suppression is not known. 
Previous theories of hypothalamic centres that subserve appetite and 
satiety are no longer tenable, and the newer ideas that relate appe-
tite to specific neurotransmitters have not enabled clear statements 
to be made about drug action (21). However, it can be stated broadly 
that PPA seems to act in a manner that is pharmacologically similar to 
amphetamine, which probably involves the release of adrenaline or 
noradrenaline in the prefornical region of the brain (22). The 
anorectic and motor activity actions of PPA have been characterized by 
Cairns et a2. (23) in which a catecholaminergic component in PPA 
action has been confirmed. 
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Phenylpropanolamine produces weight loss that may result, in part, 
from an excitatory action of PPA on brown adipose tissue (BAT) 
thermogenesis (24), which is indicated primarily via activation of 
beta-adrenergic receptors. The absence of an effect of beta-adrenergic 
blockade on PPA anorexia supports this suggestion (25). The 
thermogenic action of PPA may be attributed to the vasoconstrictive 
action of PPA that would limit the loss of heat through the skin (24). 
The discovery of brain peptides as neurotransmitters opens a new 
chapter in the study of feeding from a neural point of view. Current 
studies suggesting a limbic system framework of chemical neuroanatomy 
in which peptides play an important role in the control of eating have 
been reviewed (25). In this framework, anorectic drugs such as PPA 
act on dopamine, norepinephrine and serotonin systems that ascend from 
the hindbrain and midbrain to modulate feeding and satiety systems in 
the hypothalamus (26). 
The glucostatic theory of feeding control suggests that anorexia could 
be caused by a drug with an insulin-like action, or a direct excita-
tory action on glucoreceptors (16). A study by Resnick et aZ. (27) 
investigated the hypoglycaemic effects of intraperitoneal PPA on rats 
to test the possibilities that it might derive some of its anorectic 
properties through effects on glucostatic mechanisms. It was found 
that PPA tended to lower blood glucose levels in normal and diabetic 
rats; this is the first evidence that PPA might possibly reduce 
feeding by increasing blood sugar utilization. 
1.2.1 Structure Activity Relationships of Phenylpropanolamine 
Agents that lack hydroxyl groups on the aromatic ring, i.e. non-
catecholamine derivatives, can exhibit alpha and beta effects, mainly 
by indirect mechanisms (13). SUbsti tution on the alpha-carbon atom 
blocks oxidation by monamine oxidase (MAO), thus greatly prolonging 
the duration of action on non-catecholamines, the detoxification of 
which depends largely on breakdown by MAO since they are unaffected by 
catechol-O-methyltransferase (COMT). Compounds with an alpha-methyl 
substituent persist in the nerve terminal and are more likely to 
12 
release noradrenaline from storage sites. In general, then less 
substitution in the amino group, the greater is the selectivity for 
alpha-activity. 
FIGURE 1.8 Si tes of potential structural variance of sympathomimetic 
phenylethylamines 
Substitution of an hydroxyl group on the beta-carbon generally 
decreases central nervous stimulant (CNS) action, but enhances 
peripheral organistic activity, both at alpha and beta receptors. 
Hydroxyl substitution increases polarity and dramatically reduces 
lipid solubility. For example, the chloroform/water partition 
coefficients for dextroamphetamine, ephedrine and PPA are 146, 0.015 
and 0.001, respectively (28). Beta-hydroxyl-substituted products are 
considered to be indirect agonists (13, 29, 30), that act by enhancing 
the release of stored catecholamines and/or by inhibiting 
catecholamine uptake (31). 
1. 3 PHARMACOKINETICS OF PHEYLPROPANOLAMINE 
1.3.1 Absorption and Distribution 
After oral administration of phenylpropanolamine hydrochloride as an 
aquecus solution, absorption is rapid, being completed in less than 
2.5 hours (4). However, absorption can be altered by a variety of 
factors, particularly the presence of absorbents such as activated 
charcoal (32). Phenylpropanolamine, being a weak base will not be 
absorbed readily from the acidic stomach due to ionization. In the 
13 
alkaline intestine absorption does occur at rates determined by the 
dissociation constant and the lipid solubility of the unionized form. 
Although the pKa of PPA is 9.4, it is almost completely absorbed in 
the small intestine due to the large surface area available for 
absorption (8). 
The tissue distribution of the drug in dogs 2 hours after 
administration is kidney> lung> liver> spleen> brain> heart> muscle> 
plasma> fat> cerebrospinal fluid (4). The presence of a beta-carbcn 
hydroxyl group establishes an active site which tends to dissociate in 
solution, markedly increasing the polarity and water solubility of PPA 
(33). Water soluble, metabclically stable forms (refer to section 
1.3.2) poorly penetrate cellular barriers to reach sites of further 
metabclism, or sites of action in the central nervous system. From 
recent studies, PPA has been found to have an apparent volume of 
distribution of 300 litres (34). 
1.3.2 Metabclism 
Relatively little information has been reported on the metabclism of 
phenylpropanolamine hydrochloride. The drug is referred to by Axelrod 
as a "metabclically stable entity" (35). In urine studies with human 
subjects it was found that approximately 90% of the drug was excreted 
in 24 hours, predominantly unchanged. Sinsheimer et aZ. (36) found 
only 4% as transformation products, the major biotransformations being 
parahydroxylation to 4-hydroxynorephedrine and oxidative deamination 
of the side chain, reSUlting in hippuric acid. Phenylpropanolamine is 
also metabclised by phenylethanolamine-N-methyltransferase to the 
corresponding N-methylated 
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of C of small doses of 
metabclite. In the rat and rabbit, 80-90% 
14 hedr " ed ' h ' C norep ~ne ~s excret ~ t e ur~ne 
within 24 hours, with 1-2% of the dose being excreted in the faeces. 
In the rat, 60% occurs as the unchanged drug and 35% as 4-
hydroxynorephedrine. Small amounts of 4-hydroxyhippuric acid and 1,2-
dihydroxy-l-phenylpropane were also detected. In the rabbit, however, 
76% is excreted as deamination products consisting of 31% 1,2-
dihydroxy-l-phenylpropane, 27% I-hydroxy-2-oxo-l-phenylpropane and 24% 
benzoic acid (4). 
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Phenylpropanolamine appears as 
methamphetamine (37), ephedrine 
cathinone (39). 
a minor metabolite of amphetamine, 
(38) and as a major metabolite of 
1. 3. 3 Excretion 
The mean elimination half-life of phenylpropanolamine hydrochloride in 
man 
as 
has been reported as 3.9 hours and the elimination rate constant 
0.18 hr-l (40). In a study with human subjects under controlled' 
conditions of urinary pH, acidification of the urine resulted in the 
excretion of largely unchanged PPA.HCl, whereas basic urine conditions 
resulted in reabsorption of the drug with little influence on metabo-
lism (41). Excretion is generally delayed if the urine is alkaline. 
Since the pKa of PPA is greater than 8.5, excretion of the unchanged 
form is generally increased when the partition between acidic urine 
and more alkaline body fluids would favour diffusion into the acidic 
urine (42). PPA is excreted by filtration at the glomerulus (43). 
1.4 USES OF PHENYLPROPANOLAMINE 
First synthesized in 1910 (4), PPA has been pharmacologically and 
clinically 
potentially 
evaluated repeatedly since its identi fication 
useful sympathomimetic . Phenylpropanolamine's 
as a 
initial 
introduction into medicine was as a parenterally administered compound 
for the maintenance of blood pressure in postoperative hypotensive 
patients with significantly fewer side-effects than ephedrine . 
However, as a pressor medication, PPA was superseded by more effective 
agents and is no longer used for this purpose. 
Phenylpropanolamine is found in four types of products : 
(a) prescription (b) over the counter (arc) cough-cold and allergy 
preparations, (c) arc appetite suppressants and (d) "Look-alike" 
combinations, where it has been abused as a substitute for amphetamine 
(the availability of which has been diminished by recent federal and 
state regulatory actions in the United States of America) (44). 
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Phenylpropanolamine is used mainly as a nasal decongestant for the 
treatment of colds and sinusitis, and for symptomatic treatment of 
allergic disorders due to hayfever, asthma, allergic rhinitis, urtica-
ria, angioneurotic oedema and bronchospastic conditions accompanying 
allergic asthma (45). The drug is often used combined with analgesics, 
antihistamines, anticholinergics, caffeine, atropine-like drugs and 
other products to diminish the discomforts of upper respiratory 
conditions (46). PPA can be found in many oral formulations including 
tablets, capsules, syrups, elixirs and suspensions (47), and is 
administered in doses of 12.5 to 50 rng every 3 to 8 hours. Oral 
administration can reach areas inaccessible to topical applications 
and may provide a longer duration of action. Systemic use, however, 
may be complicated by undesirable sympathomimetic effects (48). 
Decongestion of mucous through vasoconstriction may be achieved by 
local application of PPA, which acts directly on alpha-receptors. 
Phenylpropanolamine is used in concentrations varying from 1% to 3% in 
nasal solutions and jellies (49). Topical administration has the 
advantage of more rapid onset, but may not reach all areas of the 
nasal mucosa . Also, the topical route exposes the patient to the 
possibility of the so-called rebound phenomenon in which the nasal 
mucous membranes become even more congested as the 
vasoconstrictor effect wears off, encouraging the overuse 
product (50). 
drug's 
of the 
Another action of PPA consists of a moderate inhibition of mucosal 
secretion, and an anti-allergic effect (51, 52). Phenylpropanolamine 
has a subtle but measurable anti-congestive effect (53), and is found 
to be useful in improving air flow in the nasal passages (54). 
Phenylpropanolamine is often used in combination with antihistamines 
to control nasal congestion and to counteract partially the drowsiness 
produced by antihistamines (l9) . Decongestant-antihistamine mixtures 
containing PPA in the prevention and treatment of otitis media with 
effusion in children have been found to be clinically useful (55). 
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Sporadic repor t s have demonstrated the usef ulness of sympathomimetic 
agents such as PPA in correcting retrograde ejaculation due to 
neurogenic dysfunction (56-58) PPA could be of benefit in establishing 
antegrade ejaculation even in the absence of neurogenic dysfunction 
(59). Phenylpropanolamine has recently been indicated to ameliorate 
symptoms in patients suffering from orthostatic hypotension after 
general measures of treatment have failed. Although doses of 25 mg 
can have a significant pressor effect, doses of 75 mg may be required 
with multiple system atrophy (60). It has been reported that PPA taken 
at bedtime is of some benefit for adults who suffer from mild or 
occasional snoring, the lay term for obstructive breathing during 
sleep (61). In combination with paracetamol and phenyltoxamine 
citrate, PPA has been reported to be of some benefit in cl uster 
headache (Harton's headache) (62). 
Bladder storage may be improved by increasing bladder outlet tone at 
the proximal portion of the urethra with alpha-stimulating agents (63, 
64), and PPA in a dosage of 50 mg twice daily seems to be of some use 
in relieving stress during incontinence. Schreiter et aZ. (65) 
support the idea that PPA elevates the urethral pressure more 
effectively when administered in combination with oestrogens, 
especially when used in elderly female patients with urinary 
incontinence. 
In a recent report, PPA has been found to be useful in counteracting 
and antagonizing several effects of diazepam, mainl y unwanted ones, 
without decreasing the calming effect of diazepam (20). 
Clinically, PPA.HCl has been used as an anorexiant for over 40 years, 
following the appearance of an article by Hirsch (66), in which he 
concluded that PPA was effective in controlling appetite of patients 
on an anti-obesity diet. While it has been subject to both debate and 
dispute when used as an adjunct to control obesity, a spate of studies 
in recent years have served to substantiate its efficacy as well as 
its safety for this use (45, 67-69) . In more recent clinical studies, 
comparing the efficacy of PPA in tablet form against a placebo control 
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or against a reference prescri ption appeti te suppressant, PPA was 
significantly superior i n achieving weight loss and equally effective 
as the prescription drugs, but with fewer side-effects reported by the 
PPA groups (70, 71). In a systematic study on mice, Cairns et al. 
(72) investigated the effects of PPA and sympathomimetic agents on 
food consumption . All anorectic agents caused a significant fall in 
food intake during the first hour after ingestion and thereafter there 
was a variable increase in feeding. In animal studies, weight change 
or food consumption is measured against an index of appetite. 
However, many effects of anorexiants, such as sedation, nausea, 
dyskinesia can cause reduced food intake in animals but have no 
relevance to appetite and satiation. In view of known differences in 
disposition of drugs in different species, a dose correlation as found 
in animal studies (73) should be considered a coincidence rather than 
a reflection of similarity. 
In a recent summary Weintraub (1985) (74) reviewed a number of PPA 
clinical trials, published and unpublished. His criticisms went 
chiefly to the designs constructed to show efficacy , and did not cite 
evidence of bias regarding safety data. 
Appetite suppressant products available in the United States include 
Dietac™ (50 mg) Appedrine (25 mg), Dexatrim Extra Strength™ (75 mg) 
and Panamine TM (37.5 mg). The smaller dose products are usually sold 
in immediate release formulations , while those containing higher doses 
are available only as sustained-release preparations . Recommended 
daily dosages vary, but none exceed 75 mg . Package instructions 
usually specify that the products should not be taken for more than 3 
consecutive months . 
Two firms have reached the letter-of-intent stage for development of a 
once-a-ctay nonprescription controlled-release transdermal delivery 
system described as a "molecular sponge" that has the mechanical 
properties of plastic. One of the first ingredients being considered 
for the new delivery system is the diet aid PPA (75). 
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A recent study evaluating the anorectic activity and safety of PPA.HCl 
(25 mg) in the form of liquid drops, concludes that PPA is safe and 
effective as an appetite suppressant in the treatment of exogenous 
obesity (76). For those patients who find it difficult to take 
capsules or tablets, PPA drops may be a comfortable alternative. 
In conclusion, well-conducted clinical studies have repeatedly shown 
PPA to be safe and effective as a nasal decongestant and anorexiant. 
That PPA lacks significant potential for abuse or habituation has been 
demonstrated in a series of animal and human studies (19,77). 
Phenylpropanolamine began to appear in "street stimulants" in the late 
1970' s (78). The street drug "look-alikes" were not controlled by 
prescription, and contained ingredients including' caffeine, ephedrine, 
pseudoephedrine and PPA, alone or in combination. Their sale, 
however, was banned in 1983 in t he United States of America. 
1.5 SIDE EFFECTS OF PHENYPROPANOLAMINE 
In assessing adverse drug reactions, it is often difficult to identify 
the contribution of a specific substance, in a context of drug 
interactions, pre-existing disease conditions, the possibility of 
overdose, and the hazards of accepting patient identification of drugs 
without verification of their presence by analysis of body fluids. 
For many years the medical literature has contained reports of adverse 
reactions to products which contain PPA. The most commonly reported 
reaction is a rise in blood pressure. There is no doubt that PPA in 
sufficiently large doses is capable of both alpha- and beta-agonist 
action, with a potential for causing hypertension, tachycardia, 
headaches, arrhythmias and encephalopathy. 
Evidence from reported cases confirms that ingestion of PPA may 
sometimes be associated with severe blood pressure increases in 
previously normotensive patients (2, 79-81), and in patients with 
special sensitivity to adrenergic pressor agents (82, 83). There is 
also a strong suggestion that a dose-response relationship exists (2, 
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84, 85), with most cases of spontaneous hypertension occurring after 
ingestion of more than 50 mg PPA. Reports on hypertensive episodes, 
however, lose much of their impact, because these are often related to 
concurrently used drugs, diseases and flawed experimental design. 
There have been a number of reports from Australia, Great Britain, 
Sweden and the United states of increases in blood pressure associated 
with PPA consumption. Although most of these cases have occurred 
after ingestion of higher than recommended doses of PPA, there have 
been sporadic reports of increased blood pressure after doses as low 
as 50 mg. The differences between reports of PPA-related hypertensive 
problems from European and Australian centres may be related to the 
pharmacologic effects resulting from the different stereoisomers of 
PPA which are marketed in these areas. 
Additional evidence suggests that PPA-induced hypertension may result 
in cerebrovascular haemorrhage (86-88, 93), myocardial injury (89) and 
cardiac arrhythmias (90-94) . A number of cases of adverse 
cardiovascular events following PPA ingestion have been reported (88, 
93, 95). Some of these patients had taken overdoses of PPA in either 
cough-cold or diet-aid products (93, 95), while other case reports 
failed to specify the exact dose taken (8B). That large doses of a 
sympathomimetic amine can produce hypertension, cardiac tachyarryth-
mias, headaches, encephalopathy, and even acute renal tubular or 
myocardial necrosis, should not be surprising in view of the known 
pharmacologic effects of PPA. Two young men consuming relatively 
large doses of diet-aid products for a period of time developed 
hemiparesis and evidence of cerebral infarction without evidence of 
cerebrovascular disease (96). 
"angiitis" perhaps associated 
The authors speculate 
with vascular spasm had 
that an 
occurred. 
Several adverse reactions were associated with a now unavailable 
version of the Australian product, Trimolets (82, 84, 97). 
Phenylpropanolamine has been implicated in causing injury to the 
myocardium, as described by Pentel et aZ. (89) . The authors reported 
3 cases of increased blood pressure accompanied by rises in the levels 
I; 
I 
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of serum creatine kinase and cardiac-iso-enzymes usually associated 
with myocardial infarction. Two patients had taken excessive doses 
and the third had taken a combination product. Excessive 
catecholamine stimulation in dogs can produce myocardial necrosis, 
which is thought to be an explanation for the repcrted adverse effect. 
Since information is available about undesired cardiovascular 
respcnses and anorexiant doses of PPA animal studies of relative 
pctencies are of little utility. 
In a recent literature search, four published case reports (86, 88, 
96, 98) ci ted a link between the ingestion of a PPA product and 
subsequent occurrence of stroke related symptoms. The relative 
paucity of repcrts linking stroke to PPA is noteworthy; none of these 
repcrts could prove or confirm any association between PPA and intra-
cerebral haemorrhage . Hypertensi ve crises, and intra-cranial 
haemorrhages culminating in death have also been ascribed to PPA (86, 
92, 95, 98). However, the vast majority of clinical situations 
involving look-alike stimulants have been associated with the high-
dose use of combinations of PPA with caffeine and/or ephedrine. 
There have been several case reports of psychiatric disorders related 
to the ingestion of nasal decongestants, anorexiant agents or "look 
alikes" containing PPA (alone or in combination) (99-109). Symptoms 
of psychotic episodes included auditory and visual hallucinations, 
confusion, disorientation, delusions, aggressive behaviour, 
impulsivity, mania, paranoia, agitation, anxiety, bizarre behaviour 
and depression. The mcst consistent characteristic shared by many of 
these patients is a pcsitive psychiatric history. Phenylpropanolamine 
products probably exacerbated trait-related symptoms in patients with 
pcsitive 
patients 
histories and caused 
with no psychiatric 
acute drug-induced brain syndromes in 
his tory. All cases required medical 
attention, but in cases where 
especially those containing 
hospitalization was required. 
combination 
caffeine, it 
products were 
was observed 
taken, 
that 
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Dietz (110) in 1981 reported seven cases, all emergency admissions to 
hospital, of severe side-effects occurring within a couple of hours of 
taking a single dose of a PPA-containing preparation (50 mg or 75 mg). 
The patients exhibited the same type of mental disturbance normally 
associated with the ingestion of amphetamine. Acute central nervous 
system effects also included hyperventilation, probably the result of 
stimulation of the medullary respiratory centre. Although this 
explanation is speculative, the reports indicate that patients with 
past histories of major or minor affective disorders are at special 
risk for developing PPA-related psychiatric symptoms. 
Although PPA has been on the market for over 40 years, it is only 
recently that the question has arisen as to whether it might produce 
amphetamine-like mood and behavioural effects; effects which might 
lead to its abuse. Independent animal experimental studies have 
indicated that the profile of mocd/behavioural effects of PPA is 
distinct from that of amphetamine (Ill). Overall data indicate that 
PPA is a compound of low abuse liability (77, 111-113), which does not 
produce an amphetamine-like profile of effects. 
In massive overdose in association with other drugs, PPA, by causing 
vasoconstriction may contribute to acute renal failure (114, 115). 
Three case reports describe renal damage. One patient experienCed 
acute tubular necrosis whilst another, elevated serum myoglobin (116), 
where the acute renal failure may have been related to rhabdomyolysis. 
Caperton (117) reported 3 young women with Significant complications 
of Raynaud's phenomenon which cleared when they discontinUed the use 
of PPA in either cough-cold or diet remedies. He speculated, however, 
that caffeine may have enhanced possible vasospastic effects . 
Phenylpropanolamine 
some people. A 
has been known to cause blurring of 
recent report (118) suggests that 
eyesight 
PPA was 
in 
the 
precipitating factor in causing bilateral acute angle closure glaucoma 
through pupil dilatation in a 37-year old hypermetropic woman. 
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1.6 INTERACTIONS OF PHENYLPROPANOLAMINE WITH OTHER DRUGS 
A major question concerning any active or widely consumed agent is the 
effect of its use in the presence of disease or other drugs. Many 
reports of adverse effects following the use of PPA, refer to 
situations where multiple drugs including PPA were used. 
Phenylpropanolamine is subject to the same type of drug interaction as 
other sympathomimetic amines and, obviously, acceptable doses of other 
sympathomimetic drugs added to PPA can become unacceptable by 
summation of effects (119). One of the earliest reported interactions 
was between monamine oxidase inhibi tors (MAOI) and the sympathomimetic 
amines (81). Several cardiovascular case reports of elevated blood 
pressure following normal doses of PPA occurred in patients 
concurrently consuming monamine oxidase inhibitors (MAOI) (120- 122). 
Concomitant use of an indirect-acting sympathomimetic (IASM) in a 
patient receiving a MAOI is likely to result in an excessively high 
blood pressure, severe headache, cardiac arrhythmias, chest pain, 
circulatory failure, and death has occurred. Administration of MAOI 
will increase levels of noradrenaline (NA) at its storage site because 
production of NA is continued without the usual rate of destruction. 
IASM will release this increased amount of NA from its storage site to 
act at receptor sites causing a hypertensive crisis (123). A 
controlled trial was carried out in volunteers to study MAOI-PPA 
interaction (81). Careful 
prescriptions have, however, 
sometimes fatal, interaction. 
warning instructions accompanying 
diminished the likelihood of 
MAOI 
this, 
Beta-blockers may occasionally be responsible for severe hypertension 
in patients taking large doses of PPA (124). Phenylpropanolamine 
provoked hypertension in a patient on oxprenolol (125). It was 
proposed that these interactions result from unopposed adrenergic 
stimulation in the presence of beta-blockade (126). The mechanism was, 
however, not supported in a recent study of infused phenylephrine in 
patients on beta-blockers for hypertension (127). 
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The antihypertensive action of guanethidine may be blocked by PPA 
(128), and sensitization to sympathomimetic drugs may be induced 
fol l owing the use of bethanidine whose action is analogous to 
guanet hidine in hypertensive crisis (129, 130) . It was proposed that 
PPA and the antihypertensive agents, including debrisoquine, compete 
for neural uptake. 
A patient on methyldopa and oxprenolol had a 
after taking two tablets containing PPA (125). 
hypertensive episode 
It is believed that 
beta-blockers permitted the vasoconstrictive effects of PPA to occur, 
while vasoductor effects were blocked leading to marked hypertension . 
One case was reported in which the combination of PPA and cheese, 
hypertensive 
an additive 
containing tyramine was considered to be the cause of a 
episode, which could have been due to tyramine having 
effect on the action of sympathomimetic amines (131). In addition, 
might act in red wines and pickled foodstuffs rich in tyramine 
conjunction with PPA to cause an adverse cardiovascular event. 
Chouinard et aL (92) proposed that an unexplained death oc=ring in 
a female on thioridazine was due to a ventricular arrhythmia caused by 
the reaction of a phenothiazine and PPA. However, this association 
may have been coincidental, since the patient had shown T-wave 
abnormalities while on chlorpromazine . 
More subtle drug interactions may also oc=, such as those alleged 
with indomethacin or other cyclooxygenase inhibitors such as aspirin, 
that influence the prostaglandin system (132) by reducing the 
prostaglandin-controlled negative feedback of catecholamine release at 
sympathetic nerve endings and reducing the amount of vasodilator 
prostaglandins available. 
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In one report, two women currently taking oral contraceptives (ee) 
experi enced hypertensive episodes following PPA ingestion (97), and a 
second report also attributed hypertension to ee/PPA interaction 
(133). Factors that can cause hypertension from OC use can also 
increase sensitivity to the hypertensive effects of PPA. 
Rumack et aL. (130) report CNS stimulation and elevated blood pressure 
in a patient who consumed Ornade (PPA and anticholinergics) and 
imipramine in PPA's presence. The authors felt that this case 
represented cumulative overdosage of anticholinergic drugs. 
Individuals who are sensitive to or who consume large quantities of 
coffee may appear to be at greater risk of adverse psychiatric 
reactions upon administration of PPA, since both caffeine and PPA are 
sympathomimetics with different, but synergistic mechanisms of action 
(134) . These combinations may also have greater potential to include 
cardiac arrhythmias and cardiac pathophysiology (98) as well as 
cardiovascular accident (96). Recently, Schlemmer et aL. (134) noted 
that the lethal doses of PPA in rats is decreased when combined with 
caffeine due to potential of adverse effects and could have 
contributed to stroke morbidity and mortality in this experiment. 
antagonize the effect of phenylalkylamines. There Phenothiazines may 
is evidence that the administration of 
sensitize the myocardium to the potential 
arrhythmias (128). 
general anaesthetics may 
for PPA-induced cardiac 
1 . 7 CONTRA INDICATIONS OF PHENYLPROPANOLAMINE 
Phenylpropanolamine is contraindicated in pregnancy as it could affect 
the foetus in pregnant mothers indirectly through effects on uterine 
blood flow or uterine contractility during labour (135). Drugs 
studied by Heinone et aL. (136) with alpha-adrenergic agonist activity 
were associated with increased risk of malformations. 
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Since women may be most susceptible to major affective disorders 
during the postpartum period, expectant and postpartum mothers should 
be advised against taking any sympathomimetic drugs, including PPA 
(137). Two women whose cases were reviewed took diet aids 
pregnancy and experienced psychotic episodes (138, 139). 
however been found that platelet MAO activity is reduced 
pregnancy (140). 
Phenylpropanolamine is contraindicated in patients that 
familial history of psychosis. SUsceptible individuals may 
during 
It has 
during 
have a 
develop 
psychotic reactions following the use of OTC diet-aids containing PPA 
(138). Conditions that impair the balance and control of the 
sympathetic nervous system can increase susceptibility to the 
hypertensive effects of PPA. Autonomic dysfunction has been reported 
to be one such condition (141). This is an idiosyncratic response to 
PPA. Goldin et aZ. (142) studied the variation in platelet MAO in 309 
individuals and found that genetically determined MAO activity, in 
people with naturally low levels of MAO, can also modify sensitivity 
to the blocd pressure raising effects of PPA. 
Phenylpropanolamine should not be used in hyperthyroid, depressed or 
diabetic patients (143) and is contraindicated in hypertensive and 
cardiac patients (144). 
1. 8 ISOMERS OF PHENYLPROPANOLAMINE 
Phenylpropanolamine (PPA) , chemically known as 0, l-norephedrine, is 
often confused with its various isomers. Confusion about and a 
nonchalant approach to the distinctions between these products emerged 
early in their history. Part of the confusion in many reports is the 
difficulty encountered because of the presumptive, non-probative 
nature of urine drug screening tests using immunoassays, which depend 
on a relatively nonspecific antibody. Most of the phenyl isopropyl-
amines will cross react and a "positive" may reflect the presence of a 
norephedrine, amphetamine or ephedrine isomer; or even other similar 
compounds such as phentermine or diethylpropion (145). 
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FIGURE 1.9 Chiral (asymmetrical) carbons. 
* = asymmetrical carbons 
Simplified line drawings (Fig. 1.9) reveal that both the alpha- and 
beta-carbons are chiral. Therefore PPA has four spatial arrangements 
and four distinct stereoisomers. Any of these forms or any mixtures 
of them in pharmaceutical preparations might be called 
"phenylpropanolamine" • 
The racemic product most used clinically is (±) norephedrine and is 
called phenylpropanolamine. Synthetic reactions generally produce 
racemic mixtures, equal parts of (+) and (-) isomers. Marketed U.S. 
versions contain a mixture of products A and B in Fig. 1.10. These 
distinctions are important, because enantiomorphs and diastereomers 
have different pharmacodynamic properties and effects, and these 
formulations are not interchangeable despite having been frequently 
confused. 
A recent review of chiral drug action in the rat makes this very clear 
(146). Results suggested that R-norephedrine and d, R-norephedrine are 
capable of directly activating vasopressor alpha adrenoceptors, while 
d-norephedrine had a non-significant effect. It is clear that 
differences in cardiovascular activity are observed in these 
structurally similar compounds. Careful attention must thus be given 
to the proper identification and reporting of these compounds 
describing their actions and adverse drug reactions because of their 
significantly different pharmacological properties (147). 
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FIGURE 1.10 Configurational characteristics of norephedrine isomers. 
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Reproduced from Morgan (11). 
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The analytical and preparative resolution of the enantiomers of 
norephedrine has received a great deal of attention. Analytical 
methods using indirect (diastereomers) and direct (chiral stationary 
phases) approaches have been reported (148-151), and preparative 
resolution of norephedrine have been reported by several investigators 
(152, 153). A direct enantiomeric high-performance liquid chromatogra-
phic (HPLC) resolution of norephedrine has recently been developed by 
Wainer et aZ . (154). 
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OlAPTER 2 
ANALYTICAL METHODS 
2.1 INTRODUCTION 
The technique of high-performance liquid chromatography (HPLC) , 
variously called high speed and high pressure liquid chromatography 
has made a significant contribution to pharmaceutical, biochemical and 
clinical analysis and is an ideal complementary technique to gas-
liquid chromatography. The earliest example of a liquid 
chromatographic separation is credited to the Russian botanist Tswett 
who, in 1903, separated plant pigments by adsorption chromatography 
(156) . In 1941, Martin and Synge described the discovery of liquid-
liquid partition chromatography (157) and laid the foundation of high-
performance liquid chromatography (HPLC) , and introduced the concept 
of the "height equivalent to a theoretical plate" (HETP), which has 
been adopted as a measure of chromatographic efficiency. Modern HPLC 
is characterized by short separation times, good sensitivity, 
precision, and is usually associated with high efficiency and 
continuous detection of the eluted components (158), rendering it a 
powerful technique in all facets of analytical chemistry and offers 
many advantages in drug analysis . Liquid chromatography signifies 
procedures for the separation of substances that are based on 
differences in rates of migration arising from different distribution 
ratios between a flowing mobile phase (liquid) and a stationary phase 
(solid) • 
The early columns were essentially similar to those described by 
Tswett and were based on adsorption chromatography . The breakthrough 
in HPLC came with the introduction of packing materials in which a 
stationary phase was covalently linked to silica supports. This 
resulted in the introduction of the so-called reverse phase system. 
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A silica suppor t is trea t ed with an organochlorosilane or similar 
reagent to make a stationary phase of any desired polarity. 
-SiOH + Cl-SiR3 ~ - SiO-SiR3 
The most popular supports are those where one of the groups is 
octadecyl or octyl. They are suitable for all applications where it 
is important to have no residual interaction with the silicon atoms 
which are sterically shielded. Apart from the robustness of the new 
bonded stationary phases, the new columns were suited to drug analysis 
in biological fluids. 
lipophilic components 
First, the drug is likely to be one of the most 
of the sample and hence is retained on the 
column longer than most endogenous compounds. Second, the reversed 
phase mode means that the mobile phase is aqueous, and this is a more 
appropriate medium for the analysis of an aqueous sample. The use of 
a partition system rather than an adsorption system gives sharper 
peaks with less tailing (159). 
2.2 ANALYSIS OF PHENYLPROPANOLAMINE RAW MATERIAL AND DOSAGE FORMS 
2. 2 . 1 Ultraviolet Spectrophotometric Analysis 
Periodate oxidation of PPA.HCl has been used where the sample to be 
determined is placed in a separatory funnel with NaHC03 and NaI04 . The 
solution is extracted with hexane, filtered and the absorbance 
determined at 242 nm using hexane as the reference solution. The 
amount of the oxidation product of PPA.HCl is determined by comparison 
of the sample absorbance against the absorbance of a PPA.HCl reference 
standard treated in the same manner (160) . Other organic solvents 
such as ether (40) and chloroform (161) have also been used for the 
extraction of the derivative. Wallace (162) used alkaline periodate 
oxidation to form benzaldehyde which was subsequently converted to the 
semicarbazone derivative, thereby enhancing the sensitivity and 
specificity of the procedure. The drug has also been determined after 
alkaline extraction into an organic solvent followed by back-
extraction under aqueous acidic conditions (163). 
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2.2.2 Colorimetric Analvsis 
Phenylpropanolamine hydrochloride can be reacted with ninhydrin in a 
citrate buffer at elevated temperatures and determined colorimetri-
cally at 570 nm. This reaction has been applied to the determination 
of PPA.HCl in a multicomponent mixture by an automated system which, 
after phase separation, utilizes the stream-splitting technique to 
divide the chloroform stream into segments (164). An ion-pair 
extraction technique using an acidic dye, bromothymol blue, has been 
utilized and the resulting chloroform extract determined at 420 nm 
(165) . 
2.2.3 Spectrofluorometric Analysis 
Phenylpropanolamine hydrochloride has been determined by measuring its 
fluorescamine derivative, 4-phenylspiro(furan-2(3H) ,1 '-phthal-an)-3 , 
3'-dione at 480 nm using an excitation wavelength of 398 nm (166). The 
reaction favours a pH of 9 for optimal reactivity (167, 168). 
2.2.4 Titrimetric Analysis 
After extraction of PPA.HCl from an alkaline aqueous solution with 
chloroform, 
with 
shaking with saturated NaCl solution and back-extracting 
NaOH 
2.2.5 
an excess of H2S04 , the excess acid is t itrated with a 
solution using methyl red as indicator (169). 
Raman Spectroscopic Analysis 
standard 
Both solution and solid samples of PPA.HCl in a multicomponent mixture 
have been determined quantitatively by Raman Spectroscopy (170), with-
out prior separation. A survey scan of PPA.HCl is shown in Fig. 2.1. 
FIGURE 2.1 SUrvey scan of phenylpropanolamine hydrochloride 
Delta Wavenumber d, cmwj 
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2.2.6 Chromatographic Analysis 
2.2.6.1 Column Chromatography 
A weakly basic anion exchange resin, Amberlite IR-45 , was found to be 
suitable for the separation of PPA.HCl from various dosage forms and 
yielded a 99.6% recovery of the drug which was then determined 
titrimetrically (171). Being a nitrogenous base, the drug is retained 
on a sulphonated polystyrene cation exchange resin. Determination is 
then effected by measuring the ultraviolet absorbance after elution 
with HCl (172, 173). The drug has also been determined by mixing with 
NH4COH, eluting with chloroform from a Celite column and measuring the 
absorbance at 258.5 nm (174). 
Separation of PPA.HCl from mixtures of drugs in various dosage forms 
has also been described (175). The method involves the retention of 
PPA on the first of four Celite columns followed by elution, addition 
of NaOH, extraction of the free base with chloroform, back-extraction 
using H2S04 and subsequent determination at 257 nm using H2S04 as the 
reference solution. An on-column periodate oxidation of PPA to 
benzaldehyde has also been described and the derivative determined at 
267 nm (176). 
2.2.6.2 Paper Chromatography 
A descending paper chromatographic technique using Whatman No. 1 paper 
has been reported. The solvent system consisted of a 1:1 mixture of 
butanol (saturated with 1M HC1) and methanol. After spraying with 
Dragendorff's reagent, the resulting orange-red spots were quantita-
tively determined by photoelectric densitometry (177). 
2.2.6.3 Thin Layer Chromatography 
A number of thin layer chromatographic systems have been described for 
PPA.HCl and these are listed in Table 2.1. Phenylpropanolamine is 
detected by spraying with reagents to form a coloured or fluorescent 
spot, or by overspotting the drug with a derivatizing agent. These 
procedures are necessary as PPA has a poor inherent ultraviolet 
absorptivity and consequently is difficult to detect directly. 
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TABLE 2.1 Thin Layer Chromatograph1c s ystems f or Phenylpropanolamine 
Solvent System 
Chloroform layer from a 
mixture of chloroform/acetic 
acid/methanol/water 
185 , 20 : 8 , 20) 
Not reporte::1 
Benzene/ethyl acetate 
170 , 30) 
Benzene/ethyl acetate 
(30 : 70) 
Hexane/ethyl acetate 
ISO , SO) 
Hexane/ethyl acetate 
130 , 70) 
Ethyl acetate/methanol/ 
formic acid 
169 , 30 : 1) 
n-butanol/acetic acid/ 
water (4 : 1 : 5) 
Heptane/methanol (60 40) 
Benzene/methanol (83 l7) 
Benzene/acetone /methanol/ 
dioxane (40 : 40 : 4 : 5) 
Ethyl acetate/methanol/ 
water/ammonia {85:l0:3:11 
Ol.lorofonn/methanol (4: l) 
Ollorofonn/methanol (4:1) 
Msorbant 
Silica Gel G 
(r254) (60 
Silica Gel G 
IF254) 160 ) 
Gelman ITLC 
fibre SAF 
HPTI...C Silica 
Gel 60 
OC-cellulose 
HPIt..C Silica 
Gel 60 
Silica Gel 
Silica Gel G 
Silica Gel G 
IHF254) 
Detection 
Sprayed with 0.3% ~nitroaliline plus 
5% scxtium nitrite, heate::1 at 70·C for 
15 minutes then sprayed wi th 20% Na CO 
2 3 
Sprayed with b.lffer (pH 9.3), over-
sprayed with fluorescamine/acetone 
solution and resprayed: with hlffer 
p-ni trobenzoyl chloride applied and 
heated. (lOO·C) 
Dipped into o-{:hthal.aldehyde solution 
followed by 20% polyethylene glycol 
in methanol 
Ninhj<irin reagent 
rluorescamine solution 
Sprayed: with 0.3% ninhydrin acid, 
heated at 100 C for 5 minutes, 
sprayed iodoplatinate reagent then p-
nitroaniline reagent, heavily sprayed 
with 25% alcoholic NaOH solution 
Icdine vapour 
Icxline vapour 
Rf Ref 
""t 161 
reported 
0.50 167 
0.79 178 
0.90 
0.76 
0.90 
0.40 179 
Not 180 
reported 
0.45 181 
0.37 
0.28 
Not 182 
reported 
0. 17 183 
0. 14 
33 
2.2.6.4 Gas Chromatography 
Gas chromatography has been extensively used for determining PPA in 
pharmaceutical preparations and, to a lesser extent, for the 
determination of the drug in biological fluids. The drug has been 
chromatographed directly without derivitization and also as the silyl, 
pentafluorophenyloxazolidine, acetone, butanone, trifluoroacetyltri-
methylsilyl, haptafluorobutyryl and the 2, 6-dinitro-4-trifluoro-
methylbenzenesulphonic acid derivatives. 
conditions are listed in Table 2.2. 
The gas chromatographic 
TABLE 2.2 Gas Chromatographic Systems for Phenylpro~olamine 
Column carrier Column • Detector Injected Dru; T 
source Gas Temp('cl gas 
Tablets, 2.0m x 4.0mm (i .d.l glass He 200 2.BO FIn SHyl 
syrup 0.1% silicone oil (DC-7l01 on derivative 
60-80 mesh dimethyldichlorosilane 
treated glass beads 
syrup 2.4m x 3.2rrm (o.d.l Pyrex glass He lBO LBO FID A'lenylprop-
2% SE-30 on Chromosorb W (HPI anolarnine 
Tablets 1.8m x 4rrm glass He 230 . 0.B5 FID Phenylprop-
3% OV-17 on Gas Olrcxn Q anclamine 
LBm x 6.4cM1 (Ld.) glass N 220 2.40 FIn Phenylpr~ Tablets, 
2 
capsules , 1% HI-EIT-8BP an:! 10% SE52 on anolamine 
liquids Gas crom Q h}drochloride 
4% HI-EFF-SSP on Gas Olrom Q 220 1.25 
Raw 1.4m x 4rrrn <i.d.l glass He Proqr- 2B.00 FlO Trifluoroacet-
material 3% Poly A 103 on Gas Olrom Q 
""""" 
yltrimethylsi-
70-250 Iyl derivative 
Raw 1.1m x 2.5mm glass N lBO 2.55 FID Phenylprop-
2 
material 18.8% Apiezon N on Diatoport S 13B 2. 77 anolamine 
101 3.18 
Raw l.B-2 . 4m x 3am (Ld . ) glass Ar 104 9.10 Phenylprop-
material 1.15% SE-30 on Gas Chrom P ano1amine 
13.40 Acetone 
derivative 
123.50 a>tanone 
derivative 
Ref 
lB4 
lB5 
186 
1B7 
1BB 
lB9 
150 
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Ra .... l.8m x 2:l'nI (i.d.) glass N 250 1.38 EC .2, 6-dlP.l tre-
2 
mater la! 3% OV-l on sq: . .elr:oport 4.-tr!.fluoro-
O.3m x 2.'MI ( , ,1,l glass 220 1.)8 methytbenzene 
3% SP-22S0 on Supelcoport 230 0.98 soip-!ortic acid 
deri'Jat.lve 
Raw 1.2m x 4mm (i.d.) glass N 185 1.60 fIO Phenylprop-
2 
material 2% 5£-30 and 2% Carb::lwax 20M anclamine 
on Anachrom ABS hydrochloride 
Raw 1. 8m x 2rr:m (l..d. ) glass He Prcqr- 8.36 Nitrogen Phenyl prop-
material 3% OY-17 en AnachrO'll AES ..",.,,; anolamine 
100-250 
Bio- 1m x 6Irm (o.d.) qlass N fIO Phenylprop-
2 
logical 7 .5% Carl:;::owax 20M on Chromosorb W 165 4.10 anolamine 
material .2.0% Carbowax 20M on Chr~orb G 120 1.10 
capsules 1.8rn x 2JTrn (Ld.) glass N 290 7.00 fIO Acetyl 
2 
8% 0'1-101 on O\:"orrosorh W- HP derivative 
capsules, 183an x 21m> (Ld.) glass He 190 Not fID Phenylprop-
suspen- 3% OY-225 on Gas Olrom Q re!X>!'"ted anolamine 
sians 
2.2.6 . 5 High-Performance Liquid Chromatography 
Methods and the associated conditions for the high performance liquid 
chromatographic determination of PPA alone and in pharmaceutical 
formulations are listed in Table 2.3. Relatively little has been 
published on the HPLC analysis of PPA in biological fluids (see 
Section 3.11. 
191 
192 
193 
183 
194 
195 
TABLE 2.3 
Drug 
Source 
Tablets, 
syrup 
syrup 
Tablets, 
capsules, 
liquid 
Tablets 
liquid 
Tablets 
Spray 
syrup 
J...iquid 
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High Performance Liquid Chromatographic Systems for Phenylpropanolamine. 
Column l-bbile Phase Flow rate R (mins) 
T 
(ml/min) 
Detect~on 
O.5m x 2.1rrm (i.d.) O.02M (NH ) HPO in 36% 1.0 2.2 Stated 00-
4 2 4 
Co Pon t Zipax sex dioxane/water 
O.3m x 4mm (i.d.) O.OSH KH PO in water cont- 2.0 
2 4 
Waters]J Bondapak C aining 13% (v/v) methanol 
18 
O.3m x 4mm (i.d.) water/methanol/acetic acid 2.0 
Wa ters uBondapak (55:44:1) containing O.DOSM 
>"enyl sodium heptane sulphonate 
O.3m x 4mm (i.d.) 13% acetonitrile in water Gradient 
Waters ]J Bondapak CN containing 1.8% acetic acid elution 
D.2Smx4.6rrm (i.d.) 
Whatman Partisil-
10-<;rls 
D.3m X 3.9Jr.m (i.d.) 
Waters IJEondapak 
water ]J.8ondapak C 
18 
13% acetonitrile in water 
containin;1 1.8% acetic acid 
and O. DOSH scx:lium heptane 
sulphonate 
2.B5 x 10-3M ethylenediamine 
buffer (pH 7.441/acetonitrile 
(1:11 
Methanol/water (60: 40 1 wi th 
O. 004M sodium heptane sulph-
onate and 1% acetic acid 
0.15m x 4.6 rrm (i.d.l O.lM KH PO in 10% aqueous 
2 4 
Spherisorb SSw ethanol 
0.3m x 4mm (i.d.) Methanol/water (50:50) with 
Waters uBondapak: C PIC re3I:Jeo t B- 7 
18 
D.25m x 4.6rrrn (i.d.) hexanesulphonic acid/acetic 
Zorbax 'Il1S column acid/water/methanol 
(0.1:1:68.9:301 
0.3m x 4rrrn (i.d.) methanol/water/tetrahydrofuran 
Waters ]JEondapak C 80% (Xlosphoric acid (67:29:4: 
18 
D.l) with S.Bg dioctylsulfo-
succinate adjusted to pH 3.8 
3.8 
1.0 
1.0 
1.0 
2.5 
1.3 
lyas u.v. 
3.0 254"", 
not 254"", 
stated 
7.5 254"", 
8.8 
3.3 216.Snm 
7.4 2S4nm 
11.7 
5.4 198nm 
3.1 254nm 
2.4 254nm 
7.1 254nm 
Ref 
196 
197 
198 
199 
200 
201 
202 
203 
204 
205 
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Ta.l:;~ets. O.25m x 4mm ( i.d.) Methanol / water ( 35:62.S) with 
ca~ules, Waters v Boodapak C 2.5ml PIC reagent B-5 
18 
liquid O.25m x 4.61T'lTl ( i-d.) Methanol/'Nater (30:67.5 ) with 
Whatman Partisil- 2.5ml PIC reagent B-5 
10 
C8 
Tablet, Brrm x lOan Methanol/water 
syrup Radial-PAK a.alM (NH 1 HPO 
4 2 4 
Forasil Silica 175:251 
Tablets, 300m x 4mm (i.d,) Aqueous KH PO 
2 4 
liquids Waters ).I B:mdapak. blffer, 0.02M IpH 2.61 with 
phenyl 85% aqueous solution phos-
p,oric acid (0.4 mL/L) 
Capsules, 2Scm x 4.6 rtIll ( i.d . l Methanol/Acetonitrile/pen-
Tablets 
Tablets, 
capsules 
Whatman Partisil-
10 C 
8 
2Son x •. 6mm (Ld.) 
hbatman Partisil-
PXS 005-2 10 m 
tanesulfonic acid sod. O.D05M 
in glacial acetic acid (1.7%) 
Acetonitrile/water (30:70) 
2.0 
2.0 
4.0 
2.5 
2.0 
1.7 
• Injected as the sodium metaperiodate derivative in alkaline medium 
5. I 254nm 
5.8 
2.5 254nm 
4 . 0 256"" 
4.9 254nm 
8.3 254nm 
2 . 3 DEVELOPMENT OF AN HPLC METHOD FOR THE DETERMINATION OF 
PHENYLPROPANOLAMINE 
INTRODUCI'ION 
An adaptation of a published high-performance liquid chromatography 
(HPLC) assay for phenylpropanolamine was used to examine PPA pharma-
cokinetics. Because this particular analytical method for serum and 
urine PPA determinations has not previously been reported, the method 
validation data are also presented (See Chapter 3). 
A relatively new liquid chromatography (LC) variation, paired-ion 
chromatography (PIC), was developed to solve the analytical problems 
traditionally associated with samples containing ionic samples thereby 
considerably increasing retention for these compounds. The resulting 
species can be easily chromatographed by a reverse-phase LC system. 
206 
207 
208 
209 
210 
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The following equilibri a explain this phenomenon (203) . 
I 
c. non-ionic non -ionic 
E form of form of 
~ 
~ sample counter-ion 
>-
JlK J J~ K2 en c 
0 
C ionic ion ic KJ 
~ form of + form of 
----"-
samplel 
" 
-.;-- counter-ion c sample counter-
~ 
c. ion pair 
~ 
0 
For basic samples, alkyl sulfonates (pKa<l) are used . The pKa of an 
alkyl sulfonic acid counter-ion should be less than pH 3 for ion pair 
formation with bases so that the counter-ion will be in an ionic form 
at any pH required to drive the sample to its ionic form and hence K2 
will be negligible. Minimum sample preparation and extended column 
lifetimes characterize permanently bonded reverse-phase LC systems for 
quantitative analysis. Variables include sol vent polarity, pH, type 
and concentration of counter-ion and, to an extent, the stationary 
phase. The variables give additional possibilities for optimizing 
selectivity. The method is a modification of the HPLC method reported 
by Dowse et a2. (211). 
2.3.1 Experimental 
2.3 . 1.1 Reagents 
All chemicals and reagents used were of at least analytical grade and 
used without further purification. 
fonic acidl was used as received. 
The sodium salt of I-heptanesul-
The acetonitrile2 was distilled-in-
glass grade. The HPLC water used in the mobile phase was purified 
through a Milli-Q purification system (Waters Associates). Phenylpro-
panolamine hydrochloride 3 , ephedrine hydrochloride 4 , hydrochloric 
aCidS, sodium salts of l-octanesulfonic acid and l-dodecanesulfonic 
acid6 were obtained commercially. 
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The mobile phases were filtered through 0,6 ~m cel lulose acetate 
filters 6 and deaerated under vacuum. 
1. Sigma Chemical Co ., St Louis, USA. 
2 . Burdick and Jackson Lab . Inc., Muskegon, Mich . , USA . 
3. Aldrich Chemical Co., Milwaukee, Wis., USA . 
4. Holpro Analytics (pty) Ltd., Johannesburg, South Africa. 
5. BDH Chemicals Ltd., Poole, England. 
6. Type BD, Millipore Corp., Bedford, Mass., USA. 
Solutions of drug samples were prepared in A-grade volumetric flasks 
by the addition of HPLC grade water . 
2.3.1.2 The High- Performance Liquid Chromatographic Systems 
SYSTEM A 
The chromatographic system consisted of an M45 solvent delivery system 
(Waters Associates), a model U6KB injector (Waters Associates), a 
model 1238 LKB fixed wavelength Uvicord S UV detector and a model 560 
strip-chart recorder (Perkin-Elmer) . Separation was achieved on a 25 
cm x 3 . 9 mm i .d. Techsil C18 (10 ~m) reverse phase column (HPLC 
Technology). Temperature was ambient. 
SYSTEM B 
This consisted of M45 solvent delivery system (Waters Associates) and 
a model U6K injector (Waters Associates) . The effluent from a 25 em x 
3.9 mm i .d . Techsil C18 (10 ~m) reverse phase column (HPLC Technology) 
was monitored with a 1040A Diode-Array detector (Hewlett Packard) to 
which was attached a model RIOOA strip-chart recorder (Perkin-Elmer) . 
The temperature of the column was controlled by an LC-22 temperature 
controller and column heater (Bioanalytical Systems Inc . ). 
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SYSTEM C 
This system incorporated an M45 solvent delivery system (Waters 
Associates), a WISP model 7108 automatic sample injector (Waters 
Associates), a variable wavelength LC3-UV detector (Pye Unicam) and a 
model 561 strip-chart recorder (Perkin Elmer). A model LC-22 tempera-
ture controller (Bioanalytical Systems Inc.) was used to maintain the 
Techsil C18 (10 ~m) reverse phase column (HPLC Technology) at the 
desired temperature. A Techsil 25 em x 3.9 mm i.d. C18 reverse phase 
(5 ~m) column (HPLC Technology) was used in the later stages of 
development. 
SYSTEM D 
The final HPLC system used throughout analysis of biological samples 
consisted of 
1) Model SP8780XR microprocessor-controlled modular automatic 
liquid sampling unit (Spectra-Physics). 
2) Model 114M solvent delivery system (Beckman Instruments Inc.). 
3) Model SP4290 Integrator (Spectra-Physics). 
4) Model SP8480XR UV-Visible scanning detector (Spectra-Physics). 
Separation was achieved on a 25 em x 3.9 mm i.d. Techsil C18 (5 ~m) 
reverse phase column (HPLC Technology) and a model LC-22 temperature 
controller (Bioanalytical Systems Inc.) maintained the column at the 
desired temperature. 
2.3.1.3 Ultraviolet (UV) Detectors 
The liquid chromatography detector is the key to obtaining qualitative 
and quantitative information abcut the analytes separated. The UV 
absorption detector which is relatively insensitive to temperature and 
flow variations is the most widely used detector in HPLC owing to its 
high stability, sensitivity and linear range. 
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1) The UV-Visible Scanning detector SP8480XR (spectra-Physics) 
This detector is characterized by its high sensitivity, low 
noise, and reliability. It is ideally suited for a variety of 
applications and can be used over a broad range of conditions, 
all a result of the combination of a wide dynamic range and high-
speed detector electronics. The detector is fitted with a 12 ~L 
volume flow cell, and comes with software for the SP4290 
integrator. This detector was operated at 210 nm at the maximum 
sensitivity setting of 0.001 absorbance units full scale (AUFS). 
2) The 1040A Diode-Array Detector (Hewlett Packard) 
This detector which has a standard 3.5 ~L flow cell was 
controlled and assisted by the following components: An HP 85 
personal computer, an HP 2191 dual disc drive and an HP 7470 X-Y 
plotter. It has the facilities of a diode-array detector with the 
additional advantage of a data storage facility which allows 
post-run manipulation of chromatograms as well as the ability to 
monitor and permanently store the results of chromatograms at 
eight different wavelengths. The detector was usually set to 
simultaneously monitor four different wavelengths; 205, 210, 215 
and 220 nm with the sensitivity adjusted to give the best signal/ 
noise ratio. It may be used for the scanning of peaks and genera-
tion of 3-dimensional plots of absorption vs time vs wavelength. 
3) The LC3 variable wavelength ultraviolet detector(Pye Unicam) 
The Pye Unicam LC3 UV detector is a reference compensated 
variable 
designed 
instrument 
wavelength single beam ultraviolet absorbance monitor, 
for monitoring the eluent from the HPLC column. The 
reads out in absorbance over the wavelength range 190 
to 380 nm. The variable wavelength facility is useful for 
optimizing the instrument sensitivity. Additional facilities 
included are recorder zero and adjustment for maximum energy 
throughput. The detector has an 8 ~L volume flow cell. After 
injecting aqueous samples of PPA.HCl at wavelengths ranging from 
200 nm to 250 nm, it was found that 210 nm yielded the most 
stable baseline with a satisfactory response. 
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2.3.1.4 Columns and Mobile Phases 
(i) ~18 Reverse Phase Column (10 ~m) 
This, the first column used, was a 30 cm x 4 mm i.d. steel 
column packed with Techsil 10 ~m octadecylsilane (CIS) material 
(HPLC Technology) by the method described in section 2.3 . S. 
Preliminary studies were performed on this column. These 
included the effect of ion-pair reagent strength and mobile 
phase composition on the retention of PPA. The choice of the 
optimum mobile phase and operating conditions for this column 
are summarized as systems 1 and 2 (Table 2.4). 
(ii) ~18 Reverse Phase Column (5 ~m) 
A 30 cm x 4 mm i.d. column was packed with Techsil 5 ~m CIS 
material. The optimum operating conditions for this column are 
summarized in systems 3 and 4 (Table 2.4). When the formation 
of a top-end void became evident it was repaired by application 
of a paste of Techsil 5 ~m CIS in methanol . 
(iii) ~18 Reverse Phase High Speed Column (3 ~m) 
This commercially available high speed column was only 7.5 cm 
long with an internal diameter of 4.6 mm. It was packed with 3 
~m CIS material (HPLC Technology). Numerous mobile phases, 
differing in organic/aqueous phase ratios and ion-pair reagent 
strength operated at flow rates between 1.0 and 2.5 mL/min were 
tested to obtain a suitable separation between PPA and the 
internal standard. The best combination of these variables is 
reported in system 5 (Table 2.4). 
2.3.1.5 Guard Columns 
The use of a guard column packed with 20-40 micron LC-lS pellicular 
packing (supelco Inc., Pennsylvania) was initiated at various stages 
during development as biological samples were being injected directly 
onto the column. The guard column serves to trap particulate matter 
and high molecular weight constituents such as protein, thereby 
prolonging the life of the analytical column. The 5 ~m analytical 
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column was protected by a 10 Jlm C18 cartridge guard column (HPLC 
Technology Ltd., Part no. 10C18) housed within a cartridge holder 
(HPLC Technology Ltd., Part no. GTL-EL3101) so that the non-eluting 
materials in the samples injected were retained. The guard column 
also absorbs the pump's pressure surges which damage the packing, and 
serves as a buffer, protecting the HPLC column against the negative 
influences of the sample and the LC system. The guard column 
demonstrated an absence of significant contributions to dead volume or 
extra column effects. When the guard column cartridge lost efficiency 
or caused double peaks it was disposed of and replaced by a new 
cartridge obtained commercially. 
TABLE 2 . 4. High Performance Liquid Chromatographic Systems used . 
SYSTE>1 HPLC CDLL'MN >OBi,", PHASE 'Uv"O ",,1'£ TEMPERA TIJRE PRES,lJRE 
SYSTE>1 (mL/min) ( · C) (psi) 
1 B C REVERSE O.DOSM HSS solution/ 1.2 Nnbient 1700 
18 
PHASE 10 ).1m acetonitrile (75/25) 
(TECHSIL) with 0.2% 1M tlC1 
solution 
2 C C REVERSE O.OOSM HSS solution/ 1,2 Ambient 1700 
18 
PHASE 10 )Jm acetonitrile (74/26) 
(TECHSIL) with 0.2% L" tlC1 
solution 
3 C C REVERSE O.DOSH H55 solution/ 1.2 30 2600 
18 
PHASE 5 ,m acetonitrile (75/25) 
(TECHSILl with 0.2% 1M OC1 
solution 
4 D C REVERSE O.DOSH H55 solution I 1.2 30 2540 
18 
PHASE 5 ,m acetonitrile (77/23) 
(TEC HSrL) with 0.15% 1M tlC1 
solution 
5 E C REVERSE O.DOSH H55 solution/ 1.2 Ambient 1900 
18 
PHASE HIGH acetonitrile (74/26) 
SPEED 3 ,m ~ith 0. 25% 1M tlC1 
solution 
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2.3.1 . 6 Mobile Phase Preparation 
The mobile phase was prepared by mixing acetonitrile (270 mL) with a 
. 0.005 M solution I-heptanesul fona t e (HSS) in water (900 mL) and adding 
1 M HCl (l.S mL ) . The 0.005 M sodium I-heptanesulfonate solution was 
freshly prepared by dissolving 1 . 011 g of the salt in 1.0 litre HPLC 
grade water. The solvent mixture (pH 2.6S) was filtered under vacuum 
to expel dissolved gases . Adequate time (about 1 hour) was allowed 
for the system to fully equilibriate before starting anal ysis. The 
mobile phase was recycled, resulting in a more stable baseline and 
minimal baseline drift. At the completion of a one-day run, the 
column was flushed to remove any residues or halides that are 
detrimental to the stainless steel components of the HPLc apparatus. 
Flushing was accomplished by pumping about 100 mL methanol/water 
(SO/ 50) through the system. 
2.3.1.7 Column Packing Procedure 
Columns were packed as follows using a pneumatic column packing pump. 
Packing material from a used, 25 cm x 3.9 mm i.d. steel casing 
(~Bondapak, Waters Associates) was removed and the column thoroughly 
rinsed with methanol. The column end-frits and sieves were sonicated 
for 20 min in methanol. Three grams of packing material (Techsil CIS' 
5 or 10 ~m) was slurried in 50.0 mL HPLC-grade carbon tetrachloride 
and sonicated until dispersed . After loading the carbon tetrachloride 
slurry into the column packing reservoir, 150 . 0 mL of degassed and 
filtered HPLC grade methanol was pumped through the column at a 
pressure of 5 000 psi. After this period the column was inverted 
without interruption of flow and a further 150.0 mL methanol was 
pumped through the column before removal from the column packer . The 
column was then removed from the packing system and washed with 50.0 
mL acetonitrile/water (75/25) and tested using this mobile phase and a 
standard laboratory mixture prepared as follows: 
Ten milligrams of both benz amide and benzephenone, plus 0.5 mL benzene 
were made up to 20.0 mL with acetonitrile. One millilitre of this 
soluti on was dilut ed to 50 . 0 mL with acetonitrile/water (75/25) . 
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Two millilitres of this solution were injected onto the column at a 
flow rate of 1.0 mL/min, with U.V. detection at 254 nm, a sensitivity 
setting of 0.04 AUFS and a chart speed of 1 em/min. 
2.4 RESULTS AND DISCUSSION 
2.4.1 Detector Wavelength 
Phenylpropanolamine absorbs in the low uv wavelength range but its 
inherent molar absorptivity is poo.r (34). The need to detect low 
concentrations of PPA in biological fluids (10.0-500 ng/mL) necessi-
tated the choice of a wavelength where the absorbance was relatively 
high. From Fig. 1.6 it Can be seen that PPA only significantly absorbs 
U. V. radiation below 220 nm with a wavelength of 200 nm giving the 
highest 
et a2. 
absorptivity. A wavelength of 220 nm has been shown by Dowse 
(211) to provide sufficient sensitivity when monitoring PPA 
concentrations of 25 ng/mL and more. The need for maximum sensitivity 
led to the choice of 210 nm as the wavelength of detection, as 
wavelengths below 210 nm yielded unacceptable baseline noise and 
drift, while those above did not provide sufficient sensitivity. 
Figure 2.2 depicts the decrease in detector sensitivity resulting from 
an increase in detector wavelength from 200 to 250 nm after injecting 
aqueous samples (20 J.1L) of PPA.HCl (10 I'g/mL). 
2.4.2 Detector Choice 
The Spectra-Physics detector was found to have the most favourable 
signal/noise ratio at 210 nm when set at its maximum sensitivity of 
0.001 AUFS, and was used for the majority of analyses throughout this 
study. As a result it was used as a standard for the comparison of 
various detectors as previously described. Chromatograms of PPA using 
the Hewlett-Packard 1040A, Pye Unicam LC3 and Spectra-Physics SP8480XR 
UV detectors are shown in Fig. 2.3. 
A) 250 run E) 210 run 
B) 230 run F) 205 run 
C) 220 run G) 200 run 
D) 215 run 
COLUMN: Techsil 5 \.1m 
MOBILE PHASE: 23% acetonitri1e/77% HSS solution 
(0.005M) with 0.15% 1M HC1. 
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FIGURE 2 . 3 Chromatograms of PPA (1 ) using three di f ferent detectors 
A) Hewlett-Packard 1040A 
B) , C) Pye Unicam LC3 
D) Spectra-Physics SP8480XR 
COLUMNS: A) , B) 10 J.lm Techs il 
C) , D) 5 ~ Techsil 
MOBILE PHASE: 23 % acetonitrile/?? % HSS solution (0.005 M) with 
0.15 % 1 M HCl. 
pH = 2.65 
6MINS 6MINS 
3MINS 
A 8 c o 
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2.4.3 Internal Standard 
The compound chosen as the internal standard should preferably have 
physico-chemical properties as close as possible to those of the 
analyte. Homologous or analogous compounds and isomers are preferred 
to other substances (15S). The detector response and extraction 
properties of the internal standard were evaluated in parallel to that 
of the analyte. Ephedrine hydrochloride (EPH.HCl) was chosen as the 
internal standard. It was readily detectable at 210 nm, and el uted 
after PPA. Endogenous compounds which eluted just before PPA did not 
interfere with the EPH peak. Peak shape was sharp and symmetrical and 
resolution between PPA and EPH peaks was satisfactory on the final 
chromatographic system used. 
2.4 . 4 Mobile Phase Selection 
The necessity of having an ion-pairing agent in the mobile phase for 
the elution of PPA from a CIS column was establ ished in preliminary 
studies (211). Three ion- pairing agents, namely the sodium salts of 
I-heptanesulfonate, l-octanesulfonate or I-dodecanesulfonate were 
included in the mobile phase. The compounds pair with PPA to form a 
neutral, non-polar complex. The elution order is often predictable 
based on the degree of hydrophobicity of the solute. The more hydro-
phobic, the greater is the chromatographic retention of the ion-pair. 
Baseline resolution was obtained with al l three agents, but broad 
peaks with long retention times resulted using l-octanesulfonate 
sodium (0.005 M), and deterioration in peak shape and height resulted 
from the mcbile phase containing I-dodecanesulfonate sodium (0.001 M) 
(Fig. 2.4). I-heptanesulfonate sodium (HSS) in the mcbile phase 
(0.005 M) yielded good baseline resolution. 
After varying concentrations of the counter-ion, I-heptanesulfonate 
sodium (HSS), it was found that a molarity of 0.005 M yielded the most 
satisfactory retention time and resolution (Fig. 2.4). 
FIGURE 2.4 
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The effect of ion-pairing agents in the mobile phase 
on the retention of PPA (1) and EPH (2) . 
COLUMN: 10 \fTl Techsil 
MOBILE PHASES : A) 26 % acetonitrile/74 % Heptanesul fonate sodium 
A 
sclution (0.005 M) with 0.2 % 1 M HCl 
B) 26 % acetonitrile/74 % Qctanesulfonate sodium 
sclution (0.005 M) with 0.2 % 1 M HCI 
C) 26 % acetonitrile/74 % Dodecanesulfonate sodium 
solution (0.0025 M) with 0.2 % 1 M HCl 
3MINS 
2 
B c 
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Since it was necessary to decrease the pH of the mobile phase to 
reduce tailing of the compounds of interest, hydrochloric acid was 
included as this did not interfere with detection at 210 nm. However, 
a pH range of 2-7 is recommended for monomeric CIS columns, and thus 
not more than 0.2% 1M HCl was used in the mobile phases. In addition, 
halides are detrimental to the stainless steel components of the HPLC 
apparatus. Care was taken to flush the system each night (see section 
2.3.1.7). Baseline resolution was obtained using 25% methanol/75% HSS 
solution (0.004 M), but broad peaks resulted, with long retention 
times (Fig. 2.5). 
Acetonitrile (HPLC grade) was used in place of the methanol component. 
An acidified mobile phase conSisting of 22.5% acetonitrile/77.5% HSS 
solution (0.005 M) afforded resolution at ambient temperatures, 
although a small amount of baseline drift occurred. Increasing the 
temperature had little effect on resolution, but the maintenance of 
constant temperature (30·C) decreased this baseline drift . A column 
heater set at 30·C was used for all further determinations. After 
varying proportions of acetonitrile/aqueous HSS solution (0.005 M) 
in acidified mobile phases, a final mobile phase consisting of 23% 
acetonitrile/77% HSS solution (0.005 M) with 0.15% 1.0 M HCl was found 
to be satisfactory at 30·C and was used for the determination of all 
serum and urine extracts (Fig 2.6). 
2.4.5 Column Choice 
The 25 cm column packed with 10 ~ CIS material (Techsil) was found to 
be adequate for the initial studies of the effects of mobile phase 
composition on resolut ion. However, higher column efficiency and 
sample sensitivity was required, which led to the choice of a column 
of the same length packed with 5 ~m CIS material (Techsil). The 
principal reason for using the 5 ~ packed column was to obtain 
greater separation efficiency, and was subsequently used for the 
determination of all serum and urine extracts. The 5 ~ packed column 
could be operated at relatively modest back pressures (2.54 kpsi) and 
column lifetime was approximately 10 months. Precautions were taken 
to prolong column life. To minimize instrument error, a system 
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FIGURE 2.5 Olromatogram of PPA (1) and EPH (2) 
COLU~IN : 10 IJIl1 Tee hs i 1 
MOBILE PHASE : 25 % methanol / 75 % HSS solution (0.004 M) with 0.2 % 
1 ~ Hel. pH = 2.71. 
3MINS 2 
FIGURE 2.6 Olromatogram of PPA (1) and EPH (2) 
COLUMN: 5 llm Techsil 
MOBILE PHASE: 23 % methanol/77 % HSS solution (0.005 M) with 0.15 % 
1 M Hel. 
pH = 2.65 
6MINS 
2 
FIGURE 2.7 
COLUMNS 
MOBILE PHASE 
6MINS 
I 
A 
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Chromatograms of PPA (1) and EPH (2) 
A) 3 11m Techsil 
B) 10 11m Techsil 
C) 5 11m Techsil 
A) , B) 25 % acetoni trile/75 % HSS solution 
(0.005 M) with 0.2% 1 M HCl solution , 
pH=2.51 
C) 74 % acetonitrile/ 26 % HSS solution 
(0.005 M) with 0.2% 1 M HCl solution, 
pH = 2.65 
2 
B c 
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stability test with repetitive injections of a test mix were part of 
the HPLC method protocol. The C18 high speed column (3 I'm) proved to 
be less efficient than both the 10 I'm and 5 I'm columns using a similar 
mobile phase composition, and resulted in 
peak (Fig. 2.7). An assay procedure for 
peak broadening 
the analysis of 
of the EPH 
PPA and EPH 
could be developed using the high speed 3 I'm column used in this study 
with small changes in mobile phase composition. 
2.4.6 Effect of Flow Rate 
The effect of flow rate on resolution was investigated early in the 
development programme. Although improved resolution may be achieved 
by reduction of flow rate (212), it was found that flow rate had 
little effect on peak resolution. 
An increase in flow rate from 0.5 to 1.2 mL/min in 0.1 mL increments 
provided separation and improved peak shape leading to a choice of 1.2 
mL/min as the optimum flow rate for both the 5 I'm and 10 I'm packed 
columns (Fig. 2.8). The backpressure of 2.54 kpsi in the 5 I'm column 
prohibited the use of higher flow rates. 
Flow Rate Pressure ~ (PPA) 
(mL/min) (kpsi) (min . ) 
1.2 2.48 5.28 
1.0 2.17 6.33 
0.8 1.36 7.21 
0.6 1.33 10.83 
2.4.7 Peak Area and Peak Height Reproducibility 
Good peak area and peak height reproducibility was obtained from 
replicate injections of a standard PPA.HCl solution. Reproducibility 
of the system is shown in Table 2.5 which shows retention time, peak 
area and peak height values from injections of the test mixture. 
FIGURE 2.8 
COLUMN: 
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The effect of flow rate changes on the peak shape and 
separation of PPA (1) and EPH (2) 
A) 0.6 mL/min 
B) 1.2 mL/min 
5 11m Techsil 
MOBILE PHASE: 23 % acetonitrile/77 % HSS solution (0.005 M) with 
0.15 % 1 M HC1. 
pH ; 2.68 
2 2 
6MINS 
~ 
:;; '----It--/' (Y---
A B 
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TABLE 2 5 Peak area and peak height reproducibility 
Retpnti on time Peak Area Pe.:lk flc~ 
{minutes j 
1 5.16 3504 64936 
2 5.16 3512 64951 
3 5.16 3584 64934 
4 5.16 3521 64962 
5 5.16 3522 64939 
6 5.16 3509 64973 
7 5.16 3522 65001 
8 5.16 3512 64932 
9 5 .16 3512 64935 
10 5.16 3507 64941 
11 5.16 3511 64931 
12 5.17 3531 64965 
13 5.17 3509 64955 
14 5.17 3513 64954 
15 5.17 3532 64959 
16 5.17 3515 64932 
17 5.17 3514 64931 
18 5.17 3511 64948 
19 5.17 3507 64942 
20 5.17 3507 64936 
MEAN 5.165 3517 64947 
50 0. 005 17.37 17 . 83 
R.S.D. 0.098% 2.49% 0.027% 
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CHAP-fER 3 
DETERMINATION OF PHENYLPROPANOLAMINE IN BIOLOGICAL FLUIDS 
3.1 INTRODUCTION 
Quantitative analysis of phenylpropanolamine in biological material is 
necessary for the investigation of pharmacokinetics and the 
correlation of drug levels with toxic effects. Since many of these 
studies are performed with very low doses, the requirements on 
determination limits are strong and may be as low as the lower 
nanogram range. Direct UV detection of PPA in assays presents 
problems because the molar absorptivity of PPA is very low (210). 
Hence, met hods in which the drug has been derivatized or concentrated 
to increase specificity and sensi tivity have been developed. 
Using a periodate oxidation, Heimlich (40) developed a specific 
analytical technique for determining PPA in urine according to the 
original method of Shinn and Nicolet (213), in which PPA was converted 
to its corresponding aryl aldehyde. Derivative formation by his method 
affords a sensitivity 3-4 times greater than that for direct spectro-
photometric determination of unconverted PPA. Periodate oxidation was 
also used by Chafetz (160) for the assay of PPA, but the procedure is 
not applicable to the analysis of the drug in biological specimens. 
In a procedure described by Wallace (162), phenyl ethanolamine drugs in 
biological specimens were determined by UV spectrophotometry after 
oxidation by means of alkaline periodate to benzylaldehyde. The 
sensitivity and specificity of the procedure was enhanced by 
subsequently converting the benzyl aldehyde to the corresponding semi-
carbazone derivative. An early method for quantitatively determining 
PPA in plasma and urine was developed by Axelrod (35) involving 
extraction into benzene and assay by methyl orange reaction. 
PPA in biological fluids has been assayed by thin-layer chromatography 
(TLC) fol lowing acetylation with tritiated acetic anhydride (214). 
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This method however suffers from a high coefficient of variation and 
nonlinearity. PPA has been separated and concentrated in urine by 
passing a buffered urine specimen through a column of Amberlite XAD-2 
resin, a styrene divinylbenzene copolymer that adsorbs a wide variety 
of water soluble organic compounds, and then eluting the drug with an 
appropriate solvent which is evaporated. The residue is applied to 
thin layer plates, developed in a suitable solvent system 
detected qualitatively by sequential spraying (182, 
and the drug 
215). After 
chloroform extraction of PPA from serum and urine, the drug has been 
reacted with 7-chloro-4-nitrobenzo-20xa-l,3-diazole . to produce a 
highly fluorescent compound which can be measured wi th a spectro-
fluorimeter (216). The extract is then evaporated and the residues 
subjected to thin-layer chromatography for qualitative identification 
of the drug. 
The methods described above are time consuming in comparison to gas-
liquid chromatography (GLC) for PPA in biological fluids. Kinsun et 
al. (217) described a quantitative determination of PPA in urine by 
GLC. After alkaline extraction with ether, PPA was analyzed directly 
by GLC without a derivatization step. For pharmacokinetic and bioavai-
lability studies, PPA concentrations in biological fluids have also 
been determined by GLC following derivatization (180). Cummins and 
Fourier (218) used benzene to partially purify the serum after acid 
extraction followed by re-extraction with benzene after alkalinization 
and then formation of the heptafluorobutyryl derivative which was 
detected by gas chromatography with electron capture detection (GC-
ECD). The method however is a tedious one as at least 4 hours are 
required for the derivative to form. Neelakantan and Kostenbauder 
(219) describe a GC-ECD procedure for the determination of PPA in 
plasma based on derivatization with pentafluorobenzaldehyde without 
prior extraction of the drug, to yield an electron-capturing 
derivative which is then readily extracted into hexane. The limits of 
sensitivity are 1.1 ng/3mL. A capillary GC analysis of PPA in human 
plasma after extraction with toluene from alkaline plasma, derivatiza-
tion with trifluoroacetic anhydride and detection by electron capture 
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was presented in a recent repcrt (220). Plasma concentrations above 
5 ng/mL can be determined with accuracy and precision suitable for 
pharmacokinetic studies. 
In the last few years, high-performance liquid chromotography (HPLC) 
has become a pcpular and widely used technique in the field of drug 
analysis 
biological 
from biological fluids. The methods used for treating 
HPLC system samples prior to their introduction into an 
generally fall into 2 categories - extraction or direct injection. In 
the extraction method, the compcund of interest is removed from the 
biological matrix (plasma, serum, urine, etc) using a suitable solvent 
and pH to leave behind unwanted materials. The direct-injection 
technique is by far the simplest and most rapid of the two methods. 
However, this results in a rapid increase in back-pressure and 
deterioration of column performance (221, 222) due to precipitation of 
plasma proteins as a result of their contact with organic solvents and 
buffer salts commonly utilized in mobile phases . 
An HPLC procedure described by Mason and Amick ( 223 ) invol ved 
extraction of PPA from basified plasma with 10% v/v I-butanol and back 
extraction into a small volume of 1% acetic acid. This extract was 
derivatized with O-phthalaldehyde, and the derivative was measured 
using fluorescence detection to determine concentrations of PPA as low 
as 5 ng/mL. HPLC using detection in the visible range (450 nm) has 
been used to determine PPA in urine. Endo et aI. (224) used a colour 
reaction with sodium e-naphthoquinone-4-sulphonate after extraction 
from large volumes of alkaline urine (50 mL) with hexane to determine 
PPA by HPLC. This method is time consuming and no indication is given 
as to the levels of PPA determined. Detection in the UV range 
resulted in interference from urinary consti tuents. Noggle (225) 
extracted PPA from alkaline urine with methylene chloride and then 
formed the phenyl isocyanate derivative which was detected using HPLC 
at a wavelength of 254 nm. PPA has also been assayed in biological 
fluids by HPLC following extraction and pre-column derivatization with 
4-chloro-7-nitrobenz-2,1,3 oxadiazole and sodium e-napthaquinone-4-
sulphonate (226). 
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A method for the analysis of PPA in urine was developed by Dye and 
East (227) using HPLC and post-column in-line derivatization with 0-
phthalaldehyde followed by detection with a fluorometer. Human urine 
was injected directly onto the chromatographic system and PPA was 
separated in the reversed-phase mode. The limit of detection was 0.1 
~g/mL of urine. An HPLC analysis of PPA in urine and plasma by post-
column derivatization with O-phthalaldehyde has recently been 
described (228). Plasma samples were extracted with methylene chloride 
under alkaline conditions, and urine was diluted with mobile phase 
without extraction. Using fluorescence detection, the method is 
sufficiently sensitive (2 ng/mL of plasma and 0.5 ~g/mL of urine) so 
that PPA concentrations could be measured up to 24 hours following a 
75 mg oral dose. 
The abcve mentioned HPLC methods used to determine PPA in biological 
fluids have involved derivatization methods which are relatively time 
consuming or invol ve post-column manipUlations. Determination of PPA 
in serum and urine without prior derivatization has been described by 
Dowse et aL. (211). The method involves extraction at a basic pH with 
chloroform, a single back extraction into acid. and chromotography on a 
reverse-phase column. The detection limit for PPA was 25ng/mL in serum 
and 10 ~/mL in urine. The resulting chromotograms were clean with no 
interfering peaks due to endogenous constituents. An adaptation of 
this HPLC assay for PPA in serum was recently used to examine PPA 
pharmacokinetics in dogs (229). Plasma was extracted into aqueous 
acetic acid and injected onto a cyano column . Detection was by UV 
absorbance at 210 nm and the limit of detection was 30 ng/mL of 
plasma. 
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3 . 2 METHODS OF EXTRACTION OF PHENYLPROPANOLAMINE FROM SERUM 
3.2.1 EXperimental 
3.2.1.1 Sample Preparat ion 
Aqueous solutions of PPA.HCl (500.0 ng/mL) were prepared as in section 
2.3.1.1. During these developmental stages, spiked serum samples of 
different concentrations were prepared by addition of the appropriate 
amounts of the aqueous solutions of PPA.HCl to drug free serum . The 
concentr ation ranges of serum varied between 12.5ng/mL and SOO.Ong/mL. 
3. 2.1.2 Reagents 
The sodium hydroxidel potassium hydroxide2 , sodium carbonate 
(anhydrous)2, hydrochloric acid2 and acetic acid3 were obtained 
commercially. The methylene chloride4 and chlor oformS were HPLC grade. 
1. Holpro Analytics (Pty) Ltd, H70106, Johannesburg, South Africa. 
2. B.D.H Chemicals Ltd., Poole, England. 
3. E. Merck, Darmstadt, West Germany . 
4. Burdick and Jackson Laboratories, Muskegon, Mich., USA. 
5. Waters Associates, Milford, Mass., USA. 
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3. 2 . 1 . 3 Extrac t ion Procedures 
1 . 0 mL SPIKED SERUM + INTERNAL STANDARD (EPH.HCl) + BASIFYING AGENT 
VORTEX 
l 
ADD ORGANIC SOLVENT 
1 
VORTEX OR SLOW SHAKING 
l 
CENTRIFUGE 
REMOVE AQUEOUS LAYER BY ASPIRATION 
TRANSFER ORGANIC EXTRACT TO TAPERED TUBE CONTAINING 
A SMALL VOLUME OF ACID (50-120 ~) 
t 
VORTEX 
CENTRIFUGE 
~ 
REDUCE ORGANIC EXTRACT TO ABOUT 200 ~L by ASPIRATION 
~ 
RE-CENTRIFUGE 
~ 
INJECT 15 TO 30 ~L of the ACIDIC EXTRACT DIRECTLY 
ONTO THE COLUMN 
The following extraction procedures using either chloroform or 
methylene chloride were assessed: 
a) CHLOROFORM 
I Chloroform/sodium carbonate/acetic acid 
Aqueous solutions of PPA.HCl and for spiked serum samples were 
basified with 100 ~L of a saturated sodium carbonate solut ion, 
61 
extracted by vortexing with varying volumes of chloroform (5, 8 
and 10mL) and centrifuged. The lower layer was transferred to a 
tapered tube containing 5% v/v acetic acid and vortexed for 1 min 
to initiate back extraction. The chloroform layer was reduced by 
aspiration to about 200 ~L and discarded . A 20 ~L aligout of the 
acetic acid extract was injected directly onto the column. 
II Chloroform/sodium hydroxide/amyl alcohol/acetic acid 
'!he serum sample was basified with 100 ~L 10% NaOH, 10 drops of 
amyl alcohol were added and extracted with 8 mL chloroform. '!he 
tube was vortexed and centrifuged and the lower organic layer 
transferred to a tapered tube containing 100 ~L of acetic acid 
(5% v/v). Ten to twenty microlitres of the acidic extract was 
injected onto the column. 
III Chloroform/sodium hydroxide 
'!his method was similar to that described in extraction I with 
100 ~L sodium hydroxide (10%) being used in place of sodium 
carbonate. The organic extracts were evaporated to dryness at 
40·C under a gentle stream of nitrogen and reconstituted with 
100 ~L of mobile phase before direct injection of the sample onto 
the column. 
IV Chloroform/sodium hydroxide/hydrochloric acid 
Spiked serum samples were basified with varying concentrations of 
NaOH (2.5, 5.0 and 10.0% solutions). Chloroform (8 mL) was added 
and, after shaking, the organic phase was transferred to a 
tapered centrifuge tube containing 100 ~L hydrochloric acid (0.1 
M). Fifteen to thirty microlitres of the hydrochloric extract 
was injected directly onto the column. 
b) METHYLENE CHLORIDE 
V Methylene chloride/sodium carbonate/acetic acid 
Spiked serum samples were treated as in extraction I, using 
methylene chloride (8 mL) in place of chloroform. 
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VI Methyl ene chloride/sodium carbonate/hydrochloric acid 
The serum samples and aqueous PPA . HCl samples were basified with 
100 ~L sodium carbonate, extracted in 8 mL methylene chloride, 
and subsequently back-extracted into 100 ~L hydrochloric acid 
(0 .1 M). Twenty microlitres of the acidic extract was injected 
onto the column. 
VII Methylene chloride/sodium hydroxide/hydrochloric acid 
Spiked serum samples were treated as in extraction IV using 
methylene chloride (8 mL) in place of chloroform. 
VIII Methylene chloride/potassium hydroxide/hydrochloric acid 
A number of spiked serum samples were basified with 100 ~L of 
either 0.5, 1.0, 2.5, 3.0, 5.0 or 10.0% KOH solutions . Methylene 
chloride (8 mL) was added, the tube vortexed for 20 sec and 
centrifuged . The lower layer was transferred to a tapered tube 
containing 100 pL hydrochloric acid (0.1 M) and a 20 ~L aliqout 
was injected directly onto the column . 
3.2.1.4 Chromatographic Conditions 
The following chromatographic conditions were used after 
extraction procedures I - III: 
Column and Mobile phase : 
HPLC system: 
Flow rate: 
Pressure and Temperature : 
Detection Wavelengili: 
Attenuation : 
Recorder input : 
2 
C 
(Table 2 . 1) 
(Section 2.3 . 1.2) 
1.2 mL/min 
Table 2 . 1 
210 nm 
0. 01 AUFS 
10mV 
ilie 
For the remainder of the extraction procedures, the chromatographic 
conditions used were as follows : 
Column and Mobile phase: 
HPLC system: 
Flow rate : 
Pressure and Temperature: 
Detection Wavelength: 
Attenuation: 
Recorder input: 
3.2.2 Results and Discussion 
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3 
C 
(Table 2.1) 
(Section 2.3.1.2) 
1.2 mL/min 
Table 2.1 
210 nm 
0.01 AUFS 
10mV 
When trace amounts of therapeutic substances of comparatively low 
molecular mass have to be determined in serum or urine, an isolation 
procedure of variable complexity has to be applied initially (230). 
For pharmacokinetic interpretations, the analytical method must be 
sensitive, specific, 
concentrations. The 
accurate and precise, especially at the lower 
methods used for treating biological samples 
prior to their introduction into an HPLC system fall into one of two 
categories-extraction or direct injection. Hdwever, the latter method, 
although by far the simplest and most rapid, results in a rapid 
increase in back-pressure and deterioration of column performance 
(221). To alleviate this problem, a number of sample preparation 
techniques have been described for removing proteins prior to 
injection of the sample . These include the use of pre-columns (231), 
ultrafiltration devices (232) various protein precipitants such as 
organic solvents (233) and ionic salts (234), solvent extraction and 
selective adsorption of the drug onto a suitable substrate. Strong 
acids, 
acid 
which 
such as trichloroacetic acid, perchloric acid or hydrochloric 
are frequently used to denature proteins giving a precipitate 
can be separated by centrifugation. 
heavy metals, alcohol or dialysis is never 
Protein precipitation by 
100% efficient, as the drug 
of interest often co-precipitates with the protein (235). 
Drugs are most easily extracted from biological samples using water-
immiscible solvents following the classical approach by Brodie et aI . 
(236). Solvent extraction is generally the ideal method if a single 
primary extraction followed, if necessary by a baCk-extraction, 
provides a good recovery of the desired compound. Liquid-liquid 
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extraction is an isolation and separation method based on the 
distribution bet ween two immiscible solvents that are in close contact 
with one another (158). Selective extraction with water-immis cible 
solvents relies upon the drug having a favourable partition 
coefficient, and the most common approach for protolytic compounds is 
to extract them in the uncharged form . Phenylpropanolamine, being a 
weak base with a pKa of 9.4 is most readily extracted by making it 
alkaline prior to its extraction into an organic solvent. Medium 
polarity solvents, such as chloroform and methylene chloride are 
suitable for extracting amines, which show much higher distribution in 
these solvents than the hydrogen-accepting solvents (158). The 
organic extract can then be further purified and concentrated by back-
extraction or removal of the organic solvent at elevated temperatures 
under nitrogen. Care must be taken to ensure that the drug is not 
removed by evaporation, volatilization or lost during the extraction 
process. 
Concentrations of PPA found in serum after the ingestion of doses of 
the drug between 25 and 100 Irq range from 5 to 500 ng/mL. These low 
levels make sample extraction essential to enable direct uv 
of the drug. 
Chloroform and methylene chloride (dichloromethane) are 
chlorinated hydrocarbons that, on exposure to air and light, 
to extremely reactive phosgene resulting in decomposition 
detection 
aliphatic 
degrade 
of the 
solvents. Commercially supplied chloroform contains a stabilizer such 
as ethanol, and the presence of ethyl chloroformate , has been shown to 
react with various drugs extracted with this solvent (237) . General 
points that were taken into consideration with the solvent extraction 
procedure included solvent purity (238), inadvertant exposure of the 
solvent to air and light (239), cost and toxicity of the solvent . 
The first solvent to be assessed was chloroform, the specific density 
of which can be a disadvantage in the manipUlations since it is 
heavier than water and forms the lower layer when 
has previously been used to extract PPA from 
mixed . Chloroform 
body fluids (34). 
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Initially, chloroform appeared to be very promising as it yielded an 
80% recovery from an aquecus solution (extraction I). Two problems 
with serum extraction did arise, however, one being concerned with the 
formation of a solid gelatinous emulsion intractable by centrifuging, 
a phenomenon which has been previously described (230). The other 
problem was a high serum blank which occurred. Interference resulted 
even after the injection of extremely low volumes of extract. 
Although centrifugation is often the most successful method of 
breaking emulsions, a number of other techniques have been propcsed, 
including successive freezing and thawing, filtration, tOUChing with a 
glass rod, saturating the aquecus layer with salt or the addition of a 
small amount of alcohol. Addition of alcohol to some samples that 
happen to form emulsions is undesirable if reproducibility of 
extraction is to be maintained (240). Attempts were thus made to 
develop a method whereby emulsions are prevented from forming. The 
problem of emulsi fication can be avoided by less intensive mixing of 
the phases, and a major pitfall was in the shaking technique. Too 
vigorous shaking produced emulsions, which are known to oc= between 
an alkaline aquecus phase and halogenated solvents . Although these 
emulsions could be broken by centrifugation and subsequent vortexing, 
this was found to be time consuming. Extraction carried out in tubes 
clamped near to the horizontal pcsition and shaken longitudinally at 
120 oscillations per minute for 15 minutes on a rocking table were 
favoured when chloroform was used as the extracting solvent, as this 
gentle tilting minimized the risk of emulsifi cation. 
A study was carried out to attempt to ascertain the optimum pH for 
extraction by adding varying amounts of NaOH to the serum (extractions 
IV and VI). It was found that a 10% NaOH solution gave the best 
extraction efficiency when methylene chloride was used as the 
extracting solvent . Conversely, the 2 . 5% NaOH solution gave better 
extraction efficiency than the higher concentrations of basifying 
agents added to serum samples when chloroform was used as the organic 
solvent. with the increase in concentration of NaOH from 2.5% to 10%, 
the tendency to form emulsions increased, and the use of a more 
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concentrated solution of NaOH (10%) did not have any advantageous 
effect on recovery . Extraction I, when basifying with Na2Co3 yielded 
a better recovery than when NaOH was used. 
In extraction II, amyl alcohol was added in the hope that it would 
reduce emulsion formation. It did help in preventing the formation of 
intractable emulsions but a problem encountered with this method was 
the lack of reproducibility and poor recovery (50%). An increase in 
the organic/aqueous ratio tended to increase recovery to 60%, but 
interfering peaks were observed with blank serum extracts. 
The problem encountered with extraction III was the lack of repro-
ducibility and a poor extraction efficiency of 30%, which was traced 
to the evaporation and reconstitution steps. Loss of drug seemed to 
occur during evaporation, possibly through volatilization of the free 
base form (21 7). Adsor ption to the glass may have prevented complete 
solution of the drug in the mobile phase on reconstitution. Attempts 
were therefore undertaken to eliminate the evaporation step as the 
resultant variation in analytical recovery reflected poor calibration 
lines and poor reproducibility. 
It was necessary to concentrate PPA further to enable detection at the 
lower concentrations. A final purification and concentration step was 
effected by back-extraction into a small volume of acid. This was 
favoured over the evaporation step, as recovery was much more con-
sistent. However, a pr oblem encountered wi th the acetic acid (5% v/v) 
was the appearance of an extremely large, broad hump which eluted 
about 1 hour after injection of the final acidic extract. The large 
hump interfered with subsequent chromatograms making it difficult to 
automate the system . The initial assessment was that it may have been 
due to an impurity in the acetic acid or a component that was extrac-
ted by the acetic acid during the extraction procedure. The problem 
was overcome by using a 0.1 M solution of hydrochloric acid instead of 
the acetic acid and cleaner extracts were thereby obtained. 
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The final solvent assessed was methylene chloride. This organic 
of PPA solvent had the advantage over chloroform in the extraction 
from serum in that no persistent gelatinous emulsions were formed and 
clean extracts resulted. 
However, extractions V and VI yielded relatively poor recoveries of 
about 60%. Attempts to increase recovery were four-fold: altering 
the basifying agent, increasing the volume of methylene chloride 
(organic/aquecus ratio), and finally assessment of multiple extrac-
tions and mixing techniques. Three basifying agents (Na2C03 , NaOH and 
KOH) were assessed and varying concentrations of each were added to 
the serum (extraction VI, VII, VIII). A 10% KOH solution (extraction 
VII) gave the highest recovery, and it was found that a pH of 13 
proved to be satisfactory with regard to selectivity and efficiency of 
extraction into methylene chloride. The volume of methylene chloride 
was increased from 5 to 10 mL and improved recovery by about 10%. The 
effect of multiple extractions was investigated and a 75% recovery 
after a single extraction was increased to 80% on extracting the 
sample twice. However, the slight increase did not justify the extra 
number of manipulations involved. A short, not too vigorous extraction 
was found to be more successful in producing "clean" extracts than 
long, violent encounters with the extracting solvent. Centrifugation 
was found to be advantageous in forming distinct solvent layers, 
particularly when proteins were precipitated by the action of the 
organic solvent. Care was taken to separate the two layers and the 
top layer was easily removed by aspiration with a pasteur pipette. 
It is well established that the precision of the quantitative data 
increases if an internal standard is included in the extraction 
procedure. The internal standard (EPH.HCl) was added to the samples 
before the work-up procedure started and subjected to the entire 
analytical procedure. 
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It was found that a large peak eluted at about 10 min and after a 
small 
peak 
due 
volume of methylene chloride was injected onto the column, the 
reappeared at 10 min. It was thus concluded that this peak was 
to the presence of a small percentage of methylene chloride 
dissolved in the hydrochloric acid extract which was then injected. 
The hydrochloric acid (120 ~L) remained on top of the methylene 
chloride and appeared as globules adhering to the walls of the tube. 
After back-extraction, the methylene chloride was removed down to 
about 200 ~L and discarded, thus allowing the small volume of acid to 
form a single, continuous upper layer from which aliquots for 
injection could be removed. The final method used is described in 
section 3.3.1.3. The analytical method thus developed is a simple, 
rapid process that allows the analysis of large numbers of samples. 
Analysis of pre-dose serum samples from 10 human subjects and several 
batches of pooled human serum presented no chromatographic peaks that 
interfered with the internal standard or PPA. A previous report (241) 
suggested that no significant metabolism of PPA occurs, so in vivo 
interference by metabolites was not a problem. The extraction proce-
dure produced clean extracts and very clean chromatograms, and thus 
should be considered for other primary amines. Although the method 
was developed with the purpose of studying the pharmacokinetics of PPA 
in humans following oral administration of the drug, it was also found 
to be suitable for the analysis of pseudoephedrine in humans following 
oral administration of the drug. Phenylpropanolamine would be a 
suitable internal standard for the analysis of this compound. A 
chromatogram of a serum extract containing pseudoephedrine is depicted 
in Fig. 3.5. The retention time of pseudoephedrine was 6.0 min. 
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3.3 ANALYS I S OF PHENYLPROPANOLAMINE IN SERUM 
3.3.1 EXperimenta l 
3.3.1 . 1 Sample Preparation 
Serum stock solution 
Twenty five milligrams of PPA . HCl was accurately weighed and dissolved 
in 50.0 mL water and 1 . 0 mL of this solution was diluted to 10.0 mL 
with water . One millilitre of this sol ution was made up to 100.0 mL 
with blank serum. The stock solution was agitated by slow mixing for 
1 hour. The resultant concentration in serum was 500.0 ng/mL. Appro-
priate dilutions were then made, ranging from 12.5 to 500 . 0 ng/mL. 
Internal standard stock solutions 
Forty milligrams of EPH.HCl was dissolved in 1.0 litre of water to 
yield 40 ~ g/mL. This solution was again diluted to yield a concentra-
tion of 2 vg/mL and this was used as the internal standard solution . 
The serum used to prepare the serum stock solution was obtained from 
our local hospital (Settlers' Hospital, Grahamstown , South Africa). 
It was dialysed against an isotonic NaCl solution at 4·C for 96 hours 
to remove dialysable contaminants before use. 
3.3.1 . 2 Chromatographic Conditions 
Column: 5 vm Techsil 
HPLC system: D (Section 2. 3 .1 . L) 
Flow rate: 
Pressure: 
Temperature: 
Detection wavelength: 
Attenuation : 
Mobile phase: 
1.2 mL/min 
2.53 kpsi 
30·C 
210 nm 
0.001 AUFS 
0.005 M HSS solution/acetonitrile 
(77/23) with 0 . 15% 1 M HCl 
pH = 2 . 65 
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3.3.1.3 Extraction Procedure 
One millilitre of serum, 100 ~L EPH.HCl solution (2 ~g/mL) and 100 ~L 
of a 10% potassium hydroxide solution, which adjusted the pH of the 
mixture to 12.3, were mixed and vortexed for 20 sec in a culture tube. 
Eight millilitres of methylene chloride were added, the tube 
stoppered, vortexed for 15 sec, and centrifuged at 3 500 rpm for 2 
min. A further 2 mL of methylene chloride was added, and the tube was 
re-centrifuged at 3 500 rpm for 3 min. A disc formed between the 
aqueous and organic phases. The aqueous layer above this disc was 
removed by aspiration and discarded. A pasteur pipette was used to 
transfer the methylene chloride extract to a tapered centrifuged tube 
containing 120 ~L of a 0.1 M HCl solution. Care was taken to ensure 
that no droplets of serum were transferred to the tapered tube. The 
centrifuged tube was vortexed for 30 sec and centrifuged at 1 500 rpm 
for 2 min. The methylene chloride layer was reduced by aspiration to 
about 200 ~L and the tube was re-centrifuged for a further 2 min at 
1 500 rpm. 
Aliquots of 80-100 ~L of the hydrochloric acid extract were trans-
ferred by syringe to limited volume glass inserts and inserted in the 
autosampler. Twenty microlitres of this extract was injected directly 
onto the column. 
3.3.1.4 Calibration Curve 
The serum stock solution (500.0 ng/mL) was diluted to yield six 
different concentrations, the stock solution providing the seventh . 
Concentrations ranged from 12 . 5 to 500.0 ng/mL and each concentration 
was assayed in triplicate. The calibration curve was constructed by 
plotting the ratio of the peak height of PPA to that of the internal 
standard, versus the respective PPA concentration. 
fitted by least-squares linear regression analysis. 
3.3.1.5 Precision 
The data were 
Within-run precision was assayed by extracting five spiked serum 
samples at each concentration (12.5, 25.0, 50.0, 100.0, 200.0 , 300.0 
and 500.0 ng/mL). 
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3.3.1.6 Extraction Efficiency 
i) For this study, in which the analytical recovery of PPA from 
serum was assessed, spiked serum samples were assayed in quadru-
plicate at five different concentrations. A similar extraction 
procedure to the one described in section 3.3.1.3 was applied to 
all the samples with one modification. The internal standard was 
omitted at the start of the procedure, and instead, 100 ~L water 
was added to the serum. The EPH.HCl was dissolved in the 
hydrochloric acid and was thus not carried through the extraction 
procedure . 
Standard solutions of PPA.HCl were made up with the internal 
standard solution in concentrations corresponding to those 
extracted above. The internal standard therefore accounted for 
variations in sample volumes injected. To determine the percen-
tage recovery, the ratios obtained from the serum extracts were 
compared to those resulting from the relevant standard solution 
of equivalent concentrations. 
ii) Analytical recovery of PPA.HCl from serum was also assessed 
without the use of the internal standard, . EPH.HCl. This could be 
carried out successfully with the use of the constant volume 20 
~L loop attached to the autosampler, as there is negligible 
variation (0.01%) in sample volumes injected. 
Spiked serum samples were assayed in quadruplicate at four 
different concentrations. A similar extraction procedure to the 
one described in i) above was applied to all samples with one 
modification. The internal standard was omitted throughout the 
procedure. 
Standard aqueous solutions of PPA.HCl were made up in concentra-
tions corresponding to those extracted above. To determine 
percentage recovery, the peak heights obtained from the serum 
extracts were compared to those resulting from relevant aquecus 
standard solutions of equivalent concentrations. 
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3.3.2 Results and Discussion 
3.3.2.1 Linearity and Calibration 
Linearity was established for the range of concentrations studied 
(12.5-500.0 ng!mL). The line had a slope of 0.005638, a y-intercept 
of 0.016339 and a correlation coefficient of 0 . 9977. The calibration 
curve for phenylpropanolamine in serum is shown in Fig. 3.1. Chroma-
tograms of a blank serum extract and a serum extract containing 
phenylpropanolamine and internal standard are depicted in Fig 3.2. 
The retention time of PPA was 5.6 min and that of EPH was 6.5 min. 
FIGURE 3.1 calibration curve of phenylpropanolamine in serum. 
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FIGURE 3.2 Chromatograms of (A) a blank serum extract and (B) 
serum extract containing PPA (1) and EPH (2) • 
retention time of PPA was 5.6 min. and that of EPH 
6.5 min. 
2 
A B 
Colwnn: 5 )J m Techsil 
Mobile Phase: Acetonitrile/HSS solution (0.005 M) 
(23.5/76.5) with 0.2% 1 M Hel solution 
Phenylpropanolamine 
concentration : 100 ng/mL 
a 
The 
was 
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3.3.2.2 Precision 
Results of the within-run precision study are depicted in Table 3.1. 
The method was found to be highly reproducible with R.S.D. values less 
than 10% at all concentrations. 
3.3.2.3 Extraction Efficiency 
Table 3.2 shows the analytical recoveries of PPA from serum. Results 
indicate that the recovery of PPA is constant and quantitative over 
the concentrati on range (12.5-500.0 ng/mL) s t udied. The mean r ecovery 
was 79.58% 
TABLE 3.1 Within-run precision study on serum assay 
Concentration measured (ng/mL) 
Spiked Samp 1 e number 
cone (ng/mL) 1 2 3 4 5 Mean (SO) RSO 
12.5 13.79 13.79 12.85 13.23 13.79 13 .48 ( 0.44) 3 . 25~ 
25 23.20 26.14 26.69 25.77 25.77 25.40 ( 1.34) 5.29~ 
50 53.04 50.00 49.82 49.10 49.10 50.79 ( 1.65) 3.25% 
100 100.97 106.10 99 . 56 107.87 107.87 104.47 ( 3.94) 3.77% 
200 209.06 187.99 207.30 189.74 205.55 199.93 (10.19) 5.10% 
300 292.01 284.91 292.01 284.91 284.91 287.75 ( 3.89) 1.35% 
500 491. 76 490.01 535.50 523.10 523.10 505.03 (22.70) 4.50% 
TABLE 3.2 Analytical recoveries of phenylpropanolamine from serum 
'L Recoverv 
Serun SamPTe number 
cone 
(ng/mL) 1 2 3 4 Mean (SO) RSO 
12.5 81.50 86.66 80.45 89.19 84.45 (4.16) 4.93% 
50 75.00 80.55 81.11 80.55 79.30 (2.88) 3. 63% 
100 73.00 81.87 83.94 82.51 80.33 (4.96) 6. 17% 
250 73.77 71.85 77.81 71.78 73.80 (2.82) 3.82% 
500 81.56 81.23 75.69 81.61 80.02 (2.89) 3.62% 
Mean percentage recovery (n = 20) 79.58 (4.77) 5.98% 
3.3.2.4 Sensitivity and Detection Limits 
Under the conditions of this assay and based on a minimum signal to 
noise ratio of 10:1 the detection limit for phenylpropanolamine in 
serum was 5.0 ng/mL. A chromatogram of a serum extract containing PPA 
(5 ng/mL) is depicted in Fig. 3.2.1. 
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3.3.2.5 Background Interference 
The technique of back-extraction eliminated a significant amount of 
interfering endogenous substances which had been co-extracted with 
methylene chloride. The hydrochloric acid eluted at the void volume 
and peaks from serum constituents did not interfere with the peaks of 
interest. The large peak at 9 min was due to a trace amount of 
methylene chloride which partitioned into the hydrochloric acid. 
FIGURE 3.2.1 
Column: 
Mobile Phase: 
Chromatogram of a serum extract containing 
(5 ng/mL) (1) and EPH (2). 
2 
5 11m Techsil 
Acetonitrile/HSS solution (0.005 M) 
(23.5/76.5) with 0.2% 1 M HCl solution 
PPA 
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3.3.2.6 Stability of Samples on Storage 
Spiked serum samples (50, 250 and 500.0 ng/mL) were stored at -20·C 
and were assayed every 2 weeks over 2 months. The PPA content remained 
constant with the relative standard deviation falling within the 
acceptable limits i.e., less than 10% at all concentrations. 
3.4 METHODS OF EXTRACTION OF PHENYLPROPANOLAMINE FROM URINE 
3.4.1 Experimental 
3.4.1.1 Sample Preparation 
Spiked urine samples of different concentrations (10-100 ~g/mL) were 
prepared as in Section 2.3.1.1 by the addition of appropriate amounts 
of aqueous solutions of PPA.HCl to freshly collected drug-free urine. 
3.4.1.2 Extraction Procedure 
Method I 
Spiked urine (1.0 mL) was pipetted into a test tube and basified with 
100 ~L of a 10% NaOH solution. Five millilitres of chloroform were 
added, the tube was stoppered and vortexed for 30 sec and centrifuged 
at 3 500 rpm for 5 min. The organic extract was back-extracted into 
varying volumes of acetic acid (100 ~L-500.0 ~L), and a 20 ~L aliquot 
of this extract was injected directly onto the column. 
Method II 
A modification of the final method used for serum was assessed (see 
extraction VIII on method development). The modification involved a 
smaller volume of methylene chloride (5-8 mL), and an increase in the 
volume of the 0.1 M hydrochloric acid solution used in the back-
extraction (200 Lor 500.0 ~L instead of 100 ~L). 
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3.4.1 . 3 Chromatographic Conditions 
Colwnn: 
HPLC system: 
Flow rate : 
Pressure: 
Temper ature : 
Detection wavelength: 
Attenuation: 
Mobile phase: 
5 ~m Techsil 
C, D (Section 2.3.1.2) 
1. 2 mL/min 
2.54 kpsi 
30·C 
210 nm 
0.01 AUFS (Pye Unicam detector) or 
0.001 AUFS (Spectra-Physics detector) 
0.005 M HSS solution I 
acetonitrile (77/23) with 0.15% 1 M HCl 
pH = 2.68 
3.4.2 Results and Discussion 
Urine contains numerous inorganic salts such as NaCl and also some 
organic endogenous compounds. The composition of urine varies much 
more than that of serum since it is influenced by intake of food and 
fluid. Typical urine contains upwards of 100 compounds (242) in 
concentrations that can readily be seen using a standard UV detector, 
therefore selective and effective isolation of the compound of 
interest is necessary. 
The method developed for the serum analysis was successfully applied 
to the determination of PPA in urine with minor modifications (method 
II). Analysis of freshly collected urine samples from 10 human 
subjects presented no interfering chromatographic peaks. The final 
method used is simple, reproducible and yielded an analytically clean 
extract. 
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3.5 ANALYSIS OF PHENYLPROPANOLAMINE IN URINE 
3.5.1 EXperimental 
3.5.1.1 Sample Preparation 
Urine stock solution 
Twenty milligrams PPA.HCl was dissolved in 100.0 mL blank urine to 
yield a solution of 200.0 ~g/mL. Dilutions were made from this 
solution. 
Internal standard stock solution 
Forty milligrams EPH.HCl was dissolved in 100.0 mL water to yield a 
400.0 ~g/mL solution, which was then used as the internal standard 
solution. 
3.5.1.2 Chromatographic Conditions 
COlumn: 5 "m Techsil 
HPLC system: D (Section 2.3.1.2) 
Flow rate: 
Pressure: 
Temperature: 
Detection wavelength: 
Attenuation: 
Mobile phase: 
1.2 mL/min 
2.54 kpsi 
30·C 
210 nm 
0. 001 AUFS 
0.005 M HSS solution/ 
acetonitrile (77/23) with 0.15% 1 M HCl 
pH = 2.6 
3.5.1.3 Extraction Procedure 
To 1 mL of urine in a test tube, 100 ~L EPH . HCl aqueous solution (400 
~g/mL) was added, and 100 ~L of a 10% KOH solution to adjust the pH to 
13.8. The tube was vortexed for 20 sec. Eight millilitres of methylene 
chloride was added and the tube stoppered and vortexed for 30 sec. 
The aqueous phase above was then removed by aspiration and discarded. 
A pasteur pipette was used to transfer the methylene chloride extract 
into a tapered centrifuge tube containing 200 ~L 0.1 M HCl solution. 
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The tube was vortexed for 20 sec and centrifuged at 3 500 rpm for 1 
min. The methylene chloride layer was reduced by aspiration to about 
200 ~ and discarded, and the tube was re-centrifuged for 5 min at 
1 500 rpm. Aliquots of 80-100 ~L of the hydrochloric acid extract 
were transferred to glass inserts for use in the autos ampler and 20 ~L 
of this was directly injected onto the column. 
3.5.1.4 Calibration CUrve 
The urine stock solution was diluted with urine to yield different 
concentrations, 
trations ranged 
with the stock solution providing the sixth. Concen-
from 10.0 to 200.0 ~/mL and each concentration was 
determined in quadruplicate. A calibration curve was constructed. 
3.5.1.5 Precision 
Within-run precision was assessed in a similar manner to that 
described in section 3.3.1. 
3.5.1.6 Extraction Efficiency 
The method used for assessing extraction efficiency is described in 
section 3.3.1.6. 
3.5.2 Results and Discussion 
3.5.2.1 Linearity and Calibration 
The calibration curve (see Fig. 3.3) was found to be linear over the 
range of concentrations studied (10.0-200.0 ~g/mL) with a slope of 
0.019919, a y-intercept of 0.024292 and a correlation coefficient of 
0.9916. Relevant chromatograms are shown in Fig. 3.4. 
3.5.2.2 Precision 
Results of the within-run precision study in urine are shown in Table 
3.3. 
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TABL E 3.3 With in-run prec i sion study on uri ne assay 
I Concentra t ion mea sured y..g/mL) Spik.ed Sample number 
cone) j 
v.g/mL) I 2 3 4 5 6 Mean (SO) R50 
I 
200 188.94 185.58 194 .05 184.50 205 .83 206.30 194.2 (9.77) 5 .03~ 
100 102 .9 1 105.15 104.70 105.10 104.5 ( 1.05) 1.01~ 
60 64.29 65.0 1 68.40 66 . 34 65 .96 66.67 66.11 ( 1.43) 2. 16~ 
40 41.55 45.00 44.62 42.39 43.39 ( 1.68) 3.87~ 
20 
I 
17.91 18.75 18.03 17 .97 18 .1 7 (0.39) 2.161 
10 6.91 6.77 7.1 1 6.84 6 . 81 6.83 6 .89 (O.12) 1.74% 
, 
FIGURE 3.3 calibration curve of phenylpropanolamine in urine. 
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3.5.2.3 Extraction Efficiency 
The analytical recoveries of PPA from urine are shown in Table 3.4. 
The recoveries were constant over the entire concentration range 
studied, with a mean recovery of 83.49%. 
FIGURE 3.4 
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Chromatograms of (A) a blank urine extract and (8) a 
urine extract containing PPA (1) and EPH (2). 
2 
~ 
~ 
... L-..J 
A B 
Column: 5 lim Techsil 
Mobile Phase: Acetonitrile/HSS solution (0.005 M) 
(23.5/76 .5) with 0.2% 1 M Hel solution 
TABLE 3.4 Analytical recoveries of phenylpropanolamine from urine 
$ Recoverv 
Urine Sample number 
cone 
( .. g/mL) 1 2 3 4 5 Mean (SO) RSO 
10 74.39 76.5B 7B.29 75.37 77.32 76.39 ( 1.55) 2.02'k 
40 BO.14 BO.51 80.58 77.21 80.66 79.82 ( 1.47) 1 .84~ 
60 80.00 83.24 78.92 80.72 (2.25) 2.79$ 
100 83.27 80.22 82.51 84.79 84.79 83.11 ( 1.90) 2.28$ 
200 95.34 96.98 96.43 96.43 96.41 96.30 (0.59) 0.62$ 
Mean 'I recovery 
(n=23) 83.49 (7.42) 8.88% 
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3.5.2.4 Sensitivity and Detection Limits 
Under the conditions of this assay and based on a minimum signal to 
noise ratio of 10, the detection limit for PPA in urine was 5. 0 ~ g/mL. 
3.5.2.5 Background Interference 
The hydrochloric acid and endogenous urinary constituents eluted near 
the void volume and no interference with the PPA or EPH peaks was 
encountered. 
3.5.2.6 Stability of Samples on Storage 
Spiked urine samples, stored at -20·C, were assayed over a 3 month 
period and were found to be constant with respect to PPA content, with 
relative standard deviations falling within the acceptable range i.e., 
less than 10% at all concentrations . 
FIGURE 3.5 
Column: 
Mobile Phase: 
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Chromatogram of (e) a serum extract containing pseudo-
ephedrine (3). The retention time of pseudoephedrine 
was 6 min. 
3 
c 
5 11m Techsil 
Acetonitrile/HSS solution (0.005 M) 
(23.5/76.5) with 0.2% 1 M HCl solution 
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CHAPTER 4 
THE IN VIVO EVALUATION OF PHENYLPROPANOLAMINE 
In vivo trials on human volunteers were undertaken to enable the 
elucidation of the pharmacokinetic parameters of PPA. Although exten-
sively used, there is relatively little pharmacokinetic information on 
PPA absorption and disposition. 
4.1 PILOT TRIAL 
A pilot trial using two male volunteers was conducted to establish 
various conditions such as frequency and times of sampling as well as 
the PPA concentrations which could be expected in serum and urine 
after the ingestion of a single 25 mg and 50 mg dose of the raw 
material in soluti on, and the necessity for monitoring blood pressure. 
The volunteers (GB and JM) were non-smokers and had no previous 
history of hypertension. Individual details of the volunteers are 
given in Table 4.1. Blood and urine samples collected prior to the 
trial were subjected to clinical chemistry tests and were found to be 
normal. Each volunteer received a copy of the trial protocol and 
signed an informed consent form. They received an honorarium for 
participating in the trial and practised the same standardization 
procedures as described in section 4.2.4. 
The test dose consisted of either 50 mg (subject JM) or 25 mg (subject 
GE) PPA.HCl dissolved in 200 mL water ingested at 0 hours. Blood 
samples were drawn prior to the trial as a blank and then at 0.25, 
0.5, 1, 1.5, 2 , 2.5 , 4, 5, 6, 8, 9, 12 and and 24 hours after 
ingestion of the initial dose of the drug . Urine was collected before 
the trial as a blank and at 2, 4, 6, 8, 12, 24 and then randomly 
collected up to 48 hours. Blood pressure readings were taken at 0, 4, 
9, 12 and 24 hours after ingestion of the test dose . 
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The blood pressure readings seemed to indicate an increasing trend 
after ingestion of the drug, so blood pressure was monitored in 
subsequent trials to enable early detection of any possible dangerous 
rise in blood pressure. Hydralazine was kept available for any 
hypertensive emergencies. 
4.2 CLINICAL TRIALS: METHODS AND DESIGN 
To obtain meaningful data, randomized, controlled, crossover single 
dose and multiple dose studies were undertaken. 
4 . 2.1 Volunteers 
Five normal, healthy, caucasian adult male volunteers who were non-
smokers were selected to participate in both the single dose and 
multiple dose studies. 
The exclusion criteria were: 
1) if they had received medication within four weeks preceding the 
initiation of this study or 
2) required any concomitant medication on a daily basis; 
3) had a known hypersensitivity to PPA.HCl; 
4) had a history of serious cardiac, renal, hepatic or gastro-
intestinal disease; 
5) had an inability to communicate properly with the investigator. 
6) Diabetes mellitus, asthma and/or treatment with antidepressant 
drugs. 
Individual details of the volunteers are given in Table 4.1. 
A complete medical history was taken and physical evaluation made at 
the time of the initial visit. The following haematological examina-
tions, clinical chemistry and urinalysis were undertaken: 
Haematology: haemoglobin, haematocrit, WEe, platelet count, 
differential count, RBC. 
Blood chemistry: 
Urinalysis: 
These parameters, 
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serum creatinine, serum urea, blood sugar, serum 
bilirubin, serum alkaline phosphatase, SGPT and 
SGOT . 
specific gravity, bile, pH, protein, glucose, 
RBC, WBC, epithelial cells, granular casts. 
namely physical examination, medical history, 
haematology tests, clinical chemistry tests and urinalysis were 
evaluated and subjects with abnormal values were not admitted into 
this study. All subjects were normal with systolic blood pressure 
<140 mm Hg and diastolic blood pressure <90 mm Hg. 
TABLE 4.1 Details of volunteers 
Volunteer No. Code Name lYJe Body Mass (kg) Height (cm) 
1 GB 20 59 178 
2 WE 24 84 183 
3 JM 20 75 188 
4 AH 21 85 178.5 
5 JS 23 61 183 . 5 
Mean 21.6 72 . 4 182 . 2 
+ SD 1.82 12 . 91 4.10 
-
R.S . D. 8. 4% 17 .8% 2 . 2% 
All volunteers received a copy of the protocol, and written informed 
consent was obtained . The subjects selected indicated a willingness 
and good motivation to co-operate in this study . Volunteers were paid 
an honorarium for participating in the trial. All the test doses were 
compared in each subject . 
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4.2.2 Phenylpropanolamine Dosages 
A 
B 
Phenylpropanolamine hydrochloride 
Phenylpropanolamine hydrochloride 
25 mg 
50mg 
C = Phenylpropanolamine hydrochloride 100 mg 
The raw material was dissolved in 200 mL water and ingested at zero 
time. 
4.2.3 Treatments 
TRIAL 1 - Single Dose Study 
&IDj~t Phen~lpropanolamine Dosage 
CooeName Day 1 Day 8 Day 16 
GB C B A 
WE A C B 
JM A C B 
AH B A C 
JS B A C 
Each trial subject r~eived a single dose of either 25, 50 or 100 mg 
PPA.HCl powder dissolved in 200 mL water on the respective treatment 
days by random assignment. The washout perioo between study periods 
consisted of 7 days. The crossover was completed after each washout 
perioo with each subj~t r~eiving each treatment in the manner 
described above. 
TRIAL 2 - Multiple Dose Study 
Twenty five milligrams of the pure PPA.HCl powder (A), dissolved in 
200 mL water was administered to each volunteer at 0, 4, 8, 12, 16, 20 
and 24 hours. 
4.2.4 Standardization Procedure 
Identical test conditions were used for the treatment groups, as 
factors such as fasting and physical activity can influence drug 
absorption after oral administration. 
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1. The subjects received the study medication under close super-
vision while confined t o the clinical unit. Medications were 
weighed out in individual beakers and coded by subject code and 
labelled with the appr opriate study day. 
2. Subjects were confined to bed for the first five hours of the 
trial, except when urine was voided; thereafter volunteers were 
allowed to move about freely and encouraged to resume normal 
activities, but had to refrain from engaging in any strenuous 
activities. 
3. For the multiple dose study, each subject entered the clinical 
unit after the fifth dose of medication was administered, and 
remained confined to the unit until the end of the trial. 
4. All volunteers had to conform to the following conditions: 
(a) No drugs, including over-the-counter preparations, were 
allowed for at least a week before the trial and for the 
duration of the trial. 
(b) No alcohol was consumed for at least 48 hours before the 
trial and for the duration of the trial. 
(c) No caffeine-containing food or drinks were ingested for at 
least 48 hours before the trial and for the duration of the 
trial. This included coffee, tea, chocolate and cola drinks. 
(d) No food or drink was ingested for 10 hours before the start 
of the trial up until the serving of a standardized break-
fast two hours after taking the medication. 
5. The standardized breakfast, consisted of 3 slices of toast with 
margarine and jam and 250 mL orange juice and was given 2 hours 
after the administration of the medication. A low-fat standar-
dized lunch was given to all volunteers after the initiation of 
the study. 
4 . 2.5 Sampling Schedules for the Trials 
TRIAL 1 - Single Dose Study 
The sampling procedures for the trials are given in Table 4 . 2. 
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TABLE 4.2 Sampllng Schedule for Trlals 1 and 'L. 
SAMPLING TIME TRIAL 1 and TRIAL 2 
INrERVAL 
BLOOD URINE BLOOD PRESSURE 
-10 min B U BP 
01 8.00 am 
10 min 8.10 am B 
20 min 8.20 am B 
30 min 8.30 am B 
40 min 8.40 am B BP 
1 hr 9.00 am B U 
1.5 hr 9. 30 am B BP 
2 hr 10.00 am B 
BREAKFAST 
2.5 hr 10.30 am B BP 
3 hr ll.OO am B U 
4 hr 12.00 noon B 
5 hr 1.00 pn u 
UN:H 
6 hr 2.00 pn B 
7 hr 3.00 pn U BP 
8 hr 4.00 pn B 
9 hr 5.00 pn U 
10 hr 6.00 pn B 
11 hr 7.00 pn U 
SUPPER 
12.5 hr 8.30 pn B 
14 hr 10.00 pn B U 
16 hr 12 B BP 
midnight 
1 test dose ingested at this time 
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TRIAL 2 - Multi ple Dose Study 
After the seventh (24 hour) dose was administered the sampling 
schedule for the single dose study (Table 4.2) was followed. Before 
adminis tration of the 1st, 4th , 5th and 6th doses (12, 16 and 20 hour 
respectively) blood samples were obtained to obtain PPA serum trough 
levels i.e . venipunctures were done at varying intervals before the 
subsequent dose was given, and just before the 1st dose was 
administered to obtain a serum blank. 
4.2.6 Collection and Storage of Bleed Samples 
An indwelling 0 . 8 mm butterfly catheter (21 G, Medispo (Pty) Ltd., 
Industria, South Africa) was inserted i nto a suitable vein in the 
forearm and securely strapped into position with Micropore surgical 
tape (3M Medical Products Division, Johannesburg, South Africa) to 
allow complete mobility of the arm. 
A 10 mL blood sampl e was withdrawn from the butterfly thr ough a 
sterile hypodermic needle (0 . 8 x 40 LB, Medispo (pty) Ltd., South 
Africa) by syringe aspiration. The butterfly was then flushed with 
2 mL of sterile saline solution containing heparin (50 u/mL). 
Immediately prior to the withdrawal of a further bleed sample, the 
butterfly was cleared of the hepar in soluti on by withdrawal of 2 mL of 
bleed which was discarded. In a fresh syringe, 10 mL of blood was 
collected and transferred to a labelled vacutainer tube. The tube was 
stoppered and allowed to stand for 20 minutes for the bleed to clot. 
Serum was isolated through centrifugation at 3 000 rpm for 20 minutes. 
One and a half millilitres of serum was transferred to a clean labelled 
vacutainer tube for analysis. The remaining serum was transferred into 
a second labelled vacutainer for storage. In a few cases, the serum 
contained fibrin clots, which were squeezed with the aid of an orange 
stick to free the serum. These samples were re-centrifuged to separate 
the serum. Duplicate serum samples were each labelled with a five-digit 
number. The serum sampl es were stored at -20·C for a maximum of 2 weeks 
until analysis. Spiked serum samples were stored frozen for a maximum 
of one month until the assays were performed. 
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4.2.7 Collection and Storage of Urine Samples 
The collection and accurate recording of details were the responsi-
bility of each volunteer and were not Subject to the same rigid 
control as the collection of blood samples. The importance of strict 
adherence to sampling times and accurate recording of volume was thus 
stressed verbally in the protocol. 
Volunteers were asked, for each sampling time, to void urine into 500 
mL measuring cylinders, emptying the bladder as completely as possible 
each time. The total volume was measured by both the subject and co-
ordinator before a representative sample of about 10 mL was trans-
ferred to a labelled glass vacutainer tube for storage, and a 1.5 mL 
sample transferred to a second vacutainer tube for analysis. The rest 
of the urine was discarded. Urine pH readings were taken immediately 
after collection and then frozen and stored at -20·C for a maximum of 
2 weeks before analysis. Spiked urine samples were kept frozen for up 
to 6 months before analysis and no degradation of drug was observed. 
All drug samples were stored under identical conditions. 
Urine voided at times other than those specified in the protocol were 
collected in the same way as above. The exact time of voiding was 
recorded, as well as total volume. 
4.2.B Blood Pressure Readings 
Supine blood pressure readings were recorded by cuff and ausculation 
using a standardized mercury sphygmomanometer. Blood pressure was 
recorded at 0, 0.667 (40 min), 1.5, 2.5, 4, Band 16 hours after 
dosing. 
4.2.9 Reporting of Side Effects 
Patients who entered the study were asked to report any side effects 
or minor complaints throughout the course of the trial, and these were 
noted. 
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4.3 ANALYSIS OF BIOLOGICAL SAMPLES 
4.3.1 The Analysis of Serum 
Serum samples were analyzed in randomized order to avoid sequential 
effects . The aliquots (1.5 mL) were brought to room temperature and 
mixed thoroughly on a vortex mixer before being analyzed. The method 
of sample preparation and chromatographic conditions are described in 
section 3.3. TWenty microlitres of the final extract was injected 
onto the column. Both in vitro and ex vivo serum standards were 
prepared and analyzed under blinded conditions to monitor 
bility of the method. All serum samples obtained for the 
reproduci-
test and 
reference preparations were stored under identical conditions and 
assayed by the same method. 
4 . 3.2 The Analysis of Urine 
Urine samples were brought to room temperature and mixed as in section 
4.3.1. Each urine sample was analyzed according to the method 
described in section 3 . 3 and 20 microlitres of the final extract was 
injected into the column. Urine test samples, ex vivo and in vitro 
samples were analyzed in duplicate in a randomized order and all 
samples were assayed under identical conditions. 
4 . 3.3 In vitro Quality Control for Phenylpropanolamine 
The performance of the assay procedure was continuously monitored 
during the period of assay of the biological samples by 
quality control specimens containing known concentrations 
including 
of the 
analyte. These in vitro quality control samples were stored under 
identical conditions to those applying to actual trial samples. 
4.3.4 Ex vivo Quality Control for Phenylpropanolamine 
Additional blood was obtained from all trial subjects at pre-
determined times during Trials 1 and 2 and each serum or urine sample 
was divided into five aliquots. After analyzing one aliquot of each 
sample, eight that contained the analyte at concentrations spanning 
the expected range, were selected and re-analyzed at different times 
during the course of the analytical study. Th~se ex vivo quality 
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control samples were stored under identical conditions to those 
applying to actual trial samples. 
4 . 4 RESULTS 
4.4.1 Side Effects 
Side effects were reported by 4 of the volunteers after ingestion of 
the 100 mg PPA dose, and by 3 volunteers after ingestion of the 50 mg 
dose. No side effects were noted after the 25 mg PPA dose_. Several 
relatively minor complaints were reported (Table 4.3) . 
disappeared when blood pressure returned to normal. 
TABLE 4.3 Side Effects (All Patients) 
PPA PPA PPA 
25 "" 50 "" 100 "" 
Central Nervous system 
he~ache 0 0 1 
anxiety 0 2 3 
tiredness/lightheadedness 0 2 4 
Autonomic Nervous System 
dry mouth 0 3 3 
Gastrointestinal 
heartburn/epigastric pain 0 1 0 
nausea 0 3 3 
cramps 0 1 0 
Genito-urinary 
f requent urination 0 1 2 
Miscellaneous 
awareness of heart beat 0 2 3 
Some patients reported more than one complaint 
4.4.2 Blood Pressure Response to Phenylpropanolamine 
All symptoms 
Since this study was designed primarily to measure serum levels of PPA 
no placebo group was included . 
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Table 4 4 Blood pressure response to PPA 
Basel ine 
Dose PPA BP (mmHg) Max imum BP (mm Hg) Change BP (mm Hg) 
Img) ISystiOiast) (Syst/Oiast) ISystiOiastl 
25 121>6/77> 7 120: 10/74 ! 9 '~2/-3:5 
SO 11414/78: 13 139 '17/89' 12 25!1/11!7 
100 116'12/80'4 146! 16/94' 9 3D! 1/14:t8 
-Data are x "tSD 
n == 5 B? = Blood Pressure, Syst = systolic, Oiast == diastolic 
Table 4 5 Mean supine blood pre ssures and mean PPA serum levels 
PPA: 25 I11l PPA: SO I11l PPA: 100 I11l 
BP (IMlHg) Serum level BP IIMlHg) Serum level BP (IMlHg) Serum leve 
Hour (Syst/Oi ast ) I ng/mL) ISyst/Oiast) (ng/mL) (Syst/Oiast) Ing/mLI 
0 121/77 0.0 114/78 0.0 116/80 0.0 
0.66 114/72 92.7 120/85 130.5 136/88 288.4 
1.5 120/73 95.2 127/83 172.7 146/92 385.3 
2.5 109/68 78.5 134/84 148 . 1 132/79 329.3 
4 110/66 58.3 118/68 112.9 122180 249.9 
8 110/70 31.7 120/80 60.8 120/81 139.5 
16 120/75 8.3 117/80 15.5 120/80 31.9 
n == 5 BP = Blood Pressure. 5yst == systolic. Diast = diastolic 
Phenylpropanolamine increased blood pressure in a dose related fashion 
(Table 4.4). The highest blood pressure reading after 100 mg PPA was 
160 mmHg systolic and 89 mmHg diastolic. Maximum increases occurred 
between 1 and 3 hours after PPA. Both systolic and diastolic blood 
pressures increased 90 minutes after 100 mg PPA values (Table 4.5). 
High serum levels of PPA appear to produce predictable responses in 
blood pressure. Patients receiving PPA showed small increases in mean 
systolic and diastolic blood pressure compared with baseline values 
(Table 4.4). Changes in mean blood pressure in the multiple dose 
study were found to be insignificant. Although there have been 
reports in recent years of adverse haemodynamic reactions to PPA 
(refer to section 1.5), our findings found that changes in mean blood 
pressure were clinically insignificant. 
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The variability of blood pressure readings reported throughout the 
test day is not unexpected. Pickering et aL. (243) found that normal 
subjects had varied responses to different situations, with diastolic 
pressures ranging from 64 mm Hg for sleep to a high of 81 mm Hg for 
work. 
PPA increased blood pressure with significant inter-subject 
variability. This inter-subject variability in the blood pressure 
response has been documented (83), although the reason for such 
variability is unknown and of great interest. Differences in pharma-
cokinetic parameters such as absorption, bioavailability, serum 
concentration dependency and receptor sensitivity have been proposed 
to explain this variability. American studies, which use the racemic 
mixture of PPA, have found either significant bl ood pressure 
elevations (85, 244) or no alteration (80, 245). The studies support 
marked inter-subject variability in blood pressure response to PPA 
similar to that demonstrated in this study. Individual blood pressure 
readings are listed in Table A 4.2 . 
4.4.3 Clinical Trial 
The serum and urine concentrations from Trial 1 and 2 are presented in 
Tables Al.l - Al.6 and the curves from Trial 1 depicted in Figs. 4.2-
4.6. The mean serum concentration and urinary excretion profiles from 
the 5 subjects after the ingestion of a 25 mg, 50 mg or 100 mg PPA.HCl 
solution are shown in Figs. 4.7-4.9. The concentrations were within 
the quantitative range of the described method. The results obtained 
from the multiple dose study (Trial 2) are presented in Tables A 1.7 -
A 1.8. Serum concentrations and urinary excretion profiles after the 
ingestion of a 25 mg PPA.HCl solution at 12, 16, 20 and 24 hours after 
the first dose was administered are depicted in Figs. 4.10-4.14. 
In the 25 mg single dose solution study, absorption of the drug was 
rapid with peak blood concentrations occurring 40 minutes to 1.5 hours 
after ingestion of the solution and the concentrations ranged between 
69 and 185 ng/mL of serum. Subject JM exhibited an extremely rapid 
absorption rate with a serum concentration of 185 ng/mL after 40 
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minutes, whereas the mean concentration of the other 4 subjects was 69 
ng/mL at the same time. This discrepancy could be attributed to 
individual variability. In a study reported by Mason and Amick (223), 
the mean peak level occurred 2 hours after ingestion of a 25 mg 
PPA.HCl solution. After 16 hours, serum concentrations of the 25 mg 
solution study could not be accurately quantitated since they were 
found to be below 5 ng/mL. 
Absorption of the drug in the 50 mg single dose solution study 
occurred 30 minutes to 1.5 hours after ingestion of the test dose and 
concentrations ranged between 149 and 207 ng/mL . In the 100 mg 
PPA.HCl solution study, peak concentrations occurred 1 to 2 . 5 hours 
after ingestion and ranged between 308 and 480 ng/mL. Two subjects, 
AH and JM exhibited more rapid absorption rates compared to the other 
subjects in the 25 mg, 50 mg and 100 mg PPA.HCL solution study . 
Conversely the absorption for subject WE was 1 hour slower for the 100 
mg solution study, and for Subject AH absorption was slower as the 
dose increased . 
In the multiple dose study, serum concentration trough values varied 
between 72 and 130 ng/mL. Subjects JM and AH again displayed very 
rapid absorption with peak serum concentrations occurring 30 minutes 
after ingestion of the final test dose . This rapid absorption in 
these 2 subjects compares with that in Trial 1. Maximum serum concen-
trations of the multiple dose study were higher than those of the 
single dose 25 mg study and had a fairly narrow range (168-198 ng/mL). 
Recovery of PPA from the urine after ingestion of 25 mg and 50 mg 
PPA.HCl was monitored for 24 hours in the pilot trial. An insignifi-
cant amount of PPA was found in the urine after 14 hours, and thus PPA 
was monitored for 14 hours in all subsequent trials. Sinsheimer et 
a2 . (241, 246) reported that 90% of the 25 mg oral dose was excreted 
in the urine as unchanged PPA, while in another report (247) 80-90% of 
the dose was excreted unchanged within 24 hours. Mean urinary recovery 
for the 5 subjects was : 
a) 25 mg dose: 64.03% 
b) 50 mg dose: 63.30% 
c) 100 mg dose: 72 .98% 
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Recovery could have been greater if the urine had been collected for a 
longer time as PPA was still clearly detectable in the 
hours. Urinary excretion of PPA in the 5 subjects 
dosing of 25 mg PPA.HCl was 68 mg, 67 mg, 73 mg, 
blood after 16 
after multiple 
60 mg and 61 mg 
respectively. Urine pH readings are listed in Table A 4.1. Biphasic 
serum concentration curves were observed repeatedly in a few subjects 
(WE, AH, GE) at different dose levels. This phenomenon has been 
discussed by Benet (248) and a physiological meaningful explanation 
can be given, when the possibility is considered, that the actual data 
are not concentration data of one compartment alone. A possibility 
mentioned was some kind of recycling mechanism other than biliary 
recycling (e.g. via the lymph system). 
The method of blood withdrawal using butterfly sets was convenient as 
relatively little pain or trauma occurred in the initial insertion of 
the needle and after securing the butterfly with tape, the arm could 
be moved freely. Less trauma is associated with this method than with 
multiple venipuncture. 
Table 4.6 details the inter-day precision of the method at three 
different serum concentrations using spik~i in vitro serum standards. 
In Table 4.7, the inter-day and precision at three different urine 
concentrations using sp;.ked in vitro urine standards are presented. 
The ex vivo urine and serum samples assessed during each run are 
depicted graphically in Fig 4.1. Average R.S.D.s for the method were 
less than 10% at all concentrations. 
The method of extraction and subsequent determination of PPA from 
is sensitive and precise. No derivatization is 
the extraction was relatively simple with the back-
serum and 
necessary, 
extraction 
solvent, 
urine 
and 
step eliminating the need for evaporation of the organic 
thus decreasing total sample preparation time significantly. 
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Concentrations of PPA following a single oral solution dose can be 
determined, which demonstrated that the method is adequate for use in 
bioavailability studies. 
lAB lE 4.6 Inter-day precision for phenylprop~noldmine in serum 
1 2 3 4 5 6 Mean (SO) RSO 
High concentration (s~iked; 548.4 ng/mL) 
518.5 544 .9 514 . 4 570.7 568.7 550.1 544.55 (24.02) 4.41% 
Medium concentration (spiked: 219.4 ng/mL) 
229.9 200.4 198.6 247.6 218.5 214.9 218.32 (18.51) 8.48% 
Low concentration (spiked: 25.12 ng/mL) 
21.9 24.2 26.8 28.8 25.5 25.2 25.41 (2.323) 9.141 
TABLE 4.7 Inter-day precision for phenylpropanolamine in urine 
1 2 3 4 5 6 Mean (SO) RSD 
High concentration (spiked: 128.6" g/mL) 
113.92 109.4 122.20 109.70 115.20 126.90 116.22 (7.00) 6.02% 
Medium concentration (spiked: 51.44" g!mL) 
53.36 58.47 53.02 49.36 55.20 43.76 52.2 (5.09) 9.76% 
low concentration (spiked: 10.28" g!mL) 
8.55 7.80 7. 80 9.76 11.06 9.02 8.998 (1.257) 13.97% 
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In vivo urine (a) and serum (b) samples assessed during 
each run. 
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FIGURE 4 . 3 Serum concentrations (al and urinary excretion profiles 
(bl from Subject AH after the ingestion of 25, 50 and 
100 mg PPA.HCl solution. 
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Serum concentrations (a) and urinary excretion profiles 
(b) from Subject JS after the ingestion of 25, 50 and 
100 mg PPA.HCl solution . 
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Serum concentrations (a) and urinary excretion profiles 
(b) from Subject WE after the ingestion of 25, 50 and 
100 rng PPA.HCl solution. 
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Serum concentrations (al and urinary excretion profiles 
(bl from Subject JM after the ingestion of 25, 50 and 
100 mg PPA.HCl solution. 
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Mean serum concentrations (a) and urinary excretion 
profiles (b) ± SD of 5 subjects after the ingestion of 
25 mg PPA.HCl solution . 
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Mean serum concentrations (a) and urinary excretion 
profiles (b) + SD of 5 subjects after the ingestion of 
50 mg PPA.HCl solution. 
(a) 
2 4 6 8 10 12 14 16 
TIME (HOURS) 
(b) 
2 468 10 12 14 
T I ME (HOURS) 
FIGURE 4.9 
500 
~ 
..J 
x: 400 
"-
<.:> 
z 
z 
0 JOO 
I-
< 
'" I-
Z 
w 
u 200 
z 
0 
u 
x: 100 ::::> 
'" w
(J) 
0 
<.:> 75 
5 
c 
W 
I-
W 
'" 
50 u 
x 
W 
I-
Z 
::::> 
0 25 x: 
< 
o 
o 
0 
107 
Mean serum concentrations (a) and urinary excretion 
profiles (b) ± SD of 5 subjects after the ingestion of 
100 mg PPA.HCl solution . 
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Serum concentrations (a) and urinary excretion profiles 
(b) from Subject GB after the ingestion of a 25 mg 
PPA . HCl solution every 4 hours for seven doses. 
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Serum concentrations (a) and urinary excretion profiles 
(b) from Subject AH after the ingestion of a 25 mg 
PPA.HCl solution every 4 hours for seven doses. 
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FIGURE 4.12 Serum concentrations (a) and urinary excretion profiles 
(b) from Subject JS after the ingestion of a 25 Irq 
PPA.HCl solution every 4 hours for seven doses. 
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Serum concentrations (a) and urinary excretion profiles 
(b) from Subject WB after the ingestion of a 25 mg 
PPA . HCl solution every 4 hours for seven doses . 
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FIGURE 4.14 Serum concentrations (a) and urinary excretion profiles 
(b) from Subject JM after the ingestion of a 25 mg PPA.HCl 
solution every 4 hours for seven doses. 
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O1APTER 5 
PLASMA PROTEIN BINDING STUDY USING EQUILIBRIUM DIALYSIS 
5.1 INTRODUCTION 
It is commonly accepted that binding of drugs to plasma constituents 
plays an important role in the pharmacodynamics of highly beund 
substances. Plasma protein binding of drugs may cause detectable 
nonlinearity in log C versus t plots if doses are sufficiently high to 
approach saturation of binding sites and there is negligible elimina-
tion of the beund drug (249). Quantitative implications of protein 
binding in pharmacokinetics have been evaluated by means of numerical 
methods for one and two compartment models (250). 
Although there are a variety of techniques for carrying out plasma 
protein binding measurements of ·drugs (251), equilibrium dialysis is 
one of the most popular, accurate and reliable methods available (251, 
252) . In this method, the serum sample and a non-protein drug-free 
buffer solution were placed on either side of a semi-permeable 
membrane. Unbcund drug in plasma passes through the membrane until, 
at equilibrium, the concentration of drug in the buffer solution and 
that unbcund in the plasma are equal. By measuring drug on beth sides 
of the membrane, the fraction of drug in plasma unbcund is readily 
assessed. A semi-permeable 'membrane permits diffusion of the small 
molecules (referred to as the dialysate or diffusate), and retains the 
macromolecules (the retentate). The diffusion of the small molecules 
occurs under the influence of a concentration gradient . 
5.2 EXPERIMENTAL 
5.2.1 The Dialysis Membrane 
The dialysis membrane consisted of Vis king cellulose dialysis tubing 
4465-A2 (Union Carbide), with an average pore diameter of 480 nm. 
Besides cellulose, the tubing contains glycerine, water and small 
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amounts of sulphur compounds (approximately 0 . 1%) . The latter may 
interfere with spectral methods of analysis. The membrane was 
therefore washed free of such materials and pre-treated by boiling in 
distilled water for 90 min. Excess treated membrane was stored in 
distilled water in a refrigerator (0-4 °C) for further use. 
The membrane is permeable to water and will allow low molecular weight 
compounds in aqueous solution to diffuse through while higher 
molecular weight materials such as proteins are retained. 
5.2.2 Buffer Solution Preparation 
The 0.05 M phosphate buffer used in these studies was prepared by 
adding 3.2 mL phosphoric acid to 1.0 litre of freshly prepared HPLC 
grade water. Sodium hydroxide pellets were added to the acid/water 
mixture with constant stirring on a magnetic stirrer until the desired 
pH of the buffer had been attained (pH 7.21). 
5 . 2.3 The Dialysis Apparatus 
Equilibrium dialysis was carried out in an apparatus consisting of two 
plexiglass blocks, each having five cavities and seven holes at the 
corners and sides. A small glass bead (3 mm diameter) was placed into 
each cavity to enable agitation. The pre-treated dialysis membrane 
was placed between the blocks with the cavities facing each other. 
The blocks were firmly held together by the use of seven stainless 
steel bolts and secured with stainless steel wingnuts . Each block has 
a threaded hole entering each cavity for the i ntroduction of solution 
or removal of sample for analysis. The compartments on each side of 
the dialysis membrane measured 17.5 mm in diameter and 4.0 mm in 
depth. The volume of each compartment is approximately 1.0 mL. A 
serum sample (0.9 mL) was placed into the cavity on one side of the 
membrane, and the same volume of buffer was placed on the other side 
of the membrane. The entire assembly was then stoppered tightly by 
means of plastic screw-plugs. The cell was then attached to a shaking 
device which raised and lowered the cell 30 times/min at constant 
temperature for 24 hrs. 
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5.2.4 Serum Samples 
Spiked serum samples were prepared as in Section 3.3.1.1 in concentra-
tions ranging from 50 to 500 ng/mL. The in vivo serum samples were 
taken from previous clinical trials (see Section 4.2). Samples from 
subject AH, after the ingestion of 100 mg PPA.HCl in solution were 
used for concentrations from 95 to 280 ng/mL. 
Prior to analysis the serum was thawed and allowed to reach room 
temperature. Ehrnebo et al. (253) showed that freezing and thawing of 
serum samples do not affect the binding capacity of serum. 
5.2.5 Assay Procedure 
After equilibrium, aliquots (0.750 mL) were removed from both sides of 
the membrane for analysis. Serum samples and corresponding buffer 
solutions were analyzed as described in Section 4.3.1. Each concentra-
tion was analyzed in duplicate. A calibration curve was constructed 
as in Section 3.3.1.4, from which the concentration of undialysed 
serum samples was obtained. 
5.2.6 calculation of Binding Capacity 
Equation 5.1 (253) was used to determine the percentage of bound drug: 
(C 1 - C -f ) x 100 p asma -buf er 
% bound = (5-1) 
Cplasma 
where C 1 =concentration of drug in the serum compartment after p asma 
dialysis, and Sbuffer=concentration of drug in the buffer compartment 
after dialysis. 
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5.3 RESULTS AND DISCUSSION 
Plasma contains many proteins, albumin being the most abundant of all 
(see Table 5.1). Basic drugs, however, often associate more avidly 
with other proteins, particularly alphal-acid glycoprotein and lipo-
proteins, than with albumin (254). Proteins such as gammaglobulin, 
transcortin, fibrinogen and thyroid-binding globulin also bind drugs; 
they tend to be more specific with respect to the drugs they bind and 
usually have a much smaller capacity for binding. 
TABLE 5.1 Major proteins to which drugs bind in serum. 
Normal range of 
concentrations 
Protein Molecular weight (g!liter) (molar) 
Albumin 65,000 35-50 5-7.4xlO -4 
alphal-Acid glycoprotein 44,000 0.4-1. 0 0.9-2.2xlO -5 
Lipoproteins 200,000-3,400,000 Variable 
Table 5.2 lists hypothetical drugs and the changes expected in the 
volume of distribution, clearance and half-life on decreasing binding 
(increased fraction unbound). Drug-protein binding depends on four 
major factors: the affinity between drug and protein, the concentra-
tion of drug, the concentration of protein, and the presence of other 
substances which can either compete for the binding sites or, through 
allosteric effects, alter drug binding (251). Ingestion of food, 
particularly fats can reduce drug binding, although the mechanism is 
poorly understood (255). Table 5.3 lists the plasma binding values 
obtained for phenylpropanolamine in subject AH and spiked serum 
samples. 
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TABLE 5.2 Pharmacokinetic consequences of decreased binding to 
plasma proteins 
VolUJne of 
di striootion Volume of 
Drug clearance (litres) distrirution c l earance Half-life 
-
a b 
A High 8 <-> <-> ~ 
B High 100 t <-> r 
c t ~ C Low 8 <--+ 
0 Low 100 t t <--;. 
•.. 
a 
Extraction rati o cl ose to 1.0 
b Symt:ols : -+-+. little or no change; i increase; ! , deeredse 
c 
Extraction ratio less than 0 . 1. 
TABLE 5 3 PI a5ma P t ro eln l ulg 0 f Ph 1 1 eny propano am~ne . 
Serum concentration Percentage Bound 
(Total) og/mL (%) 
1 2 lr (SO) R. S.D. 
95.76 4.91 3 . 40 4 . 155 (1.067) 25.69% 
153.89 12.66 9 . 86 11.26 (1.97) 17.58% 
220 . 03 9 . 87 12.32 11.09 (1.73) 15 . 60% 
280.69 15.68 19 . 90 17.79 (2 . 98 ) 16 . 77% 
Figure 5 . 1 illustrates a simple and useful graphical form of represen-
tation : i t may be used to directly assess the fraction of bound drug 
and hence the bound concentration for a given total plasma concentra-
tion. Other methods most commonly used for graphically representing 
t he results of a binding study in terms of linearization procedures 
include the Scatchard plot (256) or the double reciprocal plot (257) . 
FIGURE 5.1 
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Relationship between plasma binding of phenylpropa-
nolamine and concentration of drug in human plasma. 
• 
• • 
• 
• 
• 
• 
• • 
The degree of binding of 
PPA in serum obtained from 
patient AH (6) varies with 
concentration. The binding 
in this volunteer is un-
affected, however, by PPA 
administration itself: the 
• 
• control values (5) , 
100 200 JOO 400 500 
SERUM CONCENTRAT I ON ING/Mll 
obtained from the spiked 
samples were no different 
to those of subject AH (6). 
Any influence of plasma binding on drug elimination may best be under-
stood by a consideration of clearance (258). Measured directly across 
an eliminating organ, clearance is the product of blood flow and 
extraction ratio. For drugs where the extraction ratio approaches 
uni ty, and clearance approaches blood flow, all drug passing through 
the organ is extracted, whether bound or not. For such 
clearance should be unaffected by changes in plasma binding. 
the extraction ratio is low should clearance be affected by 
binding (259). 
drugs, 
Only if 
plasma 
The volume of distribution of most drugs far exceeds the plasma 
volume, so that only a small percent of the dose within the body is in 
plasma, and changes in plasma binding are too small to affect the 
unbound drug concentration. Changes in binding can affect the half-
life (t, ) , 
~ 
unaffected, 
and when binding is diminished and urinary clearance is 
the half-life of a poorly cleared drug is shortened (251). 
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Plasma protein binding of PPA was only slightly dependent on the 
concentration in serum. However, the objective here was to establish 
the influence of PPA serum concentration on the relative, not 
necessarily the absolute, drug binding capacity of plasma. Caution 
should be exercized in the interpretation of the results due to 
problems associated with protein binding studies using equilibrium 
dialysis. The problems include volume shift (260-262), adsorption of 
drugs to dialysis membranes and apparatus (263), pH shift as a result 
of bacterial growth (264) and effect of equilibration time on pH 
(265). No bacterial growth was observed in this study. However, a 
small shift in volume did occur. This volume shift was not accounted 
for as it was difficult to accurately quantify due to the small 
capacity (1 mL) of the dialysis cells. 
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CHAPTER 6 
PHARMACOKINETIC ANALYSIS OF SOLUTION DATA 
6.1. INTRODUCTION 
The word "pharmacokinetics" means the application of 
pharmacon, the Greek word for drugs and poisons. The 
pharmacokinetics is to study the time course of drug and 
kinetics to 
purpose of 
metabolite 
concentrations and amounts in biological fluids, tissues and excreta, 
and to construct suitable mathematical models to interpret such data 
(266). A major problem in pharmacokinetics is to develop an adequate 
method to describe or interpret one or more data set(s), and 
frequently the method leads to a compartment model. 
A "compartmentalized" system is an approximation for a biological 
system because variations in homogenicity of the media and diffusion 
processes are all interrelated with chemical changes. A compartment 
is thus an "average" rather than an exact state (267), and most 
pharmacokinetic models are deterministic in nature. The major contri-
bution of a suitable model is that it allows the investigator to apply 
mathematical techniques, even though these compartments have no 
apparent physiologic or anatomic reality. 
The behaviour of a drug in a biological system can usually be 
described in terms of either a one, two or multi-compartmental model, 
and most models are based on linear systems of differential equations. 
Kinetic linearity may be defined as direct proportionality of transfer 
rates to concentrations or concentration differences. It also implies 
that elimination of drug obeys first order kinetics. A consequence of 
a linear system in pharmacokinetics is that the total area under serum 
concentration-time curve is a linear function of the dose adminis-
tered, if the fraction of drug which is protein-bound in plasma 
remains essentially constant in the range of concentrations of 
interest and if the fraction absorbed remains constant. Linear 
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kinetics assuw~ that the tissues are far below the saturation level 
and that the concentration of drug in each tissue at a given time 
after dosing is a linear function of dose. 
The three most common causes of nonlinear pharmacokinetics are: a) the 
operation of Michaelis-Menten or some other nonlinear elimination 
kinetics; b) the presence of saturable tissue-binding coupled with the 
fact that doses are administered which take one into the nonlinear 
region of binding; 
enough to take 
binding. 
and c) the administration of doses which are high 
one into the nonlinear region of plasma protein 
6.2. LINEAR COMPARTMENT MODELS. 
6.2.1. The One Compartment Model. 
The one compartment model, the most simple pharmacokinetic model, 
depicts the body as a single homogenous unit. This model is useful for 
the pharmacokinetic analysis of serum concentration, and urinary 
excretion data for drugs which rapidly distribute between plasma and 
other body fluids and tissues upon entry into the systemic circula-
tion. To assume the body behaves as a one compartment model does not 
necessarily mean that the drug concentrations in all the body tissues 
at any given time are the same. However, a one compartment model does 
assume that any changes that occur in the plasma quantitatively 
reflect changes occurring in the tissue drug level. 
A second criterion for using a one compartment model is that drug 
elimination occurs from the body in a first-order fashion. Drug 
elimination can occur from the body by many processes, including renal 
and biliary pathways, biotransformation, and excretion in the expired 
air. Glomerular filtration in the kidneys and passive diffusion into 
bile are simple first-order filtration processes, whereas tubular 
kidney secretion, biotransformation and biliary secretion frequently 
involve active processes. At low concentrations these latter 
processes can be approximated by linear kinetics with the apparent 
, . 
1 
: .' 
t , 
I , 
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first-order elimination rate constant being the sum of the rate 
constants of a number of individual processes 
6.2.2. The Two Compartment Model. 
Most drugs entering the systemic circulation do not instantly 
distribute between the blood and other body fluids or tissues. Body 
fluids or tissues which are in equilibrium with the circulatory system 
form the central compartment which is accessible through blood 
sampling. The levels of drug associated with the central compartment 
should decline more rapidly during the distributive phase than during 
the post-<l.istributive phase. In contrast, levels of drug in body 
fluids or tissues into which the drug distributes slowly (peripheral 
compartment) will increase to a maximum and then begin to decline 
during the distributive phase until eventually a steady state will be 
reached which terminates the distribution phase. The access of drugs 
to the various poorly perfused tissues may occur at different rates. 
Frequently however, for a given drug these rates appear to be very 
similar and cannot be differentiated based solely on plasma 
concentration-time data and consequently, all poorly perfused tissues 
are often "lumped" into a single .peripheral compartment. The 
peripheral compartment of pharmacokinetic models are, at best, hybrids 
of several functional physiologic units. Drug elimination and 
transfer of drug between body compartments in multicompartment systems 
are assumed to occur by first-order processes. 
There are· 3 possible types of two compartment models (depicted in Fig. 
6.1) • They differ in that elimination occurs either a) from the 
central compartment, b) from the peripheral compartment, or c) from 
both these compartments. It is usual to assume that drug elimination 
from two-compartment systems takes place exclusively from the central 
compartment and all subsequent equations in this section are based on 
this assumption. The basis of this assumption is that the major sites 
of biotransformation and excretion i.e., the liver and kidneys, are 
well perfused with blood and are therefore rapidly accessible to drug 
in the systemic circulation. 
FIGURE 6.1 
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Schematic representation of three types of two 
compartment systems consisting of a central compartment 
and a peripheral compartment. 
! a ' I b l 
1< I 
Definition of terms: 
= 
= 
= 
first order rate constant for transfer of drug from 
central compartment to peripheral compartment. 
first order rate constant for transfer of drug from 
peripheral compartment to central compartment. 
first order rate constant for elimination of drug by all 
processes from central compartment. 
first order rate constant for elimination of drug by all 
processes from peripheral compartment. 
6.3 ASSESSMENT OF PHARMOKINETIC PARAMETERS 
6.3.1 Bioavailability 
Bioavailability has been defined as the measurement of both the 
relative amount of 
circulation (i.e. 
an administered dose that reaches the general 
the extent of absorption of a given dose) and the 
rate at which this occurs (268). In all cases, except where a drug is 
administered intravenously in the form of a true solution, the drug 
has to be released from the dosage form and then be absorbed into 
systemic circulation by passing through various membranes . Differences 
in onset, intensity and duration of the pharmacological or clinical 
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effect are primarily due to differences either with the 
(physiologically modified bioavailability) or the dosage form 
form modified bioavailability). 
patient 
(dosage 
In testing bioavailability one has to carefully design the protocol in 
order to minimize physiologically based modifications of bioavailabi-
lity where possible. These include age, sex, physical state of the 
patient, time of administration, stomach emptying rate, type and 
amount of food and body weight, and the logical consequence is a true 
cross-over design. 
The ~n vivo bioavajlability of a drug product is demonstrated by both 
the rate and extent of absorption of the active ingredient. There are 
several possible approaches to measure bioavailability, namely blood 
level data, urinary excretion data and pharmacologic data. If blood 
level studies are not feasible, they can sometimes be substituted by 
urinary excretion studies. If the drug cannot be accurately assayed in 
biological fluids, a pharmacologic method can be used to substitute 
for blood level or urinary excretion studies. 
Although, in general, we assume that the drug concentration in blood, 
plasma or serum correlates with the pharmacologic response, it is not 
applicable to all drugs and the actual bioavailability testing does 
not attempt to determine the drug concentration at the site of the 
drug action but in the systemic circulation. Even if the biophase, 
the locus of interaction between the drug and the cell, is not in the 
systemic circulation but somewhere in the tissues, the drug 
concentration in the systemic circulation may still correlate with the 
therapeutic response, since the transfer of free, non-protein bound 
drug from the circulation to the tissue depends on the concentration 
gradient and can be described mathematically. 
active transport is involved. 
Exceptions are where 
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The most precise evaluation of extent and rate of bioavailabi l ity is 
obtained from single or multiple intravenous dose blood level studies 
followed by single- or multiple dose urinary excretion studies. The 3 
parameters that charac terize the rate an extent of bioavailability are 
a) area under curve (AUC) b) actual peak height and c) time to reach 
the peak. When a given dose of drug is administered at uniform time 
intervals, the serum concentration-time profile in each dose interval 
will change in such a manner that the maximum and minimum concentra-
tion both increase with increase in number of doses until eventually a 
steady state is reached. Linear pharmacokinetic theory indicates that 
the area from zero to infinity under a single dose curve will be equal 
to the area within a dosage interval at the steady state, provided 
that the dose, the fraction of the dose which is absorbed, the dosing 
interval and the mean clearance remain constant in a given subject. 
Pharmacokinetic methods for determining availability are often model-
independent and when dose independent kinetics are assumed, all 
distribution and elimination processes are assumed to proceed in a 
firs t-order fashion. The availability of a drug or its active 
metabolite(s) to the end-organ is controlled by t hree factors: a) the 
rate and extent of release of drug from the dosage form b) the so-
called "first pass" effect whereby, when a drug is administered 
orally, only a certain fraction presented to the gastrointestinal wall 
and the liver reaches the general circulation intact, and c) the 
combined processes of plasma protein-binding, tissue-binding , drug 
distribution, metabolism and urinary, fecal or lung excretion . 
6.3.2. Assessment of Extent of Absorption 
Absorption of drugs involves the process of uptake of the compound 
from the site of administration into the systemic circulation (269). 
Methods of assessing extent of absorption which do not involve the 
determination of the absorption rate, rely on fewer assumptions and 
are easier to apply to experimental data than methods for assessing 
the absorption rate. Calculation of the fraction, F , and the dose , D, 
which is absorbed and reaches the general circulation reflects the 
extent of absorption. 
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The most frequently used approach to the measurement of extent of 
absorption is to compare ~he area under the concentration-time curve, 
and the method for estimatIng area under the curve (AUC) is usually 
the linear trapezoIdal method: 
AUC (6-1) 
Errors arise if sampling intervals are long relative to the half-life 
of the drug and if the function to be assessed shows marked curvature. 
The use of the linear trapezoidal method results in considerable 
under-estimation of the area during the absorption phase and over-
estimation of the area in the post-absorption phase, where the curve 
decreases in an approximately exponential manner. Chiou (270) and Yeh 
and Kwan (271) investigated errors associated with trapezoidal 
integration. 
The log trapezoidal method, which employs an exponential rather than a 
linear approximation to the data, has been applied to the post-
absorption phase where the function declines monoexponentially. The 
log trapezoidal equation is shown below: 
Cn -Cn_ 1 
AUC = (6-2) 
To determine AUC the assumption is made that concentration decreases 
monoexponentially after the last data point. When elimination is by a 
first order process, this decline must be measured for a sufficient 
time prior to the last data point to enable an accurate estimation of 
, . 
i ' 
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the slope of the terminal portion of a semilogarithmic plot of concen-
tration vers~ time . Another model-independent method proposed for 
assessing the extent of absorption is based on estimating the renal 
clearance, plasma clearance and urinary excretion of the unchanged 
drug (272). 
6.3.3. Assessment of Rate of Absorption 
Drug absorption after oral administration is frequently assumed to 
occur by an apparent first-order process, and is therefore quantified 
in terms of an apparent first-order absorption rate constant ka. This 
may be accomplished by appropriate evaluation of serum concentration-
time data and sometimes urinary excretion data. Numerous methods for 
determining absorption rates have been reviewed (273-277). The 
maximum blood concentration, C
max
' and the time at which the maximum 
occurs, t
max
' give a crude indication of the absorption rate and are 
estimated directly from the serum concentration versus time data. 
Although the rate of absorption controls t
max
, absorption which 
continues after t has no influence on this parameter. 
max 
In the statistical moment theory, absorption is regarded as a 
stochastic process. Since statistical moments are characteristic of 
the shape of the statistical distribution curve, such as the time 
course of serum concentration following a single dose of the drug, 
they are only dependent on the observed time course data and are 
model-independent. This approach allows separation of the absorption 
from the disposition phase and summarizes in a single figure the 
salient features of the absorption rate. The zero moment represents 
the AUC which has been discussed. The area under the first moment of 
the curve (AL~) is defined as the product of the area under the curve 
of time, t, from zero time to infinity. Using this approach the mean 
residence time (MRT) can be calculated as follows: 
MRT = = 
AUMCa, (6-3 ) 
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The MRT can be defined as the mean time for intact drug molecules to 
transit theoughout the body and it yields information on all kinetic 
processes incl uding in v~vo release from the dosage form, absorption 
into the body and all disposition processes. 
Mass balance methods are based on the assumption of a compartmental 
model and amounts absorbed at any time are calculated from the sum of 
the amounts in each compartment plus that which has been eliminated. 
The Wagner-Nelson method (278) is based on the one compartment open 
model. The Loo-Riegelman method (279) is based on the two compartment 
open model and requires that the drug be administered intravenously. 
In application of both methods, the amount of drug absorbed to some 
time divided by the volume of distribution is obtained as a function 
of time. The main application of the Wagner- Nelson method would be in 
studying absorption profiles of drugs in which compartment kinetics 
have been shown to exist. Assuming first order elimination, the 
fraction absorbed (Fa) to time, t, is equal to: 
F = a Cp + k AU~ k AUC; (6-4) 
The rate constant, k, may be estimated from the slope of the terminal 
concentration-time data if absorption is sufficiently rapid . 
Other approaches to the assessment of absorption rates include 
deconvolution methods, which include a) finite differences methods 
(280-282)), b) the least squares method (283), c) exact methods (284, 
285), d) curve fitting methods (286), e) nonparametric methods (287), 
and f) first order rate constant methods (288). 
" ;i 
" 
j 
1, 
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6.4 RESULTS AND DISCUSSION 
6.4.1 Bioavailability Parameters 
The 25 mg, 50 mg and 100 mg solution data were initially treated using 
model-independent methods. Maximum PPA concentrations, C
max
' and the 
time to reach this concentration, t
max
' were determined from indivi-
dual PPA serum concentration profiles. The terminal rate constant, 
K
el , was calculated from the terminal slope of the semilog plot of 
serum concentration versus time. 
half-life, t
" 
was calculated where 
'1 
From these data, the elimination 
0.693 
Kel 
(6-5) 
The apparent volume of distribution, V, was estimated using the 
following equation, assuming F=l: 
v = ~F,.:-' =-:D -;--
AUC",. Ke 1 
where D is the dose in ~g. 
The above equation should 
absence of intravenous 
include a bioavailability term, 
data absolute bioavailability 
(6-6) 
F. In the 
cannot be 
determined. However, a fairly accurate estimate of bioavailability 
may be obtained from the portion of dose recovered in the urine at 
time infinity. One investigator reported that 90% of the 25 mg oral 
dose was excreted in the urine as unchanged PPA (241, 246), while in 
another report (247) 80-90 % of the dose was excreted unchanged within 
24 hours. 
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From our studies, recovery of PPA from the urine after the ingestion 
of the PPA solutions was monitored for 14 hours with 54% to 81% of the 
unchanged drug (free base) being recovered. Mean urinary recoveries 
obtained f rom the 25, 50 and 100 mg solution studies were 64.1 %, 
63.3 % and 72.9 % respectively. Recovery could have been greater if 
urine had been collected for a longer time as PPA was still detectable 
in the blood after 24 hours (Pilot trial). 
Area under the curve (AUC) data was calculated using the linear 
trapezoidal equation in the absorption phase and the log trapezoidal 
method in the post-absorption phase where the function declines 
monoexponentially. 
TABLE 6.1 
BIOAVAILABILITY PARAMETERS FOR THE 25 50 AND 100mg SOLUTION DATA 
"A""''' "", TEST 
DOSE SUBJECT ' t
max Cma x AUC- Kel t'fl (litre/ (hrs) (ng/ml) (ng/ml.hr) (hr) (hrs) kg 
2S mg GB 3 69.39 536.7 0.176 3.93 4.3 
PPA.HC! AH 0.67 81.81 491.1 0.162 4.28 2.7 
SO LUTION JS 1.5 102.01 758.9 0.144 4.81 3.6 
W1l 1.5 127.16 719 .0 0.168 4.12 2.4 
JM 0.67 185.25 690.4 0.144 4. 79 3.3 
ME~~ 1.47 113.12 03'T.7 T:6IT ~:i~ ~:~S 0.953 45.86 118.1 
50 m9 GB 1.0 149.09 1116.3 0.185 3.75 4. I 
PPA.HCl AH 0.5 204.44 1034.3 0.194 3.58 3.0 
SOLUTION JS 1.5 193.60 1432.0 0.154 4.51 3.7 
WB 1.5 157.21 1277 .9 0.175 3.95 2.7 
JM 0.5 207.06 1392.2 0. 198 3.50 2.4 
Mt~~ O.~ '~U~ '~~ff5 g:~~~ g:~~ g:~O 
100 mg GB 1.5 480.60 2679.2 0.165 4.19 3.8 
PPA .HC! AH 1.0 308.43 1920.7 0.160 4.32 3.8 
SOLUTION JS 2.0 437.13 3552.8 0.186 3. 73 2.5 
WB 2.5 343.80 2408.8 0.291 2.39 1.8 
JM 1.5 414.16 2913.3 0.159 4.39 2.9 
Mt~~ ~:~7 j~n~ <~6rf ~ g:~~ g:~6 
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TAB LE 6 .2 BIOAVAI LABlllTY PARAMETERS FOR MULTIPLE D0SE STUDY 
- -- -
PARAMETERS 
Tmax Cmax AUC Kel t'l2 C Cmi n 
SUBJECT (hr) (ng/mL) -I (ng/mL.hr ) (hr - 1) (hr, ) (n~/mL ) (ng/mL) 
GB 1.0 16B .63 S87 .8 0.15 4 .62 117.15 125.96 
AH 0.5 179 . 53 461.1 0.14 4.95 10Q . 15 72 . 53 
JS 1.0 179.67 660.2 0.134 5.17 172 .08 130.79 
WB 0.67 198 .67 704.9 0.15 4.62 159.15 10 1. 73 
JM 0.5 187.47 550.4 0.166 4.17 131.88 104.65 
Mean 0.734 182.79 572.9 0.148 4.71 137.88 107.13 
± SO 0.25 11.12 73.9 0.012 0.37 26.98 23.16 
TABLE 6.3 Fluctuation Index (PI) and Percentage Fluctuation 
values for the multiple dos e study. 
Subject P' . I. Percentage FlUctuation 
GB 0.36 33.B7% 
Ali 0.98 147.52% 
JS 0.28 37.37% 
WB 0.61 95.29% 
JM 0.63 79.14% 
MEAN 0.57 77. 83% 
+SD 0.27 4.7. 62 
I t is sometimes desirable to determine availability of a drug based on 
steady state plasma drug levels following multiple dosing (289). The 
drug concentration in the serum at any given point in time during a 
dosing interval will increase as the number of doses increases and 
approach a constant level. After multiple dosing for a time equal to 
approximately four times the biologic half-life of a drug, the serum 
concentration is within 10% of its plateau or steady-state level . 
After a period of time equal to 7 half-lives, the drug concentration, 
at any point in time during a dosing interval is within 1% of the 
plateau level (289) . 
I : 
~ . , , 
! : 
i 
I 
i 
i . 
, 
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The parameters t , t" AUC, V and the terminal rate constant Kel 
max ~ 
were obtained from the individual serum concentration versus time data 
at steady state. Other parameters obtained from serum concentration-
time data were the maximum and minimum steady state serum 
concentrations, Cmax and Cmin. A parameter which is very useful in 
multiple dosing is the average concentration of drug in plasma at 
steady state, C. This parameter can be predicted by employing 
C = AUC (6-7) 
where T is the dosage interval and AUC is the area within the dosage 
interval at steady state using the linear trapezoidal equation. This 
equation does assume, however, that V and Kel are constant over the 
entire dosing period. From simple geometric considerations, C 
represents some plasma concentration between Cmax and cmin. A 
limitation of the C approach is that it gives no information about the 
fluctuations in plasma levels. Thus, the fluctuation index, (FI), and 
percentage fluctuation were calculated where: 
cmax - Cmin 
FI = (6-8) 
and Percentage Fluctuation = 100 . Cmax - Cmin 
(6-9) 
cmin 
The administration of a drug on a multiple dose regimen will result in 
the accumulation of drug in the body. By knowing the elimination rate 
constant, the extent to which a drug would accumulate in the body 
following a fixed dosing regimen can be calculated by employing 
R = (6-10 ) 
where R is the index of accumulation, which is independent of dose . 
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In most subj ects, the t 
max 
tended t o lncrease with increase in dose. 
Subjects AH and JM displayed the shortest t 
max 
values in both the 
multiple and single dose trials . The apparent volume of distribution 
is large, which would account for the low concentrations of PPA in the 
serum . This rather high distribution volume indicat ed that PPA is 
extensively bound to extravascular sites, which agrees with results of 
a previous study (290). 
The half-life values from the single dose study for all subjects did 
not differ to any great extent, except for subject WE, who displayed a 
larger Kel and consequently a shorter half-life than the other 
subjects in the 100 mg solution study. There was a general trend for 
the elimination rate constant to decrease in the multiple dose study, 
and consequently the half-life increased , ranging from 4.2 to 5 .2 
hours . The AUC values for subject JS was the highest of the 5 
~ 
Subjects, partly due to the slow elimination of the drug. 
An important consequence of a linear system in pharmacokinetics is 
that the total area under the blood or serum concentration-time curve, 
is a linear function of the dose administered . This is one of the 
best tests of linearity in pharmacokinetics . The area under the curve 
values for each subject was plotted versus the respective dose 
administered (Fig. 6 . 2). A straight line fit of the data was made by 
least-squares linear regression analysis, and for all subjects the 
AUC~ values increased proportionately with an increase in dose. 
Phenylpropanolamine thus appears to exhibit linear kinetics as can be 
seen particularly from results exhibited by subjects JM, AH and WE. 
There was an approximately 10% difference in bioavailability based on 
AUC between the single- and multiple-dosing trials wi t h the same PPA 
dose (25 mg) given to the same subject. It was therefore very likely 
that there was a slight change in the clearance between the single-
and multiple-dosing tests. A small change in the elimination rate 
constant 
multiple 
multiple 
is evident when the single dose (25 mg) is compared with the 
dose profiles . The elimination rat e constants for the 
-1 dose tended to fluctuate about a mean value of 0.148 hr , 
FIGURE 6.2 
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Area under the curve (AUC) values for each subject 
versus the r espect i ve dose administered. 
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which is smaller than the value estimated after the single dose. The 
reason for this apparent change in half-life remains obscure. Whether 
it is due t o a real change in the pharmacokinetics of the drug upon 
repetitive dosing is not known. Data collected during steady-state 
conditions contain little information about the volume of distribution 
parameter, although the pharmacokinetic parameters estimated from the 
single dose studies are in good agreement with previously reported 
parameters DoHse et aL (290). 
Of all the subjects, JS had the highest AUC values for both the 
single and multiple dose studies. The elimination rate constant for 
all subjects in the single dose trials did not differ to any great 
extent except for subject WE who displayed a larger Kel and 
consequently a shorter half-life than the other subjects in the 100 mg 
trial. The AUC", value for subject AH was the lowest of the 5 subjects. 
Subject AH was large in stature and had the highest body weight, 
thereby possibly accounting for this phenomenon. Serum trough levels 
after 7 oral doses of PPA.HCl every 4 hours are given in Table 6.4, 
and averaged 109.3 ± 21.7 ng/mL. 
TABLE 6.4 Serum trough levels of the multiple dose study. 
Subject Serum concentration (ng/mL) Mean (SD) 
GB 115.3 129.3 133.1 125.9 125.9 (7.65 ) 
AH 66.3 75 . 5 84.1 72 .5 74.6 (7.40) 
JS 139.9 117.3 129.6 130.8 129.4 (9 . 28) 
WE 111.5 111.7 114.2 101.7 109.7 (5 . 52) 
JM 114.9 96.2 111.5 104.6 106.8 (8.26) 
109.3 (21. 7) 
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6.4.2 Wagner-Nelson Absorption Plots 
The solution data were treated assuming a linear one compartment model 
with first order absorption. The Wagner-Nelson equation was applied to 
the serum concentration-time data to yield absorption plots of frac-
tion absorbed versus time. Wagner-Nelson plots of serum concentration-
time curves are depicted in Figs. 6.3-6.5. The absorption rate 
constants were calculated from the slope of the semi log plot of 
fraction of dose remaining to be absorbed versus time and are shown in 
Table 6.5. 
TABLE 6.5 Values of ka for the 25, 50 and 100 mg soluti on studies. 
TEST SUBJECTS MEAN (SD) 
OOSE GB AH JS WE JM 
25mg 1.16 4.16 2.24 1.85 7.49 3.38 (2.55) 
50mg 1.69 4.63 1.54 1.63 9.69 3.83 (3.52 ) 
100mg 1. 76 4.45 1.15 1.17 7.83 2.20 (1.37) 
Subjects AH and JM exhibited a much larger absorption rate than the 
other subjects, which is consistent with the short t from these 
max 
subjects. Absorption of the drug is rapid, with peak concentrations 
occurring between 40 min and 3 hours after ingestion, which agrees 
with the results of previous studies (290). 
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FIGURE 6.3 Wagner-Nelson absorption plots of serum concentration-time 
curves after administering the 25 mg PPA.HCl solution. 
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FIGURE 6.4 Wagner-Nelson absorption plots of serum concentration-time 
curves after administering the 50 mg PPA.HCl solution. 
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FIGURE 6.5 Wagner-Nelson absorption plots of serum concentration-time 
curves after administering the 100 mg PPA.HCl solution . 
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6.4.3 Renal Clearance 
The renal clearance of a drug is that volume of blood that is cleared 
of the drug per unit time via the kidneys. Drugs may be eliminated 
from the systemic circulation by different pathways i.e., into the 
urine, bile, intestines, saliva, alveolar air, sweat and milk. The 
two major pathways of excretion are via the kidneys into the urine and 
via the liver into faeces. Drugs are usually filtered through the 
glomerulus in a non-selective process if they are in free, non-protein 
bound form . If a drug is not bound to plasma protein it is filtered 
in an amount equal to: 
F = Cpo GFR (mg/min) 
where F = amount of drug filtered through the glomeruli (mg/min) 
Cp = drug concentration in plasma (mg/mL) 
GFR = glomerular filtration rate = renal clearance (mL/min) 
(6-11) 
The rate of filtration of many drugs can be retarded due to their 
binding to high molecular weight plasma proteins which are not fil-
tered. The reabsorption of weakly acidic or basic drugs may be highly 
dependent on urine pH, since the relative amounts of the ionized and 
unionized form of a drug would vary with changes in urine pH. The 
urinary pH in man varies between pH 4.8 and pH 7.5 with an average of 
5.8, and a significant change can be expected if a basic drug has a 
pKa between 7 to 11 i.e. renal clearance will increase in acidic 
urine, and conversely decrease in basic urine. Additional factors 
which may influence the extent of reabsorption of a drug from the 
distal tubules is urine flow rate and the functional integrity of the 
kidneys. Elimination of a drug may depend on hepatic and renal blood 
flow, hepatocellular enzyme activity and renal secretion (active). 
The effect of altered binding on renal clearance of a drug depends on 
its extraction ratio. For a drug that is virtually all removed as it 
passes through the eliminating organ, the extraction ratio approaches 
1 and clearance approaches its maximum value, organ blood flow. If 
the extraction ration is high, renal clearance depends upon blood flow 
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and not upon plasma binding. Conversely, if the extraction ratio is 
low, renal clearance is sensitive to plasma binding. Phenylpropanola-
mine has a high extraction ratio and is eliminated almost exclusively 
by the kidney. An increased hepatic and renal blood flow can thus be 
produced by increased cardiac output. 
Interpretation of urine data with regard to levels of drug in the body 
is complicated for drugs whose renal clearance varies. The slight 
increase in renal clearance in the multiple dose study may be attri-
buted to increased cardiac output by the sympathomimetic stimulatory 
effects of PPA. Sympathomimetic stimulation affects both the heart 
and the systemic circulation. It makes the heart a stronger pump, it 
increases the mean systemic pressure and increases the resistance to 
venous return. Approximately 25% of the cardiac output, 1.2-1.5 
litres of blood per min., goes to the kidneys and renal blood flow is 
increased by increased cardiac output. 
An interesting observation may be made with regard to renal clearance 
of weak bases. At low urine pH the renal clearance approaches the 
renal blood flow and such a clearance value usually suggests active 
secretion. Active secreti on is inferred when the rate of excretion 
exceeds the rate of filtration of a drug, especially weak bases. Some 
reabsorption can occur but it is less than secretion. The secretory 
processes are located predominantly along the proximal tubule although 
these transport systems lack a high degree of specificity. Secretion 
can be so extensive that virtually all the drug in the blood is 
removed whether or not bound to plasma protein or located in blood 
cells. 
When studying the pharmacokinetics of PPA, a weak base, it was found 
to be important to consider the pH of urine. Urine pH readings 
monitored throughout the trials (listed in Table AI) were found to 
fluctuate between 5.16 and 7.50. Phenylpropanolamine, being a weak 
base with a pKa of 9.4 would not undergo a Significant change in 
tubular reabsorption at these values. 
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Renal c learance may be estimated in several ways 
1. The average of the ratios of d Ae/dt (6-12) 
C 
2. The slope of the plot of d Ae/dt versus C at mid-points of 
excretion intervals. 
where d Ae/dt is the amount of drug (mg ) eliminated per unit time 
(hr), CL is the renal clearance (L/hr) and C is the concentration of 
the drug in serum/plasma (ng/mL). Linear kinetics occurs only when 
clearance is constant, with the rate of elimination being directly 
proportional to concentration. 
The semilog plots of serum concentration versus time for 25, 50 and 
100 mg solution studies are shown in Fig. 6.6., and those for the 
multiple dose solution study are shown in Fig. 6.7. From these 
curves, it is difficult to extract any definite characteristics and no 
predictions concerning the presence of Micnaelis- Menten kinetics could 
be made from these graphs. 
FIGURE 6.6 
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Semilogarithmic plots of serum concentrations versus 
time after the ingestion of a 25 mg (~), 50 mg (~) and 
100 mg (+) solution of PPA.HC1. 
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Semi10garithmic pl ots of s erum concentrations versus 
time of the multipl e dose study. 
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The relationship between renal clearance and serum concentrations in 
this study was determined under dynamic conditions, as serum 
concentrations of PPA were changing rapidly. Usually, relatively 
constant serum concentrations are maintained by continuous infusion of 
the drug. The point arises whether clearance is an artifact due to 
distribution effects. Unfortunately, volume of distribution could not 
be calculated due to lack of intravenous data. Distribution volumes 
and clearance, however, are usually separate and non-interacting 
pharmacokinetic elements. 
Renal clearance was calculated for each time interval using Eq. 6-12, 
and the results can be seen in Table 6.6-6.9. The graph of urinary 
excretion rates versus the serum concentration at the mid-point of the 
urine collection interval was then plotted, the slope of which gave 
renal clearance values over the entire duration of the trial (see Fig. 
6.8) . 
TABLE 6.6 Clearance values from the 25 mg solution study. 
Time CL 
(hrs) (L/hr) 
GB AH JS WE JM 
0.5 50.42 20.23 16.67 10.79 13.48 
2 36.01 27.22 17.88 14.29 35.47 
4 32.13 27.19 26.27 34.16 41.42 
6 34.79 33.35 25.17 34.48 38.68 
8 29.43 34.46 21.99 22.13 23.85 
10 33.35 37.21 21.69 65.87 25.01 
12.5 19.22 36.38 13.74 4.03 0.46 
Mean 33.62 30.86 20.49 26.54 29.59 
+SD 9.27 6.18 4.58 20.78 10.64 
-
* Graph 37.09 32.50 21.80 20.07 22.61 
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TABLE 6 7 Clearance values from the 50 mg solution study. 
Time CL 
(hrs) (L/hr) 
GB AH JS WE JM 
0.5 17.31 7.05 22.59 35.63 14.11 
2 21. 36 21.10 16.33 25.75 27.35 
4 46.75 17.51 31.35 22.08 36.96 
6 26.63 41. 74 18.36 47.25 31.86 
8 28.49 46.25 32.02 29 .14 30.15 
10 33.64 23.05 25.05 12.85 37.93 
12.5 26 . 63 61.12 31.36 56.85 31. 77 
Mean 28.69 31.11 25 .29 32.79 30.01 
+SD 9.51 19.02 6.51 15.11 7.93 
-
* Graph 21.80 28.20 20 . 01 25 . 01 29.63 
TABLE 6 8 . Clearance values from the 100 mg solution study . 
Time CL 
(hrs) (L/hr) 
GB AH JS WE JM 
0.5 - 31.03 17.32 17. 80 13.20 
2 26.29 47.30 25.11 19.45 20.27 
4 73.30 43.25 20.22 26.28 26 . 55 
6 16 .17 40.34 32.91 21.93 39.32 
8 17.28 68.18 22.78 27.85 25.59 
10 26.59 85.96 29.44 34.95 32.82 
12.5 22.96 41.23 25.91 33.42 24.39 
Mean 30.43 51.04 24.81 25.95 26.02 
+SD 21.50 19.14 5.32 6.65 8.40 
-
* Graph 26.5 41.8 24.5 .22.6 21.9 
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FIGURE 6.8 Plots of urinary excretion rate versus serum 
concentration at the mid-point of the urine collection 
interval after the ingestion of a 25 rrg (,,) , 50 mg ( <>.) 
and 100 rrg ( +) solution of PPA.HC1 . 
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TABLE 6.9 
GB 
AH 
JS 
WE 
JM 
Mean 
+SD 
-
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Mean clearance values from the 25, 50 and 100 mg 
solution studies . 
CL (L/kg/hr) Mean Data 
100mg 50mg 25mg 
0.52 0.48 0.57 
0.60 0.38 0.38 
0.41 0.42 0.34 
0.32 0.42 0.34 
0.35 0.40 0.40 
0.44 0.42 0.41 
0.11 0.03 0.09 
* The excretion rates were plotted against the serum concentrations 
at the mid-points of the excretion intervals and renal clearance 
was obtained from the slope of this line. 
From the multiple dose study, the apparent renal clearance of PPA was 
calculated from the 4 hour dose interval after the last dose using the 
linear trapezoidal rule: 
Dcse (p.o.) 
CL ; (6-13 ) 
AUC 0-4(p.o . ) 
where the Dcse is in~. The results can be seen in Table 6 . 9. The 
seemingly critical assumption in the approach outlined above (aside 
from the assumption of linearity) is that clearance remains the same 
between treatments in the same individual. This assumption can only be 
an approximation, as intra-subject variability in drug disposition is 
well documented. It follows that there is interest in reducing the 
effect of intra-subject variability in bioavailability studies which 
could be accomplished if differences in systemic clearance (CL) in the 
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same individual from one treatment to another is accounted for . 
Unfortunately, this is usually not possible because one cannot 
determine CL after oral administration without making some assumption 
concerning bioavailability. An alternative approach is based on 
differences in drug half-lives (291). 
TABLE 6.10 Clearance values from the multiple dose solution study 
SUbject Clearance (L/hr) Clearance (L/kg/hr 
GB 42.53 0.72 
AH 54.22 0.64 
JS 37.86 0.62 
WE 41.32 0.52 
JM 45.42 0.61 
Mean 44.27 0.62 
+SD 6.18 0.07 
-
6 . 5 MODELLING OF DATA 
The serum concentration-time data obtained following single dose oral 
administration of the solutions were fitted to appropriate linear 
pharmacokinetic models (see Fig. 6.9). The digital computer, nonlinear 
regression analysis programme (NONLIN) of Metzler (292) was used to 
attempt the various fits, with the DFUNC subroutine being modified for 
each function, and equal weighting of the data points. The three 
models used in this study include a conventional one-compartment open 
model with either apparent first-order absorption and linear 
elimination (Model Al), or apparent zero-order absorption and linear 
elimination (Model A2), and a two-compartment model with continuous 
first-order absorption and linear elimination (Model Bl). Each set of 
data were fitted individually. 
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FIGURE 6.9 Pharmacokinetic models for phenylpropanolamine. 
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In all the following equations describing rate of change in drug 
concentration in the body, the bioavailability term, F, was assumed to 
equal 1.0 (See Section 6.4.1) . 
Symbols are defined as follows: 
dCjdt = rate of change of drug concentration in the central 
compartment 
k = first order absorption rate constant a 
D = dose of drug 
V = volume of central compartment 
"'2 = amount of drug in peripheral compartment 
Cl concentration in the central compartment 
KID = elimination rate constant 
K12 ~ 
K21 ~ 
t ~ 
to ~ 
kO ~ 
T ~ 
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first order rate constant for transfer of drug from the 
central to the peripheral compartment 
first order rate constant for transfer of drug from the 
peripheral to the central compartment 
time after drug administration 
lag time between drug administration and appearance of 
drug in the serum 
apparent zero absorption rate constant 
a constant corresponding to the absorption time, after 
absorption apparently ceases. (During absorption, T is 
a variable and equal to t) 
The first model incorporated a one body compartment model (lBCM) , a 
first order absorption rate constant and linear elimination. The 
differential equation describing the model is shown below: 
(6-14 ) 
The lag time (tl ) was introduced to accommadate the delay in onset ag 
of PPA absorption. 
The data were then fitted to a 2BCM wi th continuous absorption and 
linear elimination. The 2BCM was included in an attempt to account 
for the observed rapid decrease in concentration which occurred just 
after the peak. The differential equation describing the rate of 
change of drug in the peripheral and central compartments are shown in 
Eg. 6.15. 
(6-15) 
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The interpretation of PPA absorption as zero order input was assessed 
by fitting the data to the following equation : 
(6-16) 
Goodness of fit of data to Models AI, A2 and Bl was assessed by 
calculating the correlation coefficient for each data set of observed 
and predicted data, and by visual observation of the curves. In 
pharmacokinetic analysis of the time course of plasma concentration of 
a drug, it is important to determine the number of parameters in a 
pharmacokinetic model. Akaike's Information Criterion (AIC) was thus 
used to select an appropriate model (293) with the equation having the 
minimum AIC regarded as the best characterizing the data set. 
ArC _ = nlnRE _ + 2p 
J J 
(6-17) 
where n is the number of observations, p, the number of parameters, 
Re, the weighted sum of squared deviations and j represents the jth 
data set. It should be remembered however, that the minimum AIC 
estimation does not select the "correct" model or equation but rather 
the simplest representation of a particular set of pharmacokinetic 
data. 
6 . 6 RESULTS 
The observed values and the resultant fits to models Al and A2 can be 
seen in Figs . 6.10-6 . 12. In Appendix 2, the observed and predicted 
values for serum data from the 25, 50 and 100 mg solution studies 
resulting from the fits to models A2 and Bl are shown in Tables A2 . 1 
and A2 . 2 . The parameter values for all three model s are depicted in 
Table A3.I. Observed and resultant fits to model Bl can be seen in 
Figs . 6 . 13-6.15. The results of AIC values for individual subjects 
are shown in Table 6 .11 . 
FIGURE 6.10 
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Observed data and predicted fits to the 25 mg serum 
da ta using models Al and A2. 
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Observed data and predicted fits to the 50 mg serum 
data using models Al and A2. 
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Observed data and predicted fits to the 100 mg serum 
data using models Al and A2. 
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Observed data and predicted fits to the 25 mg serum 
data using model B1 . 
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Observed data and predicted fits to the 50 rrg serum 
data using model Bl. 
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Observed data and predicted fits to the 100 mg serum 
data using model Bl. 
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The IECM with first order absorpti on (Model AI) was unable t o account 
for the rapid absorption phase and resulted in a l arge over-estimation 
of initial concent rations followed by an inabil ity to attain the hi gh 
peak concentrations. The predicted fit to the entire curve was poor 
and exhibited a more rounded peak which was unable to account for the 
rapidly decreasing values tailing off to a gentle slope in the 
elimination phase. The value of r for the mean serum fits were 0.974 
(25 mg study), 0.987 (50 mg study) and 0.983 (100 mg study). 
A rapid increase in drug concentration after oral administration 
f ollowed by a fairly rapid decline is reported to be characteristic of 
zero order absorption (294). Therefore, a model incorporating zero 
order absorption was used in an attempt to improve characterization of 
the absorption and immediate post-absorption phases. This however, 
did not result in an improvement of fit as indicated by the correla-
tion coefficients (which decreased from a mean of 0.981 to 0.952), AIC 
values and visual observation. 
The fit for the 2BCM with first order absorption (Model 81), as 
indicated by the values for r, (0.98, 0.99, 0.99) was better than the 
fit for the lECM (Model AI), with an improved fit of the latter part 
of the curve . In general, however, the absorption phase was still 
poorly characterized by an inability to attain the high peak 
concentrations. A slight improvement of fit, as indicated by the 
correlation coefficients, AIC values and visual observation resulted 
from Model 81. 
The pharmacokinetics of PPA after oral administration has previously 
been described by a two compartment model with discontinuous 
absorption (290). OUr studies indicate that the two compartment model 
(Model 81) adequately described the serum data of PPA after oral 
administration . The lECM also described PPA plasma data well but 
fitted poorly in some Subjects (JM , WE and JS) as evidenced by over-
estimation during earlier doses. Simple two compartment distribution 
with linear formation and elimination seems to adequately describe the 
disposition of PPA in these subjects . 
i 
I 
• • ; 
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AlC values for individual subjects 
roSE' MODEL SUBJECI'S 
(mg) GB AM JS WE JM Mean 
data 
25 B7.67 117.06 117.14 136.60 164.34 125.36 
50 Al 131.51 169.05 151. 40 133.1B 15B.96 130.7B 
100 176.97 174.92 16B.27 174.59 176.07 164.05 
Mean 132.05 153.67 145.60 148.12 166.15 140.06 
25 142.98 109.02 148.18 152.72 152.99 127.99 
50 A2 139.45 165.80 177.24 176.21 153.40 149.31 
100 196.36 164.08 207.94 205.88 190.69 189.48 
Mean 159.59 146.30 177.78 178.27 165.65 155.0 
25 82.64 111.71 107.76 137.99 162.91 119.48 
50 Bl 127.39 172.80 153.16 129.73 151.50 134.49 
100 164.67 165.12 162.94 166.88 168.06 156.32 
Mean 124.90 149.87 141. 28 144.86 160.B2 136.76 
After intake of PPA solution, a double peak phenomenon was observed. 
The irregular profile or hump is a complicating factor in the 
interpretation of the data. However, during the conduct of the study a 
publication appeared (300), which suggested a more flexible way to 
correct for this phenomenon according to a double-site model for drug 
absorption as a determinant of kinetic parameters. The use of mUlti-
fraction absorption models where drugs in the gastrointestinal tract 
are assumed to be divided into several fractions, each with its 
respective lag time and absorption rate is described by Murata et aZ. 
(295). The choice of a suitable kinetic model requires decisions with 
respect to both the compartmental and absorption characteristics of 
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the drug. Discontinuous absorption characteristics may be inferred 
from a graphical representation of experimental data or from poor 
computer fits obtained using continuous absorption models . 
6 . 7 DISCUSSION 
A number of digital computer programs are routinely employed in 
pharmacokinetics for the nonlinear least squares estimation of 
pharmacokinetic parameters and for the simulation of the time course 
of the drugs in pharmacokinetic systems . Several programs, e.g., NLIN 
(296), SAAM (297), and NONLIN (292), are available for the nonlinear 
least squares regression analysis of pharmacokinetic systems. Of all 
three programs, NONLIN appears the most versatile in that either 
intergrated or differentiated equations can be employed, more than 
one set of data can be fitted simultaneously and it can be employed 
for simulating data. In addition, zero order processes and nonlinear 
pharma90kinetic models can be fitted employing this program. 
A frequent problem in nonlinear least squares fitting of observed data 
to a mathematical model is that the so-called "least squares parameter 
estimates" are dependent upon the initial estimates of the parameters, 
which are part of the input data provided to the digital computer . 
The lack of convergence to the same set of least squares estimates of 
the parameters may be caused by the lack of consistency of the para-
meters from one treatment to the next as is assumed in simultaneous 
fitting . Simultaneous fitting, however, has the distinct advantage of 
reducing standard deviations of the estimated parameters . Lack of 
convergence to the same set of least squares parameter estimates when 
the initial parameter estimates are changed is also partly caused by 
1) error in data 2) the model not being appropriate for the data, and 
3) convergence to a local minimum on the least squares surface rather 
than the true minimum. 
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Drug absorption from the gastrointestinal tract 
considered to occur by passive diffusion through the 
is generally 
gastrointestinal 
membrane. Some exceptions have been described where active processes 
are involved (298), and first order absorpt~on is unable to depict 
correctly the appearance of the drug in the blood stream. The same 
occurs for drugs that exhibit enterohepatic recycling for which 
particular pharmacokinetic models have been developed (299). For such 
drugs, reabsorption leads to non-monotonicity in the shape of plasma 
concentration curves with the appearance of successive peaks. Other 
physiological phenomena may explain such curves. Non-homogenous 
absorption of drugs through the gastrointestinal membrane could lead 
to a similar multiple peak phenomenon. This phenomenon has been 
observed and interpreted accordingly to a double-site model for drug 
absorption (300) where the concept of an "absorption window" by Kubler 
(301) was developed. 
In addition, discontinuous absorption models (302) have been proposed 
for the analysis of plasma drug concentration data with irregular 
absorption, in which the absorption rate constant is variable through 
the process of absorption. It has been shown that Metzler's NONLIN 
program can be used for fitting these discontinuous absorption 
profiles. The absorption phase of PPA from the use of a biphasic, 
discontinuous absorption model has been well-characterized by previous 
workers (290) using serum data after the administration of a solution 
of PPA. 
A previous report (303) described a digital computer method which 
utilized all serum concentration data collected during repetetive 
dosing studies to estimate pharmacokinetic model constants and to fit 
the entire time course of drug concentration in serum/blood. This 
method can be used for detecting changes in pharmacokinetic model 
constants and for characterizing Michaelis-Menten kinetics during 
multiple dosing and accomodates changes in dose or dosing interval 
during a multiple dose regimen. Several investigations found that 
pharmacokinetic parameters of certain drugs change in a systematic way 
during repetetive drug administration (41-43). Self-induction, self-
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inhibition and product inhibition of metabolism are possible causes of 
variation in elimination rate constants. Under certain conditions, a 
drug subject to capacity-limited metabolism will demonstrate 
pharmacokinetic characteristics similar to that of a drug Subject to 
self-inhibition or product-inhibition i.e., the half-life will appear 
to increase during multiple dosing. Variability in absorption rate 
constants and/or the amount absorbed as well as 
apparent volume of distribution from dose to dose 
during a repetitive dose regimen. 
changes in the 
may also occur 
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CHAPTER 7 
CONCLUSIONS AND DISCUSSION 
Although extensively used, there is little pharmacokinetic information 
on PPA disposition in the li t erature, possibly due to the difficulties 
inherent in the determination of PPA especially at low concentrations 
encountered in the blood after the administration of oral dosage 
forms. The HPLC method described using UV detection at 210 nm has 
been shown to be precise, speci fic and sufficiently sensitive so that 
reliable measurements of PPA concentrations may be obtained f or serum 
and urine for up to 16 hours following a 25 mg oral dose, and 
demonstrates that the method is adequate for use in pharmacokinetic 
and bioavailability studies. Previous HPLC methods used to determine 
PPA in biological fluids are relatively time consuming with respect to 
sample preparation or relatively insensitive to detection of low 
concentrations in serum, and the method described here is rapid and 
relatively simple. The general approach presented produced very clean 
chromatograms and thus should be considered for other primary amines . 
The potential for an adverse hypertensive effect following the use of 
PPA has, over the years, been the topic of sporadic case reports and 
studies. Some of these reports are anecdotal while others refer to 
situations where frank overdoses and/or multiple drugs, including PPA, 
were used (44, 82, 84, 85, 244). OUr findings, however, were 
consistent with other reports and controlled clinical studies in the 
literature (80, 245) that found no significant changes in the blood 
pressure and pulse rate in individuals with normal blood pressure 
receiving PPA . It was observed that PPA increased blood pressure in a 
dose-related fashion with significant inter-subject variability . Some 
volunteers reported side-effects although these were considered by the 
investigator to be minor . 
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Phenylpropanolamine is marketed as a racemic mixture of two enantio-
mers, and in this study, the pharmacokinetic properties of the racemic 
mixture were examined. To pursue the possibility of stereoselective 
differences in the binding in plasma and in the disposition of PPA, 
further studies could be carried out to examine the pharmacokinetic 
properties of d- and R- norephedrine. 
Bioavailability parameters were calculated from the in vivo solution 
data by use of noncompartmental methods, which do not require the 
assumption of a particular compartment model. Results obtained from 
noncompartmental methods are more physiologically significant than 
those obtained from methods using empirically derived models. 
Subjects AH and WB consistently displayed rapid absorption rates. 
Both Subjects were of average weight and age for this study and 
discrepancies can only be attributed to individual variation. The 
serum AUC values calculated for AH were, in all trials, relatively 
low. In contrast, the serum AVe values calculated for subject JS 
were relatively high. SUbject AH was large in stature and had the 
highest body weight, and subject JS was small in stature, thereby 
possibly accounting for this phenomenon . Interestingly, subject JS 
displayed the highest changes in blood pressure and experienced more 
side-effects than the other subjects. Serum AUC values appeared to 
increase in proportion to the increasing dose administered for all 3 
trials. Deviation from linearity, however, was noted in the C
max 
values. Renal clearance of the drug after administration of the 
solutions was also investigated. Renal clearance was found to be 
relatively constant throughout the trial, except in subject AH, where 
the renal clearance fluctuated, with higher values occurring at higher 
serum concentrations of the drug. The pharmacokinetic parameters 
estimated are in good agreement with previously reported parameters. 
The high clearance values as wel l as volume of distribution values, 
were similar to those of Dowse et aL. (290). 
No reliable protein binding data appear in the literature for PPA, 
protein binding of drug being a phenomenon which could account for 
higher clearance values at increased concentrations. Plasma protein 
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binding of PPA was investigated, and was found to be only slightly 
dependent on the concentration in blood: 4.2 ±l.l% at 95 ng/mL and 
17.8 +2.9% at 280 ng/mL. This small change in binding was regarded as 
irrelevant for the interpretation of pharmacokinetic data of PPA. As 
the renal clearance exceeds the glomerular filtration rate, active 
tubular secretion is a possible mechanism by which additional PPA may 
be excreted. 
The solution data were fitted to compartmental models which were 
characterized by a series of differential equations. The inability of 
the IBCM with apparent zero order absorption to describe the kinetics 
of PPA in the body was immediately apparent. The use of the IBCM with 
apparent first order kinetics slightly improved characterization of 
the curve, but the best fit was obtained using a two compartment model 
which improved characterization in the distribution phase immediately 
after maximum concentration. In the absorption phase, however, the 
predicted peak for most subjects was slightly lower than the experi-
mentally observed value. The elimination via linear kinetics was 
studied, and the 25, 50 and 100 mg solution data were well described 
by this process. 
larly absorbed. 
Upon oral absorption, PPA was rapidly, but irregu-
Some subjects displayed irregular profiles of drug 
concentration serum profiles which were difficult to describe. 
However, this phenomenon could be interpreted according to a double-
site model for drug absorption (300). 
There have been no published reports in which intravenous data were 
used to estimate oral PPA bioavailability in humans. Bioavailability 
has been estimated from urinary PPA recovery since PPA is largely 
excreted unchanged in the urine. This method, however, could overesti-
mate bioavailability in cases in which the drug is metabolized and the 
analytical method is not specific. The availability of intravenous 
data would enable the calculation of the absolute bioavailability of 
the drug, the volume of distribution, and the total clearance from the 
body. In computer modelling, known values such as volume of distribu-
tion obtained from an intravenous study could be incorporated as a 
constant, decreasing the number of parameters to be optimized. 
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APPENDIX 1 
TAaLE A I. 1 
Phenylpropanolamine Serum concentrations after the administration of 
2S mg PPA.HCi. dis solv ed in 200 mL of water. 
rmt lllUN Uf PPA IN ""UM Ing/ml} 
(HRS) - c;g- Al1 Js- lIB JM 
0 0 0 0 0 0 
0.17 9.86 14.96 15.24 10.39 11 .48 
0.33 28.07 43.89 35.45 36.07 83 . 49 
0.50 41.28 67.48 54 . 90 93.99 163 .81 
0 .67 46.65 81.81 73.19 76.33 185.25 
1.00 57.62 76.10 77 . 36 107.99 157.18 
1.50 67.47 69.44 102 . 01 127.16 109.72 
2.00 65.76 59 . 92 89 .42 101.52 88.96 
2. 50 62.64 57 . 46 82.97 100 . 68 88.70 
3.00 69 . 39 54.13 68.78 84.62 72.28 
4.00 58.33 47.73 61. 78 70.41 53 . 00 
6.00 42 . 25 32.50 52.76 44 . 23 33.09 
8.00 29.39 25.91 40.79 35 . 47 26 .83 
10.00 18.74 15.96 33.10 23.00 20 .87 
12 . 50 12.84 11 . 27 22.56 18.20 14.39 
14 . 00 11 .31 9. 21 17 . 20 11.90 11.29 
16.00 6.74 6.95 11.90 8.20 7.78 
TA8LE A 1.2 
The cumulative urinary excretion (Ae) of PPA after the admini-
stration of 25 mg PPA.HCl dissolved in 200 mL of water. 
Ae,mg-T 
ry:S) G8 AH JS W8 JM 
0 0 0 0 0 0 
0-1 4.16 1.37 1.00 1.02 2. 21 
1-3 9.01 4.63 4. 11 3.91 8 .44 
3-5 13.47 7. 22 7. 36 8.72 10.64 
5-7 16.41 9 .39 10.02 11.77 13.20 
7-9 18.14 11.18 11.81 13.34 14 .4 7 
9-11 19.39 12.36 13.25 16.37 15 . 52 
11-14 20.13 13.59 14.17 16. 59 15.54 
MEAN 
0 
12.39 
45 .39 
84.29 
92.65 
95.25 
95.16 
81. 13 
78.49 
69.84 
58.25 
40 .97 
31.68 
22.33 
15.85 
12.18 
8.31 
., 
" '; 
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TABLEA1.3 
Phenylpropanolamine Serum concentrations after the administration of 
50 mg PPA.HCl dissolved in 200 mL of water. 
, '"' 
CUN"N'""' 'UN U' "~A 'N ""UM ,ng/ml} 
(HRS) 
"" 
AH J' W" J" 
0 0 0 0 0 0 
0.17 35.99 64.58 8.45 18.06 50 . 73 
0.33 92.47 176.79 49.63 36.42 199.86 
0.50 116 .80 204.44 87.59 70 . 43 207.06 
0.67 147 .65 129.36 103.60 92.00 179.73 
1.00 149.09 101.40 177 .89 112.95 204.83 
1.50 134 .21 188.51 193.60 157 . 21 190.11 
2.00 116.12 167.55 166.42 138 . 98 168.91 
2 . 50 131.36 159.81 144.40 141.88 163.14 
3.00 123.12 107.16 138.81 141. 15 171. 66 
4.00 102.03 89.07 133.64 130.00 109.84 
6.00 80.19 69.64 97.12 110.26 76.03 
8.00 56.15 46.27 76.54 54.57 70.64 
10.00 48.44 29.11 55 . 76 63.79 69.60 
12.50 22.90 20.45 37.28 23.04 28 . 33 
14.00 19.28 12.58 26.02 28.12 21.90 
16.00 13 . 18 9.48 22.98 17.54 14 .22 
TA8LE A 1.4 
The cumulat Ive urinary excretion (Ae) of PPA after the admini-
stration of 50 mg PPA.HCl dissolved in 200 ml of water . 
Ae 111191 
, !~~S) GB AH JS WB JM 
0 0 0 0 0 0 
0-1 2.02 1.44 1.9B 2.51 2 . 92 
1-3 6.9B B.51 7.42 9 . 66 12.16 
3-5 16.51 11.63 15.76 15 . 39 20.2B 
5-7 20 . 7B 17 . 45 19.33 25.Bl 25.11 
7-9 23.97 21.68 24.23 28.98 29 .36 
q-ll 27 .73 23.02 27.02 30 . 61 34.64 
11-14 29.09 26.77 30.53 34.52 37 . 34 
"tAN 
0 
35.56 
111. 03 
137.26 
130.47 
149.23 
172.73 
151.60 
148.12 
136.38 
112.92 
86.65 
60.83 
53.34 
26.40 
21.58 
15.48 
169 
TABLE A1.5 
Phenyipropdnolamine Serum concentrations after the administration of 
100 mg PPA.HCl dissolved \n 200 mL of water. 
I1Mt LU"Lt" ' "A ' IUN u, eYA IN ,t"UM IOg/m" 
(HRSI G8 AH JS W8 oM 
0 0 0 0 0 0 
0.17 68.31 23 .36 30.6 1 8.06 5.07 
0.33 165.29 168.37 157.59 33.68 173 . 4ll 
0.50 255.1\ 300.19 218.94 152.33 316.01 
0.67 309 .58 290 .59 339.65 160.02 342.16 
1.00 321. 99 308 .43 363.53 279.98 390.98 
1. 50 480.62 277 . 26 414 . 73 339 . 53 414.16 
2.00 356.22 230.00 437.13 317.27 369.01 
2.50 359.62 195 .86 394.45 343.80 352.71 
3.00 255 . 17 195.09 393.91 267.52 303.06 
4.00 247.94 157.03 328.45 243.15 273.05 
6 .00 211.54 128.75 304.18 183 .28 193.57 
8.00 108.78 86.68 2\3.75 152.97 135.12 
10.00 76.71 65.61 128.74 110.43 94.62 
12 . 50 55.48 44.14 69.47 64.82 74.12 
14.00 44.98 35.52 59.95 35.37 48.64 
16.00 37 .56 24.79 49.92 7.79 39.64 
TABLE A1.6 
The cumulative urinary excretion (Ae) of PPA after the admini-
stration of 100 mg PPA.HCl dissolved in 200 ml of water. 
Ae \mgl 
I (~~SI G8 AH JS WB JH 
0 0 0 0 0 0 
0-1 0 9.31 34 . 46 2.72 4.17 
1-3 18.73 31.08 102.10 15.04 19.12 
3-5 55.10 44.66 57.74 27.81 33.62 
5-7 61. 93 55.05 111. 18 35.85 48 .84 
7-9 65.68 66 .86 108.08 44 .37 55.76 
9-11 69 .75 78 . 14 79.60 52.09 61.97 
11-14 73.57 83 .59 83.18 58 .59 67 . 39 
MEAN ! 
0 
27 .081 
\39.68 
248.52 
288.40 
332.98 
385.26 
341. 93 
329.29 
282.95 
249.92 
204.26 
\39.46 
95.22 
61.61 
44.89 
31. 94 
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TABLE AU 
Phenylpropanoiar:'line Serum concentrations of the multiple dose 
study (25 m9 PPA.HC1). 
IIMC IIUN U, eeA IN ',"UM In9/mL} 
(HRS) U" AI1 J> W" JM 
0 125.97 72.53 130.79 101. 73 104.65 
0.17 121. 14 153.20 125.58 108.81 94.53 
0.33 146.01 152.57 140.94 145.44 184.20 
0.50 159.79 179.53 158.30 190.03 187.47 
0.67 158.96 161. 32 170.18 198.67 181.84 
1.00 168.63 155.25 179.67 178.46 176.99 
1. 50 165.09 123.01 178.62 162.83 155.49 
2.00 149.81 112.04 164.70 156.15 138.42 
2.50 153.44 99.77 176.54 140.93 126.64 
3.00 142.56 85.40 163.94 141.00 113.11 
4.00 109.52 74.91 156.05 125.36 98.90 
6.00 90.11 58.41 115.97 80.13 75.07 
8.00 61.49 43.53 83.34 64 .16 58.89 
10.00 49.77 30.45 59.09 57.29 43.46 
1
12
.
50 36.81 23.57 52.37 33 . 90 26.74 
14.00 25.63 21.99 43.10 25.85 20.51 
16.00 20.32 13.14 27.83 20.48 15.07 
TA8LE A 1.8 
The cumulative urinary excretion (Ae) of the multiple dose 
study (25 mg PPA.HC1). 
"",UN I CALKClCU Im9) 
'~~~) GB AH J5 W8 JH 
0 17.10 23.49 9.45 20.76 23.96 
0-1 26.26 30.06 24.45 27.34 29.67 
1-3 39 .07 41.96 44.97 38.72 41. 3 I 
3-5 46.36 50.34 53.26 49.20 48.89 
5-7 51.44 57.41 61.60 56.73 53 . 04 
7-9 54.70 61.76 66.80 61.26 57.13 
9-1 I 57.55 65.65 70.67 63.95 60 . 03 
11-14 60 .20 68.13 73.17 67 .72 61.81 
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APPENDIX 2 
TA8LE A2. 1 
Observed and model-predicted serum concentrations of pheny lpropano-
lamine (using model A2l following administration of d 25, 50 and 100 mg 
solution of the drug (Mean Data). 
~~A~gO~¥~t ~~A~g o~¥~t 
TIME 
(HRS) 085. 1 PREO . 2 085. 
0 0 0 0 
0. 17 12 . 39 34.38 35.56 
0.33 45.39 56.37 111.03 
0.50 84.29 71. 96 137 . 26 
0.67 92.65 81. 91 130. 47 
1.00 95 . 25 91.08 149.23 
1.50 95.16 92.06 172.73 
2.00 81. 13 87. 11 151. 60 
2.50 78.49 80 . 53 148.12 
3.00 69.84 73.81 136.38 
4.00 58.25 61.50 112.92 
6.00 40 .97 42.47 86.66 
8.00 31.68 29.32 60 .83 
10.00 22.33 20.24 53 .34 
12 . 50 15.85 12.73 26.40 
14.00 12.18 9.64 21.58 
16. 00 8.31 6.66 15 .48 
1 Observed serum concentra t i on (ng/mL) 
2 Predicted serum concentration (ng/mL) 
PREO. 
0 
58.08 
95.79 
123.05 
140.41 
158 . 44 
162.65 
156.19 
146.46 
136.09 
116 . 53 
84.94 
61.88 
45 .08 
30.35 
23 . 93 
17 . 44 
1~~A~gO~¥~t 
085. PREO. 
0 0 
27 . 08 99 . 43 
139 . 68 170 .86 
248 .52 228.23 
288.40 270 .61 
332 .98 321.74 
385.26 350.34 
341. 93 348.37 
329.29 332.67 
282.95 311. 42 
249 .92 265.95 
204 . 26 188.46 
139.46 132.75 
95.22 93.46 
61.61 60.27 
44 .89 46 .32 
31.94 30.6 1 
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TABLE A2.2 
Observed and mOdel-predicted serum concentrations of phenylpropano-
lamine (using mode! Bl) following administration of d 25, 50 and tOO mg 
solution of the drug (Mean Data). 
~IME 
~~A;(D~¥~l ~~A~g D~¥~l 
(HRS) OBS . 1 PRED. 2 OBS . 
0 0 0 0 
0.17 12.39 32.99 35.56 
0.33 45.39 55.75 111.03 
0.50 84 .29 72 . 15 137.26 
0.67 92.65 83.20 130.47 
1.00 95.25 94.15 149.23 
1.50 95.16 94.93 172.73 
2.00 81. 13 87 .91 151.62 
2.50 78.49 78 .95 148.12 
4.00 58.25 56 .65 112.92 
6.00 40.97 39.92 86.65 
8.00 31.68 29 .83 60.83 
10.00 22 .33 22.63 53.34 
12.50 15.85 16.08 26.40 
14 .00 12.18 13.11 21.58 
16.00 8.31 9.98 15.48 
Observed serum concentratIon (ng/mL) 
2 Predicted serum concentration (ng/ml ) 
PRED. 
0 
57.93 
96.24 
122.98 
140.67 
158 .57 
162.80 
156 . 24 
146.38 
116.28 
84.78 
61.85 
45.14 
30 . 45 
24.05 
17 . 55 
l UU mg UUSE 
MEAN DATA 
OBS. PRED . 
0 0 
27.08 96.01 
139.68 168 .25 
248.52 225.77 
288.40 269 .64 
332.98 326.02 
385.26 359 . 11 
341. 93 357.83 
329.29 340.26 
249.92 265 .30 
204 . 26 185.10 
139.46 132. 19 
95.22 95.79 
61.61 64 .51 
44.89 50.95 
31.94 37.21 
173 
APPENDIX 3 
TABLE A3.1 Parameter estimates from computer modeillng of the 25, 
50 and 100 mg solution data. 
Model Parameter SUbjects Mean 
GB AM JS WB JM Data 
2S rrQ solution stud 
ISCM k 1.02 2 . 59 LSI 1.37 3.2 2.08 0' lk V, 293 351 2B7 232 275 295 
linear k 
• 
0.175 0 .1 78 0.143 0.220 0.25 0.184 
elim. tll!lg 0 . 14 O.OB 0 . 16 0 . 26 0.19 0.15 
r ' 0.994 0.974 0.979 0.965 0.911 0.974 
IOCM kO 45401 50677 57658 65655 B2B3J 60267 
Zero- V 330 321 315 29B 251 311 
order Abs KIO 0.14 0 . 15 0.14 0.14 0.249 0.136 
linear T 0 . 5 0.5 0 . 5 0.49 0.5 0.49 
elim . r 0 . B38 0.9B5 0.87 0.91 0. 96 0 . 97 
2SCM ko' 1.08 1. 43 0 . 85 0.99 1.69 1.13 
l K V, 2B6 214 200 200 200 200 
linear k12 0.01 0.57 0 . 286 0.144 0.48 0. 43 
elim. k" 0 . 16 0.29 0.22 0 . 26 0.30 0 . 29 
tlO 0 . 08 0 .18 0 . 45 0.50 0 . 50 0.42 
r 0 . 995 0.980 0 . 987 0.970 0 . 93B 0.978 
SO IT'Q solution stud 
lSCM k. , 2.42 4.29 1.17 0.796 3. 49 2.02 
1 k V, 353 353 272 254 317 318 
linear k. 0.149 0.178 0.161 0.177 0.167 0. 158 
elim. t lag 0.08 0.07 0.182 0.18 0.11 0.126 
r 0.983 0.91 0 . 963 0.983 0.96 0.987 
1 SCM kO 82907 99986 95179 80568 99999 88133 
Zero- V 270 200 290 285 200 264 
order Abs k,O 0. 13 0.164 0.13 0.13 0.149 0.12 
linear T 0. 5 0 . 367 0 . 499 0.5 0 . 437 0.49 
elim. r 0 . 97 0.93 0.81 0.75 0.972 0.962 
20CM k. , 1. 78 0.72 0.74 2.51 1.99 
1 k V, 265 297 200 227 231 281 
linear k" 0.34 0;01 0.195 0.02 0.28 0.01 
elim. k" 1.0 0.01 0.34 0.06 0.71 0.77 
k 0.192 0.169 0.236 0.175 0.208 0.16 
t , o 0.103 0.416 0.479 0.115 0 . 132 0.07 
r 0.983 0.911 0.97 0 . 981 0.97 0.99 
174 
]00 IT'O solution study 
1>01 k
d
, 0 .142 2.57 1.07 0.701 1.61 1. 41 
1 k V, 258 357 225 231 266 274 
linear k 0.205 0 .194 0.163 0.202 0.184 0.1 75 
• 
ehm. t 1aq 0.21 O. OB 0.274 0.213 0.20 0.186 
r 0.967 0.95 0 .984 0 . 972 0. 965 0.983 
lOCM 
'0 155355 137020 160000 146250 171259 158240 
zero- V 203 224 200 245 211 231 
order Abo k,o 0.14 C. lS7 0.14 0 . 14 0.14 0. 11 
linear T 0.5 0.49 0.5 0.5 0.49 0 .49 
clim . r 0.893 0.976 0 . 821 0.73 0.931 0.924 
2>01 ka' 0.886 1.36 l.05 0.581 0.989 0.918 
1 k V, 200 213 203 200 200 200 
linear 
'" 
0.167 0.525 0.01 0.06 0 . 26 0.22 
elim . k" 0.34 0.48 0.01 0.29 0 .45 0.55 
k 0.279 0. 29 9 0. 15 0.25 0.26 0.25 
" 0 0. 49 0.188 0.19 0.46 0.46 0.35 
r 0.98 0.962 0 .983 0.968 0.98 0.985 
, 
Garrelation coefficient as an indication of the goodness of fit 
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APPENDIX 4 
TABLE M. l Urir.e pH Readings. 
SUBJECT OOSE SUBJEcr roSE 
TIME (HRSI 25 50 100 TIME (HRSI 25 50 100 
Ali 0 5.16 5.59 5.05 GB 0 5 . 78 5 . 93 S.2S 
0-1 6.63 5.98 5.67 0-1 6.41 6.69 -
1-3 7.40 6.00 7.35 1-3 6.94 6.92 6.57 
3-5 7 . 01 5.51 6 . 37 3-5 6.56 6.89 6.78 
5-7 5.89 5.44 6.72 5-7 6.77 6.17 5. 88 
7-9 6.28 5.56 6.82 7-9 5.91 5.95 6.08 
9- 11 5.92 5.26 5.70 9-11 5.55 5.69 5 . 85 
11-14 5.66 5.47 5 . 79 11-14 6.21 6.65 5.71 
MEAN 6.24 5. 60 6.18 MEAN 6 . 26 6,36 6.01 
+ SD 0.738 0.259 0.75 .±. SO 0.49 0.48 0.51 
"" 
0 5.64 5.67 5 . 58 JM 0 5. 37 5 . 73 5.26 
0-1 7.24 6.96 7.22 0-1 5 . 37 S.38 7.46 
1-3 7.38 7.50 7. 61 1-3 6.06 6.65 6.72 
3-5 6 . 25 6.97 7.03 3-5 6 . 36 6.40 6. 98 
5-7 6.15 7.21 6.03 5-7 5.28 6.34 6.82 
7-9 6.39 6.95 6.25 7-9 5.54 5.92 6.93 
9=11 5 . 41 5.94 5.46 9-11 5.92 5.32 6.35 
11-14 5.68 6.09 5.86 U-14 5. 70 5.73 5.48 
MEAN 6.26 6.66 6.38 MEAN 5 . 70 5.93 6.50 
+50 0.725 0.666 0.80 + SD 0 . 38 0.48 0 . 76 
JS 0 5.41 5. 61 5 . 90 
0-1 5.84 6.47 5.78 
1-3 6 . 10 7.13 6 . 52 
3-5 6.00 7.24 7.21 
5- 7 5.47 6.54 6.62 
7-9 5.45 5.81 6.09 
9-11 5.06 5.44 5 . 38 
11-14 5.34 6.00 5.43 
MEAN 5.58 6.28 6.11 
+ SD 0.358 0.67 0.63 
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TABLE "4 .2 slood Pressure Readlngs. 
1 25 OOSE PPA HCl :!!l 
BlOOD PRESSUR!:: 
TI ME (HRS) SUllJECr 
AM GB we JS JM 
0 125 / 85 115/70 115/80 120/80 130/70 
0.666 110/80 110/ 80 110/65 120/75 120/60 
1.5 110/65 110/70 130/90 130/70 120/79 
2.5 110/70 110/70 120/80 100/70 lOa/50 
8 100/70 110/70 110/60 110/70 120/60 
16 115/75 110/70 115/70 110/70 120/70 
2. 50 rro DOSE PPA. HCl. 
0 115/90 115/70 110/90 110/60 120/80 
0 . 666 90/70 120/86 120/90 138/100 130/ 80 
1.5 90/70 130/88 135/85 150/100 130/80 
2.5 110/70 150/100 120/76 140/80 150/90 
8 110/60 120/70 120/78 110/60 130/70 
16 115/90 120/70 120/80 108/70 120/80 
3. 100 fI"I"I OOSE PPA. HC!. 
0 110 / 85 105/80 120/80 110/80 135/75 
0.666 120/80 120/86 130/85 140/90 ] 70/100 
1.5 155/100 136/100 130/80 140 /90 170/90 
2.5 110/90 118/65 120/65 140/85 130/76 
8 120/80 110/80 130/ 86 120/85 115/75 
16 120/80 110/80 120/80 110/80 120/75 
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